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Samples of human tissues used in biological research are often impure. Such samples contain
cells of the type under study and multiple ancillary cell types, leading to inaccurate expression
estimates and analysis for the cell type under study. While estimates of cell type abundance can be
of interest on their own, their use is critical to the correction of differential expression testing in
heterogeneous cell type samples to account for differential cell type abundance across conditions.
This dissertation develops and examines three statistical models for the estimation or use of cell
type abundance profiles in the analysis of RNA-seq data from heterogeneous cell type samples.
Regarding estimation of cell type abundance profiles, we propose two models: IsoDeconv and
ICeD-T. The IsoDeconv model approaches abundance estimation using isoform-level expression.
We extend the IsoDeconv model to allow for biological variability in isoform expression across
samples. The IsoDeconv model is assessed via simulation and through use of in silico mixtures of
genuine RNA-seq expression datasets from non-cancerous human cell lines. The ICeD-T model
approaches abundance estimation deconvolution using gene-level expressions while allowing for
aberrant gene behavior within mixed cell type samples. Estimation properties of ICeD-T are
assessed via simulation and validated in both microarray and RNA-seq datasets.
Transitioning to the use of abundance profiles in the analysis of heterogeneous cell type samples,
we propose pTReCASE. pTReCASE is an expression quantitative trait locus (eQTL) mapping
technique for use in bulk tumor samples. pTReCASE extends current eQTL mapping methods for
tumor tissues to estimate eQTLs within tumor and normal cells separately. The type I error and
iii
power of pTReCASE are assessed via simulation before application to the study of breast cancer
data from 547 Caucasian women.
iv
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CHAPTER 1: INTRODUCTION
Almost invariably, tissue samples collected from human sujects are not restricted to a single
cell type. Instead, each sample is a mixture of cell types (e.g. immune cells, fibroblasts, etc.). In
tumor tissues, mixtures arise naturally from incomplete separation of normal cells from the tumor
section or from the infiltration of normal cells into the tumor itself (e.g. immune cell infiltration).
It is often of interest to examine the composition of such mixtures with respect to the constituent
cell types. In the case of immune cell infiltration within tumors, abundance profiles can provide
biological insight into the body’s response to cancer and can identify possible deficiencies in this
response. When the abundance profile itself is not of interest, cell type composition is crucial to the
study of cell-type specific differential expression. Failing to consider differential abundance profiles
risks conflating expression differences due to shifting profiles with true differential expression.
Physical methods exist to separate the mixture tissues into their distinct, constituent cell types.
However, these techniques can be prohibitively expensive and remove the cells from the natural
environment in which they live. The use of computational methods to deconvolute gene expression
from mixed cell type samples sidesteps these obstacles while still providing useful information
in their analysis. It is the purpose of this dissertation to explicitly model cell type abundance
profiles and incorporate such profiles into the study of heterogeneous cell types samples using gene
expression profiles from RNA-seq experiments.
In chapter 3, we develop IsoDeconv, a model for cell type abundance estimation which utilizes
isoform expression information. Since isoform expression is a more granular examination of the
expression products utilized by a cell, it may be more sensitive to cell type differences existing
between cells of similar lineages (e.g. CD8+ T-cells, γδ T-cells) than gene-level expression.
Thus, the proposed methodology would be more accurate than current gene-level methods for
deconvolution of highly similar cell types. IsoDeconv is extended to allow for biological variation
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in isoform expression across samples. This model is assessed via simulation and through the use of
in silico mixtures of genuine RNA-seq expression datasets from non-cancerous cell lines.
In chapter 4, the abundance estimation problem is revisited using gene-level expression data.
We propose a model for the estimation of immune cell abundance within tumor tissues called ICeD-
T. ICeD-T is designed to estimate immune cell abundance profiles in the presence of aberrant gene
behavior using tumor purity estimates, if available. ICeD-T is validated on microarray expression
data from human blood and an RNA-seq expression dataset from melanomas. ICeD-T is also
applied to the examination of response-to-treatment for an immune checkpoint therapy.
Chapter 5 transitions to the use of cell type abundance profiles in the analysis of heterogeneous
cell type samples rather than the estimation of such profiles. In this chapter, we propose a statistical
model for the identification of expression quantitative trait loci (eQTL) within tumor tissues called
pTReCASE. As outlined above, tumor tissues contain tumor cells and normal cells. pTReCASE
extends current tumor-tissue eQTL mapping techniques to estimate eQTLs in tumor and normal
cells separately. We demonstrate that pTReCASE provides proper Type I error control and improved
power in the detection of eQTL. pTReCASE is applied to the study of gene expression data from
the breast cancers of 547 Caucasian women.
2
CHAPTER 2: LITERATURE REVIEW
2.1 The Biology of Transcription and RNA-Seq
Next generation sequencing technologies (NGS) provide a wealth of knowledge for the analysis
of the cell. For example, one can examine the genetic sequence, interrogate the use of DNA-protein
interactions, and explore the transcriptional activity of the cell in order to uncover the biological
determinants governing cell behavior and function. Ribonucleic acid sequencing (RNA-Seq) allows
examination of the latter, providing a snapshot of the building blocks each cell uses to create proteins.
These proteins, in turn, are the basic units used to perform work within a cell. Thus, by providing a
snapshot of the transcriptional activity of a cell, RNA-Seq allows examination of a cells identity by
examining the tools it will use to perform work.
Before discussing RNA-Seq, a discussion of the basic biology it examines is warranted. In order
to create proteins, cells translate the genetic information contained in DNA into RNA through the
process of transcription. Once the DNA has been transcribed into RNA, cellular mechanisms edit
the RNA transcript. This editing removes regions of code, termed introns, which will not be used in
creating proteins. The remaining regions of code, called exons, are retained in the final messenger
RNA (mRNA) transcript and will be expressed through proteins. A single gene in the genome
can produce multiple mRNA transcripts and thus multiple proteins through the use of alternative
splicing [1]. Alternative splicing, occurring in at least 90% of human genes, is the process by
which a single RNA transcript has various exons removed from the final mRNA transcript to create
multiple, unique transcripts called isoforms [2]. RNA-Seq measures the presence and amount of the
final, processed mRNA transcripts within the cell.
The process of RNA-Seq begins with the purification of the RNA sample. This typically
involves processes to remove ribosomal RNA – a subset of non-coding RNAs which comprise 90%
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of RNA product in the average cell – or the enrichment of the sample for messenger RNA (mRNA).
Once a sample of purified RNA is obtained, these molecules are often sheared to reduce the length
of fragments before sequencing and to remove structural impediments to downstream processing.
These RNA sequence fragments are then reverse transcribed into complementary DNA (cDNA).
This cDNA is then amplified for sequencing and sequenced on one of numerous massively parallel
DNA sequencers including Illumina Genome Analyzer, ROCHE 454, or SOLiD sequencers. Often,
these sequenced RNAs are then mapped back onto a reference human genome to determine their
site of origin and summarized by genomic locus or isoform [3].
The output of the typical RNA-Seq experiment involves counts of the number of sequence
fragments at various sites in the genome. However, comparison of counts both across and within
samples requires normalization. Archetypical normalization attempts to remove imbalances in
RNA-Seq read counts due to differences in the amount of RNA procured in a given experiment
and/or the length of the genomic feature of interest. This is typically performed through use of
Fragments per Kilobase per Million Mapped reads (FPKM) correction, which divides each observed
count by the amount of mapped sequence present in each sample and multiplied by the length of
the genomic feature [4]. In this way, counts across different samples and genomic features can be
viewed on a similar scale.
Notable sources of bias in RNA-Seq counts at different genomic loci include mappability biases,
GC-content biases, and nucleotide start site biases. Mappability bias implies that regions of DNA
with fewer repetitive elements and longer stretches of unique arrangements of DNA will see larger
observed RNA-Seq read counts [5]. GC content biases indicate that regions with a large proportion of
GC nucleotides tend to experience larger RNA-Seq read counts [6, 7, 8]. Finally, though somewhat
attributable to a preparatory technique known as random hexamer priming, it was observed that
RNA-Seq reads tended to start at genomic loci with G or C nucleotides [8]. The correction for these
biases is most critical in situations where attempts are made to compare transcription activity levels
between different genomic locations, not for the examination of transcriptional activity at the same
genomic loci across different conditions.
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Compared to RNA microarrays, RNA-Seq provides numerous improvements. While microar-
rays can only consider pre-specified genomic locations or splice junctions, RNA-Seq provides a
large dynamic range of reads covering the genome. This allows for the discovery of novel genes,
transcripts, and splice sites [9, 10]. In addition, RNA microarray data processing often requires the
use of opaque normalization techniques whose impacts on resulting measures of signal strength
are not readily comprehensible. Current popular RNA-Seq normalization techniques are simple to
apply and their effects on resulting signal strength measures are much clearer.
2.2 Count Models for RNA-Seq Expression
As discussed in the previous section, RNA-Seq output comes in the form of observed sequence
counts at various genomic loci or transcripts. Typical models for RNA-Seq data have involved
count distributions such as the multinomial or discrete model, the Poisson model, and the negative
binomial model. Each of these will be discussed briefly.
Early models of RNA-Seq expression assumed that reads represented independent, random
realizations from a selection process that was uniform across the length of a transcript and dependent
on the activity level of the transcript or locus in question [11]. Thus, the multinomial model was a
natural starting point. The multinomial models can occur on one of two scales which summarize
the same data in different ways. The first scale is to model expression at each genomic locus.
The second scale models the likelihood for each individual RNA read. RNA-Seq by Expectation
Maximization (RSEM) is a good representative of the individual RNA read level model [12]. Let θi
be the proportion of expression and li denote the length of a transcript i. The probability that one
would observe a read fragment r that arises from transcript i is given by:
P {r ∈ i} = θili∑
θjlj
This modeling technique accounts for the length of different isoforms in generating RNA-Seq reads.
RSEM also incorporates corrections for positional biases and sequencing errors by adding weighting
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factors for each possible location that a given read can map within the genomic feature of interest
[12].
As RNA-Seq expression libraries are quite large, and the expression of typical genes can be
considered quite small in relation to the entire library, the multinomial model lends itself well to an
approximation via Poisson counts. Marioni et al [13] assess the variability in read counts at certain
loci across technical replicates of RNA-Seq expression. A technical replicate is data arising from
sequencing of the same biological sample on differing lanes or runs of a DNA sequencer. They
found that, at least in the technical replicate setting, a Poisson model accounting for library size and
average transcript expression adequately captured the mean and variance for differential expression
testing [13]. It has been proven that estimation of transcript abundance using the multinomial and
Poisson counts is identical under identical bias models [14].
It has been noted, however, that the Poisson model does not adequately capture the variance
in expression levels across biological replicates as compared to technical replicates. It was found
that the observed variance in expression tended to exceed the mean across biological replicates,
suggesting the presence of overdispersion [15, 16]. It is in this setting that the negative binomial
models were introduced to correct differential expression analyses for this greater observed variation.
Anders and Huber utilized a library-size and locus specific expression dependent model of mean
expression. In a low replicate setting, Anders and Huber borrow information across genes to
estimate overdispersion by hypothesizing a functional relationship between average expression
and variance using local regression to obtain estimates [15]. Robinson and Smyth proposed an
alternative estimator for the overdispersion using a weighted likelihood approach, which acts as a
penalty on a genes estimate of overdispersion towards a common overdispersion using a likelihood
function motivated by Empirical Bayesian estimates of penalty parameters [16].
In a model titled IsoDOT, Sun et al provided an extension to the negative binomial models
often used in RNA-Seq that shifted focus from the modeling of gene or transcript level expression
to exon set level expression. By breaking down expression within a gene into sets of reads which
overlap particular groupings of exons, Sun et al were able to interrogate the alternative splicing
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mechanisms used in transcription regulation and thereby model isoform specific abundances across
varying conditions (e.g. cell type, disease status) [17].
The following introduces the structure of the IsoDOT model for a single gene, which will set
the stage for further extensions of this model to deconvolution of expression data from multiple
cell type sources. Consider exon sets A and B. A and B are distinct groupings of non-overlapping
regions of exonic code within a particular gene. Exon sets A and B may contain one or more exons
in common, but their set difference is non-empty. Each read is partitioned to a single exon set if and
only if it overlaps each exon in the set and no others [17].
One can expect the number of reads mapping to exon sets to depend on, at the very least, two
factors. The first is the length of the exon set. As noted above, larger genomic features produce
larger counts due to the fragmentation of RNA output for sequencing. Additionally, more reads will
be expected for a particular exon set if the isoforms which use the exons in this set are more active
[17].
Sun et al incorporate these features into the mean structure of a negative binomial model by
defining an effective length of each exon set within each transcript. Thus, for exon sets with exons
not composing an isoform I , the effective length of this exon set for this isoform is 0. Otherwise,
the effective length of an exon set A in isoform I is the expected number of start sites for a read
covering these exons assuming the ordered composition of an isoform I [17].
In summary, Sun et al model the count of reads across a group of exon sets in a single experiment
the following way, where X is an E × I matrix of effective lengths, γ is the vector of normalized
isoform expressions, and ti is a measure of read depth within the sample:








The true novelty of this approach is in its partitioning of reads at the gene level into varying exon
sets which create the information necessary for probabilistically estimating the isoform expression
values without probabilistically assigning reads to transcripts [17].
Sun et al also incorporate an iterative adaptive lasso penalty in the optimization of the γ param-
eters to limit the number of estimated isoform parameters above 0. In this way, it simultaneously
performs variable selection while estimating isoform expression. Differential usage testing of
isoforms across conditions uses a bootstrapped likelihood ratio statistic [17].
2.3 Expression Deconvolution Using RNA-Seq Data
Almost invariably, sequencing data derived from human tissue samples are contaminated.
Such samples contain not only cells of the type desired for study, but also contaminating cell types
such as blood or epithelium. The need for statistical procedures which can deconvolute these
sequencing data into components from contaminating cell types and those cell types of interest
has frequently been addressed in the literature. Accurate estimates of cell type abundance provide
useful information in the correction of analyses for differential expression of genes or transcripts
for differences in cell type composition, estimating the presence of immune cell contamination in
tumor samples, and the guiding of patient care in the presence of intra-tumor heterogeneity or the
presence of multiple competing cancers in a single tumor.
There are two main approaches to the deconvolution of mixed cell type samples into their
constituent cell types expressions for analysis. The first is the mechanical separation of cell types into
groups of purified cell types using techniques such as laser capture microdissection or fluorescence
activated cell sorting (FACS). Concerns exist as to whether these physical procedures influence the
cellular environment and thus the expression patterns of cells [18]. The second approach attempts
to deconvolute expression in silico through the use of statistical models to mathematically predict
cell type proportions. One can group the in silico approaches into a few different subcategories:
ratio based models of expression, linear models of expression, infiltration score models, models
which incorporate prior information about cell type abundance, and perturbed expression models.
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Ratio based models of expression typically handle the two cell type case. These cell types
can be two different normal cells or two subsets of cells (e.g. normal and tumor). Consider a
mixture sample composed of cell types A and B. Let EiA represent the expression of gene i
in cell type A. Let EiAB be the expression of gene i in the mixture tissue. It is assumed that
EiAB = pAEiA + (1− pA)EiB . The idea behind ratio-based models is to compare the expression of
a gene i in a pure sample of one cell type A, against the expression of this gene in a mixture sample
of types A and B. Thus, define RiAB = EiAB/EiA where a reference value of EiA is known a priori.
In the absence of noise, one would expect the minimum of this ratio across genes to approach pA
since one considers genes more highly expressed in A and more lowly expressed in B. However,
the presence of biological or experimental noise complicates the analysis and ruins estimation of
the proportions.
Two different approaches to handle this noise were examined. In the approach used by Gosink
et al, several realistic simulations are computed across a range of values for pA. For each simulation,
the RiAB are ranked by magnitude. The fifth percentile RiAB score is used in a regression equation
to predict pA. The model used was selected from multiple regression models considering the q-th
percentile RiAB and its square as covariates. The one which provided the best R2 value was chosen
[19]. Clarke and Seo, however, accounted for noise using a transformed version of the RiAB values.






values uses an optimized choice
of correction factor (α) found by computing the ”elbow” of a plot of the mean transformed RiAB
values against the correction factor. The minimum tRiAB was found to be a good estimator of pA
[20].
Another ratio based method, UNDO uses the ratios of expression (Ri) between two mixed
tumor/normal samples across all available genes i. A gene is considered a marker gene if it falls
within some pre-specified small-ε neighborhood of the minimum and maximum Ri. As before,
these maximum and minimum Ri are indicative of genes used exclusively in one cell type. Using a
simple relationship between these marker genes expressions and cell type proportions in each of the
mixtures, namely that the ratios are bounded by ratios of cell type abundances one can estimate
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cell type specific proportions for each cell type from sample mean expression values in the mixture
tissues [21]. Without the use of pre-specified pure sample references, one could term this method
unsupervised estimation.
Linear models of expression all begin with the following underlying model for the expression in
a mixture tissue with K-constituent cell types. Let Y , a g × n matrix, be appropriately normalized
gene expressions in n mixture tissues. Let C, a g ×K matrix, be the appropriately normalized,
Gold-standard reference expression at each gene for each of the K cell types. Let W , a K × n
matrix, represent the mixing fractions of the different cell types across the k tissues. The model
for expression in the mixture tissue is then given by Y = CW . The majority of these methods
require a Gold-Standard reference expression profile, preferably composed of genes with differential
expression across cell types.
The earliest methods in linear models were designed and fit using simulated annealing pro-
cedures to obtain estimates of the matrix W [18, 22]. In the Lu paper, simulated annealing to
minimize prediction error was used to fit the linear model. Lu et al investigated yeast cell popu-
lation dynamics under various environmental conditions [22]. Shen-Orr applied the technique to
human blood samples [18]. Early linear modeling procedures required post-estimation correction of
physically impossible results such as negative proportions or proportions which did not sum to one
by renormalizing positively estimated proportions to fall between 0 and 1[23].
After the advent of RNA-Seq, Gong et al tested the applicability of the linear modeling
procedures previously developed in the microarray setting. Advocating proper normalization, such
as RPKM in the RNA-Seq setting, their method DeconRNASeq utilizes quadratic programming to
find an estimate of W which minimizes the squared prediction error and is subject to the normal
physical constraints of proportions. DeconRNASeq also refines the Gold-Standard expression
matrix by utilizing a subset of rows of the reference matrix with the smallest condition number,
thereby producing more stable estimates of the cell type proportions [24].
Much like DeconRNASeq, CIBERSORT uses a refined Gold-Standard reference profile A that
is made robust through the use of condition number selection to remove uninformative genes from
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the selection matrix. However, CIBERSORT uses support vector regression to obtain estimates of
cellular proportions [25].
The digital sorting algorithm (DSA) was designed by Zhong et al to incorporate the linear
model in the absence of a reference profile matrix. Applied to gene-level, normalized microarray
data, DSA requires a priori knowledge of marker genes genes expressed in only one of the K
cell-types. Let C∗ be a diagonal matrix with the average expression across all marker genes of
cell type k at C∗(k, k) . Let Y ∗ be the corresponding observed average expression values in the
mixture cell type samples. Assuming that the number of mixture samples exceeds the number of cell
types in the mixtures, then C∗−1Y ∗ creates an overdetermined system of equations for the C∗(k, k)
since each column of the matrix C∗−1Y ∗ must sum to one. Once these values are estimated, the
estimation of the W matrix is simply W = C∗−1Y ∗ [26].
Finally, the DeMix model uses a similar linear structure for mean intensity in non-log trans-
formed microarray data, but it does so only in the two cell type case of tumor versus normal
cells. It proposes a log base-two normal distribution for microarray intensity in tumor and normal
cells, leading to a mixture expression distribution that is the weighted convolution of these two
distributions. Estimation proceeds through use of a mixture of Nelder-Mead optimization steps
to cyclically update estimates of tumor purity, mean and variance parameters across samples for
each genes tumoral and normal expression, and tumoral intensity expression at each gene until
convergence of the likelihood. Multiple mixture samples are required for proper deconvolution [27].
In stark contrast to the majority of the previously described models, two methods of RNA
expression deconvolution focus on the estimation of gene expression values from within a mixed cell
type sample using prior information regarding cell type abundances. In the absence or pure sample
expressions, prior information regarding cell type abundance allows for identifiable models of cell
type specific gene expression. TEMT uses RNA-Seq data and a model similar to that discussed
for RSEM to quantify cell type specific gene expressions. The authors of TEMT encourage strong
information regarding cell type proportion for proper deconvolution of cell type specific gene
expression signatures [28].
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DSection also makes use of prior information regarding cell type proportions in the decon-
volution of microarray intensity data. Under a normal distribution model, DSection utilizes a
weighted sum of cell type specific expressions for the mean with heteroscedasticity across genes.
It incorporates the use of normal priors on cell type specific expression, gamma priors for probe
specific variance measures, and Dirichlet priors for cell type proportions. Parameters regarding
sample specific contributions of cell type intensity, probe specific variance measures, and cell type
proportions are updated through the use of MCMC sampling [29].
The last subset of deconvolution models can be termed perturbation models. In these models,
the reference expression levels of various cell types in the mixture are perturbed versions of pure
sample reference expression levels. These models attempt to correct for differences in mixture
sample and reference sample profiles arising from environmental effects, cell culture effects, or
mutational effects leading a cell to become a cancerous version of itself.
PERT, a model designed by Qiao et al, uses microarray RNA expression to estimate cell
type abundances. PERT assumes that the latent reference gene expression profile (D∗) of the
heterogeneous cell type sample is a multiplicative perturbation of a true expression reference (D)
given by a renormalized version of diag(P ) ∗D where each column sums to 1 and P is a vector of
perturbation factors for each gene. Maximum likelihood estimation of cell type abundances and
perturbation factors is performed assuming a discrete model for each unit of intensity. Regularization
of cell type abundances and perturbation factors is incorporated across multiple mixture samples
using dirichlet and gamma priors, respectively [23].
IsoPure, the successor of ISOLATE [30], models mRNA microarray expression in a tumor
in the following way [31]. As before, let C be a reference expression matrix for each normal
cell type, normalized so that each column sums to one, dn be a reference profile for sample ns
particular cancer, and θn be the mixing proportions of sample n. Let ω define an indicator vector
of the cell-type origin of the cancer being examined in the study. Then, we may model yn, the
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dn ∼ Dirichlet (knm)
m ∼ Dirichlet (k′Cω)
θn ∼ Dirichlet (ν)
In this way, they model cancer as a random perturbation of a single cell type profile, allow for each
individual’s cancer profile to vary about the true cancer profile and regularize cell type proportions
across individuals. The IsoPure model provides cancer purity estimates, an identification of the
cell-type of origin of the cancer under study, while at the same time restricting cell-type abundances
to follow a similar profile across subjects [31].
The majority of these proposed methods were designed specifically to handle microarray data.
Only DeconRNASeq, Undo, Cibersort, TEMT, and IsoPure were designed specifically with RNA-
Seq methodology in mind. Of these, only DeconRNASeq, TEMT, and EPIC specifically applied to
and validated using RNA-Seq data. The remaining models suggest validity in the RNA-Seq case,
but do not test for it. Thus, the proposed methodology for cell type expression deconvolution in
RNA-Seq data is limited.
Additionally, some models require prior information or regularization procedures with respect
to cell type abundances for deconvolution. Prior information with respect to cell-type abundance
may difficult to obtain due to cost, infeasibility of good cell type separation, or a desire to maintain
natural environmental conditions for the heterogeneous cell type samples. Models such as IsoPure
or Isolate, which require regularization of cell type abundance parameters, are somewhat limited
to the case where multiple mixed tissue samples exist or natural regularization parameters are
available.
Finally, the majority of these models measure expression on the gene level. Thus, deconvolution
among cell types necessitate cell types that express differently at the gene level. However, as noted
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earlier, at least 90% of genes utilize alternative splicing[2]. It may be the case that alternative
splicing could be more sensitive to cell type differences than gene expression, especially in cells of
highly similar lineage, for example different varieties of B-Cells. Extension of these models to the
transcript level expression would require that accurate transcript level expression information is
available. Often, however, reads map to multiple transcripts and the estimation of transcript level
expression is inexact and this uncertainty in reference expression profiles would not be captured.
2.4 Immune Cell Expression Deconvolution in Tumor Tissues
The developing relationship between a cancer and its host’s immune system is well summarized
in a hypothesis known as immunoediting. In summary, the immune system’s attack upon a burgeon-
ing cancer cell population becomes a driving force behind the development of immunosubversive
cancer cells [32, 33]. Such cells are capable of hiding from the immune system, killing its cytotoxic
population or even recruiting its suppressors to reduce further response [34, 35]. Much therapeutic
development has been focused on therapies, called immunotherapies, which enhance the bodys
natural immune response by counteracting these self-defense mechanisms in cancer. Despite recent
successes in prostate cancers and melanomas, immunotherapies have been demonstrated to be
highly disease- and subject-specific. For example, immune checkpoint blockade therapies have
produced response rates as low as 12% in head and neck squamous cell cancers and as high as 85%
in Hodgkins lymphomas [35, 36]. As immune cell composition estimation within human cancers
has demonstrated prognostic value [37, 38, 39], such an approach provides a potential avenue for the
investigation of therapeutic efficacy of immunotherapies as well as the identification of mechanisms
for novel interventions.
Bulk expression analyses such as RNA-seq and RNA microarrays have become standard tools in
the interrogation of infiltrating immune cells within the tumor microenvironment (TME). However,
as bulk expression experiments capture the totality of expression from all cells within the TME,
there is a need for statistical models which can disentangle the individual contributions of each cell
type in order to estimate the composition of the TME.
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The previous section discussed the bulk-expression deconvolution problem and several methods
used in its address for general tissue types. Here we focus on an additional subset of deconvolution
models used specifically to estimate immune cell proportions in tumor tissues. Pioneering methods
sought to quantify immune cell infiltration by proxy using infiltration scores. In this setting,
infiltration scores are quantities which are correlated with immune cell proportion in the tumor
body; the larger the score, the more abundant the immune cell population they measure. Two such
methods utilized the normalized expressions of a select few immune-specific genes (e.g. CD8A,
GZMA, PRF1) to examine infiltration of cytotoxic immune cells within the tumor body [40, 41]. A
similar method, MCP-counter, extended these models to compute infiltration scores for an increased
array of immune cell subsets including B-cells, CD4 T-cells, CD8 T-cells, Monocytes, macrophages
and more [42]. Becht et al computed the infiltration score for any category as the log-2 average
gene expressions computed across genes with cell-type specific expression in the given immune
cell subset. Infiltration scores are limited in their interpretations. At best, they allow one to rank
subjects with respect to the level of immune cell infiltration. However, they do not allow one to
assess whether there are more cells of one type than another.
An alternative to infiltration score techniques, linear regression based models remain popular
deconvolution techniques for use in tumor expression datasets. However, within tumor tissues,
the previously described approaches must be modified to account for the presence of a tumor cell
type. This modification is often performed by restricting the “gold-standard” reference matrices to
immune-specific genes, or genes expressed only within immune cells and not within tumor cells.
With an appropriate selection of immune-specific genes, the mixture expressions being modeled
remain a linear combination of the expressions across non-tumor cells only. To this end, the
CIBERSORT team developed the Leukocyte Matrix 22 (LM22) to characterize reference immune
expression across 22 different immune cell subsets at genes expressed only within the immune
population[25]. TIMER uses a similar approach by constructing a “gold-standard” reference
expression matrix for several immune cell subsets and restricting genes to those anti-correlated
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with tumor sample purity. In addition, the TIMER methodology removes high-expressions genes as
these such genes tend to have high variability and exert undue influence on model estimates[43].
The most recent linear model for tackling immune cell deconvolution in tumor tissues is
called EPIC [44]. EPIC utilizes constrained, weighted least squares to simultaneously estimate the
proportions of several immune cell types and the proportion of tumor cells within the sample. EPIC
uses a weighting scheme which considers the ratio of average gene expression to gene expression
variance. Higher weights are assigned to genes with lower expression variance in accordance with
the magnitude of their average expression across reference profiles. For use within tumor samples,
particularly melanomas, EPIC creates a reference expression matrix, TRef, constructed from single
cell RNA-seq expression profiles conducted on melanoma samples. Racle et al argue that immune
cell expression profiles developed from circulating immune cells may not adequately capture their
behavior within the tumor microenvironment. By assessing expression profiles directly from tumor
infiltrating immune cells, EPIC seeks to correct for this possible disagreement [44].
Previously proposed methods for immune cell deconvolution in the tumor microenvironment
suffer from three main disadvantages. First, each method fails to utilize knowledge of the level of
non-tumor cell infiltration into the TME should this information be available. Second, as expression
mixing occurs in linear-space, each of these methods deconvolve expression in the linear space.
However, this fails to incorporate the beneficial properties of the log-transformation for RNA-seq
and microarray expression experiments. Finally, previously proposed methods fail to provide a
mechanism which can both control for and identify loci within individual mixture tissues which are
inconsistent with measured references.
2.5 Expression QTL Mapping Using Gene Expression Data
Genome wide association studies (GWASs) have long been used as a tool for establishing a
link between genetic variation and phenotypes. Genetic variation in GWASs is examined through
the use of single nucleotide polymorphisms (SNPs), or single base pairs which vary across human
subjects. The phenotypes considered often involve indicators of disease (e.g. cancer) [45].
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The complex regulatory landscape that governs phenotypic expression made interpretation
of GWAS results difficult. While a link between a disease and a SNP could be established,
the biological mechanisms behind this association remained unclear. The advent of expression
microarrays and RNA-Sequencing expanded the phenotypes available for GWAS examination to
include RNA expression of individual genes. Investigation of gene-level expression afforded by
such techniques allows for direct examination of the functional role of genetic variation in gene
expression and helps to interpret GWAS results [46].
SNPs linked to changes in gene-level expression are termed expression quantitative trait loci
(eQTL). EQTL are categorized in two groups, cis-eQTL or trans-eQTL, distinguished by the
patterns of expression change they induce in affected genes [47, 48]. In order to understand the
distinction between these two types of eQTL, recall that humans are diploid organisms. Normal
cells within humans contain two homologous copies of each chromosome: a maternal and a paternal
copy.
A locus is considered a cis-eQTL if it regulates expression of the gene it effects in an allele-
specific manner [48]. For example, consider a mutation on a single allele at a transcription factor
binding site which inhibits the initiation of transcription. Alleles which lack this mutation are able
to successfully bind the transcription factor and thus initiation of transcription proceeds uninhibited.
Such a mutation acts in an allele-specific manner and is thus considered a cis-eQTL. Cis-eQTL
are often found close to the gene whose expression they alter. As a result, cis-eQTL are often
misleadingly labeled ”Local eQTL”[47].
On the other hand, trans-eQTL are distinguished by genetic variants which impact expression
of both alleles of a gene [48]. A common mechanism employed by trans-eQTL is the mutation of
loci involved in the production of transcription factors which bind to all copies of a gene. Altering
the expression or functionality of a transcription factor would thereby impact both alleles of the
gene. Trans-eQTL may be found near the genes whose expression they alter but can also be found
at a distance, possibly from a different chromosome [47].
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Traditional eQTL mapping methods implicitly assume that an eQTL has the same effect on all
cells within a sample. This is a reasonable assumption for samples with a relatively homogeneous
cell population. However, tumor samples invariably contain both tumor cells and infiltrating normal
cells (e.g. immune cells) and eQTL effects could differ between these two cell types. Previous
eQTL studies in tumors ignored tumor purity, defined as the proportion tumor cells among all cells
within the tumor sample,thereby assuming that tumors are composed of homogeneous cell types.
For example, such studies regressed normalized gene expression on eQTL genotype and other
population stratifying factors such as genotype principal components or gender [49, 50, 51, 52].
Other regression-based techniques propose first regressing tumor gene expression on estimates of
methylation and/or somatic copy number before regressing the resulting residual expression on
eQTL genotype[53]. Identification of tumor-specific eQTL is generally ad-hoc, labeling an eQTL
tumor-specific when analysis within tumor tissues suggests an eQTL where none is found in a
separate analysis of normal tissues.
An extension of these linear models has been developed to incorporate measures of tumor
purity or, in the normal tissue setting, cell-type specific abundance. Westra et al utilize a proxy
for neutrophil abundance as a covariate in a linear regression model to identify neutrophil specific
eQTL within whole blood samples[54].
As an alternative to tumor purity, several studies have incorporated allele-specific expression
(ASE) in analyses of eQTL within tumor tissues to strengthen conclusions. For example, Li et al
also propose use of RNA-Seq data to examine allelic imbalance, or the proportion of reads mapping
to one allele or another. Deviation of this proportion from 0.5 is termed imbalance[53]. However,
by failing to integrate the regression and ASE components of the model, such studies restrict ASE
analysis to a supportive role in eQTL identification. In a framework developed by Sun et al [55], it
has been demonstrated that concurrent incorporation of ASE and gene-level expression improves
power in the detection of cis-eQTL within normal tissues.
We briefly describe the model proposed by Sun for eQTL identification in normal tissues[55].
Sun examines expression data from RNA-Seq by modeling two distinct, yet overlapping components:
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total read count and allele specific read count. Employing a negative binomial model, the total
number of reads mapping to a gene are examined to estimate trans- or cis-eQTL effects. The
subset of total reads which are uniquely mappable to a single allele are modeled in a beta-binomial
framework and can only identify cis-eQTL effects. For cis-eQTL, these two components of the
model are linked through use of a common eQTL parameter which is defined for a composite,
normal tissue type. Previous extensions of this model have attempted to remove its dependence on
prior genotype imputation and haplotype phasing [56].
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CHAPTER 3: ISODECONV: CELL TYPE ABUNDANCE ESTIMATION USING RNA
ISOFORM EXPRESSION
3.1 Introduction
Sequencing data derived from human tissue samples are often mixtures of heterogeneous cell
types. Such samples contain not only cells of the type desired for study (e.g. tumor cells, B-cells), but
a milieu of additional cell types. It is often of interest to quantify the abundance of each constituent
cell type found within a heterogeneous cell type sample. In some cases, the abundance profiles
themselves contain relevant information regarding biological response, such as the case of immune
infiltration within a tumor. In others, abundance profiles are crucial for proper cell type-specific
differential expression analyses. Cell-sorting and other physical separation techniques exist to
partition heterogeneous cell type samples into purified samples of their constituent cell populations,
but such methods can be costly and may even induce changes to the cellular environment which
impact expression profiles [18]. As an alternative to physical separation methods, the development
of statistical models for the deconvolution of expression profiles from heterogeneous cell type
samples has become an active area of research.
In silico expression deconvolution models can largely be separated into three main develop-
ments: ratio-based models, linear models, and infiltration scores. Ratio-based models rely upon
computing expression ratios between a mixed expression profile and a “gold standard” reference for
a single cell type. The minimum of these ratios across genes roughly approximates the proportion
of the referent cell type [19, 20, 21]. These methods are often limited to the two cell group case (e.g.
tumor vs normal). In response to the limited cell populations interrogated by ratio based methods,
linear modeling of mixture expressions was introduced. The traditional linear model framework
assumes that appropriately normalized mixture expressions can be modeled as a weighted sum of
contributions of “gold-standard” expression profiles from two or more cell types [22, 24, 25, 26].
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Recent deconvolution models have been applied to the study of immune infiltration in tumors and
have focused on the computation of infiltration scores, or unitless quantities designed to reflect
increasing abundance of a certain immune cell [42, 43].
Almost exclusively, the proposed methods have been designed to examine and validate on gene-
level expression only. Thus, appropriate deconvolution requires that cell types express differently at
the gene level. In the case of highly similar cell types (e.g. CD8+ T-cells vs. γδ T-cells), however, it
may be the case that gene-level expression differences are minimal. Through a process known as
alternative splicing, a single unprocessed mRNA transcript produced by a gene can form multiple
distinct processed transcripts, or isoforms. Isoform expression, therefore, represents a more granular
examination of the expression products utilized by a single gene [2]. In the case of highly similar cell
types, the differential usage of isoforms may be more sensitive to cell type identity than higher-level
gene expression.
In this chapter, we outline the development of two statistical models for expression deconvolu-
tion in mixture tissues which are capable of utilizing isoform-level expression differences between
cell types. The first, IsoDeconvNB, posits a negative binomial structure for mixture expressions
across cell types. The second, IsoDeconvMM, is the successor to IsoDeconvNB which is designed
to explicitly model biological variability in reference isoform expression profiles.
3.2 Statistical Methods
3.2.1 The Data
Consider a biological tissue sample composed of K different cell types. The abundance of each
cell type k, or the proportion of cells of type k in the heterogeneous cell type sample, is unknown
and must be estimated. In order to estimate these proportions, IsoDeconv requires a single RNA-Seq
experiment performed on the mixed cell type sample. In addition, it is assumed that there exist
RNA-Seq experiments for each cell type k performed on purified samples of cells of this type; for a
single cell type k, these Nk sets of reads are considered cell-type specific RNA-seq profiles. For
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each experiment, read counts are summarized at the exon level by counting the number of reads
overlapping various sets of exons.
IsoDeconv assumes that there exists a list of cell-type specific genes wherein there are gene-
and/or isoform- expression differences across the K cell types. Such a list of genes can be found
using one of many differential expression testing methods for RNA-seq data. For the following,
the Cufflinks suite was used to determine differentially expressed and/or regulated genes for use in
deconvolution [57].
Furthermore, it is assumed that a detailed gene and isoform construction model is available
for each gene at which expression is assessed. The gene construction model assumes knowledge
of all non-overlapping exons utilized by the gene and their locations within the gene body. The
isoform-construction model for each gene assumes knowledge of all isoforms used by the gene and
their construction with respect to the known exons. For further details regarding the formation of
these gene and isoform construction models, please see the supplementary materials of Sun et al
[17].
3.2.2 IsoDeconv - Negative Binomial Model (IsoDeconvNB)
Within the IsoDeconv model, estimation of cell-type abundances is first estimated for each gene
and each sample separately. Then the final estimates for each sample are derived by aggregating the
gene-specific estimates. In the following, we first describe the IsoDeconv model for a single gene.
Consider a hypothetical gene composed of m non-overlapping exons. These m exons are
utilized by I isoforms, or distinct mRNA transcripts formed by unique combinations of these exons.
As specified in the assumed gene- and isoform-construction models, the locations of these exons
within the gene are known as are the identities and compositions of all isoforms used by this gene.
In order to model isoform expression and cell-type abundance, IsoDeconv examines read counts at
the exon-set level. We define the read count at any exon set e as the number of fragments which
overlap each of the exons in e and only these exons.
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To visualize the following setup, consider the hypothetical gene displayed in figure (3.1). This
gene is composed of m = 4 exons utilized by I = 3 different isoforms. Suppose that isoforms 1, 2,
and 3 compose the set of all isoforms used by this gene and that their structure with respect to the
exons is as given in the figure. Consider the exon set e := {1, 2, 3}. The read count at e is defined
as the number of RNA-Seq reads which, when mapped, overlap exons 1, 2, and 3 but do not overlap
exon 4.










Exon 1  Exon 4  
Isoform 1 
Exon 1  Exon 2  Exon 4  
Isoform 2 
Exon 1  Exon 2  Exon 3  Exon 4  
Isoform 3 
Figure 3.1: Hypothetical gene and isoform construction model.
The IsoDeconv model posits three main factors influencing the observed read count at an exon
set e within purified reference sample j of cell type k: the read depth of the RNA-seq experiment
(tkj), the length of the exon-set feature e within each utilized isoform i (xei), and the expression
levels of the isoforms used by cells of type k (γk = (γk1, ..., γkI)
′) . As discussed in Chapter 2,
RNA-seq expression is commonly corrected for read-depth and feature length. Previously, however,
the notion of feature length pertained to the length of the genes or isoforms being measured and
not to the lengths of exon sets. Sun et al. [17] extend the definition of feature length for exon-sets
and name it as effective length of an exon set. It is calculated as the expected number of starting
locations for an RNA-Seq fragment from that exon set. If an exon set is not included in an isoform,
its effective length in the isoform is set as 0. For detailed information on the computation of the
effective lengths of each exon set, please see the supplementary materials of Sun et al [17].
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The negative binomial variant of IsoDeconv models the read count at an exon set e for pure
sample j of cell type k, denoted by Ykje, in the following way:






and φk is a cell-type specific overdispersion parameter. Given the isoform activity levels γk, read
counts are assumed independent across exon sets within a single gene, across genes within a single
sample, and across different samples.
This model is extended to the heterogeneous cell type mixture by introducing cell type specific
abundance parameters. Let Y ∗ke be the unobserved read count at exon set e attributable to cells of
type k within the mixture, Ze be the observed read count of exon set e in the mixture, tm be the






Y ∗ke ∼ NB (µ = tmpkuke, φk)
Assuming that the expression of cells of type k in the mixture is independent of the expressions
across all other cell types, Ze is a convolution of independent, negative-binomially distributed
random variables with differing means and overdispersions.
3.2.2.1 Model Fit Algorithm
Model parameters are estimated through the maximum likelihood framework on a gene-by-
gene basis. Thus, an estimate of pk is obtained independently for each gene and aggregated across
genes to provide a final estimate of cell type abundance. Within a single gene, optimization proceeds
via block coordinate ascent. The steps are as follows:
(1) Assume the γk and φk are fixed, update pk.
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(2) Assume the pk are fixed, update γk and φk.
Steps (1) and (2) are cycled until convergence of the cell type proportions pk. Within step (1),
optimization of the pk proceeds using gradient-free LBFGS. A gradient is not supplied to avoid
the intractability of the likelihood and its gradient in the case of convolved negative binomials.
Optimization in step (2) proceeds using an EM algorithm described in the following section. This
algorithm relies upon use of LBFGS methodology to optimize the γk and φk.
3.2.2.2 EM Algorithm
Optimization in the setting of a convolution of negative binomial random variables is a
challenging problem. Within step (2), an EM algorithm was developed to transform the negative
binomial likelihoods into hierarchical gamma-poisson mixtures to simplify the likelihood. Define
λkje to be the unobserved mean read count at exon set A in pure sample j of cell type k and λ∗ke to









∣∣λ∗ke ∼ Pois (λ∗kje)
λ∗ke ∼ Gamma
(
ν = φ−1k , µ = tmpkuke
)
The transformation of this problem into gamma-poisson mixtures allows separation of the complete-
data log-likelihood into K components, one for each cell type, which can be optimized in parallel
when cell type proportions are fixed.
To see this, consider the complete data log-likelihood (`) given below, where: `(j)ke is the
complete data log-likelihood for pure sample j of cell type k at exon set e; `(m)e is the complete data
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log-likelihood for the mixture sample at exon set e; `C|D represents the log-likelihood for a random
variable R given another random variable D; f(·) is the density function of the specified random



















































Under the gamma-poisson framework, Ze is now a Poisson random variable conditional upon
the missing data λ∗e since it is the sum of K Poisson variates. Thus, the complete data log-likelihood













ke. As a Poisson




only depends upon the sum of the λ∗ke but does not depend on
the parameters γk or φk for any k. Thus, during optimization, this term may be discarded. For a
similar reason, the Poisson likelihoods from the pure samples may be discarded as well.
According to the EM algorithm, parameter updates proceed by maximizing a Q-function given
by Q(γ1, ..., γK , φ1, ..., φK) = E
[
`
∣∣Y11, ..., YKE, Z1, ..., ZE] where this expectation is computed
with respect to the unobserved λkje and λ∗ke. Thus, four posterior means found in the remaining
gamma log-likelihood terms are necessary for updates in the expectation step of the EM algorithm
proposed above, namely λkje, λ∗ke, log (λkje) and log (λ
∗
ke). For the missing parameters λkje, it is
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possible to define closed form posterior expectations. For the λ∗ke, no such closed forms are possible.
E[λkje
∣∣Ykje] = νk + Ykje
νk/µkje + 1
E[ln (λkje)
∣∣Ykje] = − ln(νk/µkje + 1) + Φ(νk + Ykje)
E[λ∗ke




∣∣Ze] = E [− ln(νk/µ∗ke + 1) + Φ(νk + Y ∗ke)∣∣∣∣Ze]
The latter posterior means for the heterogeneous cell type sample can be determined numerically
since Y ∗ke only has mass on the set {0, 1, ..., Ze}. A finite-summation, numerical approximation to
the distribution of convolved negative binomials is utilized to compute the necessary conditional
probabilities[58].
3.2.2.3 Simulation Study
The fit of the negative binomial variant of the IsoDeconv model was first assessed using 9 in
silico mixtures of RNA-seq expression experiments from two cell lines, GM12878 and HSMM.
GM12878 is a non-cancerous blood cell line and HSMM is a non-cancerous human skeletal muscle
myoblasts dataset, both derived from human tissues. Expression experiments for these cell lines
can be found at the Encyclopedia of DNA Elements online database (ENCODE)[59]. The fit was
characterized in the low-sample size setting where only a single reference sample is available for
estimation in each cell type.
To generate a set of simulated mixture and reference samples, two paired-end RNA-seq
experiments each of GM12878 and HSMM were downloaded from the ENCODE database. From
each cell type, read pairs overlapping chromosome 1 from a single replicate were randomly sampled
to obtain files from 1 million to 9 million reads each. These downsampled files are merged in silico
to create mixture files of 10 million reads each. Thus, to create a mixture sample of 30% GM12878
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and 70% HSMM, 3 million reads are downsampled from the GM12878 experiment and 7 million
from HSMM. Reference samples were generated in a similar manner using the remaining replicate
for each cell type.
Composition P̂G No. Clusters Restricted
(φmax ≤ 1.5) P̂G
GM - 10 / HS - 90 0.395 9 0.137
GM - 20 / HS - 80 0.456 13 0.221
GM - 30 / HS - 70 0.551 11 0.287
GM - 40 / HS - 60 0.583 10 0.475
GM - 50 / HS - 50 0.652 9 0.419
GM - 60 / HS - 40 0.708 7 0.445
GM - 70 / HS - 30 0.750 7 0.687
GM - 80 / HS - 20 0.812 7 0.788
GM - 90 / HS - 10 0.880 6 0.813
Table 3.1: Examining estimation quality under biological replicate mixture generation. Composition
defines the structure of the simulated mixture (i.e. GM-10/HS-90 refers to a sample that is 10%
GM12878 and 90% HSMM) and P̂G represents the estimated proportion of GM12878. The final
two columns discuss model estimation characteristics when the estimating gene set is restricted
to genes where maximum overdispersion between GM12878 and HSMM is limited, namely the
number of such genes available and the proportion estimate across these genes.
Reducing the estimating set to approximately 300 genes identified by Cufflinks as differentially
expressed or spliced, the model was fit to nine different simulated mixtures. Examining table (3.1),
we note that the estimation of cell type abundance was poor when the entire estimating set was
used. However, it was also noted that the estimated overdispersions for each cell type (φk) were
quite large for the majority of genes. In fact, for most samples, fewer than 10 of the 300 genes
had a maximum estimated overdispersion across GM12878 and HSMM cell types of less than 1.5.
However, by restricting to genes with lower levels of estimated overdispersion, estimates were seen
to improve (Table 3.1).
These discoveries led to the hypothesis that biological variability across samples was impacting
the results of the IsoDeconvNB model fit. It was supposed that this extra variability was entering the
model through use of different biological replicates to construct the mixtures and reference samples.
In essence, it was supposed that the cell type specific isoform abundances and gene expressions
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varied across biological replicates of a cell type. Thus, the provided reference samples differed too
much from the samples used to generate the mixture tissue. This discrepancy between the mixture
cell types and the reference cell types resulted in poor model fit and inflated the observed variances
in the exon-set level counts.
To test this hypothesis, we utilized the GM12878 cell line and a non-cancerous human mammary
epithelial cell line (HMEC) used for early model validation. A single replicate each of GM12878
and HMEC were selected for examination. While true technical replicates were not available from
ENCODE, pseudo-technical replicates were generated by randomly splitting the given files in half,
generating two non-overlapping sets of reads from each cell type and sample. Mixture files were
then produced by downsampling reads from one of these pseudo-technical replicates and combining
them in the manner discussed previously. The remaining pseudo-technical replicate was used as the
cell type reference. Due to the limited read count available in each file, the range of proportions
used for generating mixture datasets is restricted.
In addition to the use of technical replicates for cell type abundance estimation, three different
methods for restricting the estimating gene set were used. The first restriction limits consideration to
genes noted by Cufflinks as having gene-level or isoform-level differential expression. The second
restriction considers only genes with noted isoform level differential expression. Finally the last
estimating set of genes is restricted to all genes under the first restriction which have estimated
maximum overdispersions less than 1.5. These restrictions were designed to assess the impact
of different estimating sets on the quality of abundance estimates and to examine the impact of
technical replicate use on observed overdispersion.
Immediately, it is seen from table (3.2) that the quality of estimation improves dramatically
over the biological replicate simulations examined in table (3.1). All estimates hover within 5% of
the truth regardless of the estimating gene set used. Restriction sets (1) and (2) estimate similarly
across all samples, suggesting that the use of genes with gene-level expression differences only is
not damaging to IsoDeconvNB’s abundance estimates. Additionally, examining restriction set (3),
the number of available genes with estimated overdispersions less than 1.5 increased by 3- to 4-fold
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Gene or Isoform Isoform Diff. Overdispersion
Diff. Only Restriction
Composition # Genes P̂G # Genes P̂G # Genes P̂G
GM - 40 / HM - 60 354 0.398 158 0.396 42 0.403
GM - 50 / HM - 50 354 0.481 158 0.481 41 0.491
GM - 60 / HM - 40 354 0.580 158 0.581 38 0.598
GM - 70 / HM - 30 354 0.664 158 0.665 42 0.678
GM - 80 / HM - 20 354 0.760 158 0.761 32 0.801
GM - 90 / HM - 10 354 0.859 158 0.871 35 0.910
Table 3.2: Examining estimation quality under pseudo-technical replicate file generation. Results
are presented for 3 different estimating gene sets: genes with gene or isoform expression differences,
genes with isoform expression differences only, and genes with maximum overdispersions less than
1.5. # genes specifies the number of genes in the estimating set and P̂G details the estimation of the
proportion of GM12878 across these genes.
over the samples seen in table (3.1). These results suggest that the additional variability observed in
previous simulations was likely due to the use of biological replicates instead of technical replicates
in the creation of mixture and reference samples. However, due to to the limitations of the number
of quality replicates for the HMEC cell line, a direct assessment of the impact of technical replicates
compared to biological replicates is not possible in these cell lines.
Thus, a final set of RNA-seq samples were downloaded from ENCODE consisting of two
RNA-seq read experiments from biological replicates of CD20+ monocytes and two biological
replicates of GM12878 experiments. Using these experiments, two sets of reference and mixture
files were generated. In the first set, the pseudo-technical replicate approach described previously
was used to generate references and mixtures. In the second set, the biological replicate approach
described previously was used to generate references and mixtures.
Table (3.3) reinforces the idea that the quality of estimation drops dramatically when inde-
pendent biological replicates are used to produce the mixture and reference samples. While the
the number of genes with maximum overdispersion less than 1.5 does not differ much between
these technical and biological replicates, each cell type displays fewer genes with overdispersion
values less than 1.5 when comparing biological to technical replicates across the majority of the
simulations. We do note a slight discrepancy in this trend for the CD20 cell type at low proportions
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Technical Replicates Biological Replicates
Composition φG φC max(φ) P̂G φG φC max(φ) P̂G
GM - 30 / CDT - 70 41 85 13 0.274 33 58 19 0.232
GM - 40 / CDT - 60 42 69 11 0.371 40 54 18 0.210
GM - 50 / CDT - 50 50 55 19 0.452 42 51 19 0.357
GM - 60 / CDT - 40 50 46 17 0.582 50 45 21 0.380
GM - 70 / CDT - 30 69 41 15 0.658 51 40 15 0.598
GM - 80 / CDT - 20 83 22 14 0.783 63 37 13 0.710
GM - 90 / CDT - 10 108 21 14 0.895 84 30 13 0.760
Table 3.3: Examining change in estimation quality when using the various replicate strategies. φG
and φC summarize the number of genes for each cell type where the overdispersion is less than 1.5.
max(φ) refers to the number of such genes where the maximum overdispersion is less than 1.5. P̂G
considers estimation quality within the set of genes with limited maximum overdispersion (≤ 1.5)
to ensure comparability across replicate settings and previous experiments.
of CD20 in the sample. However, this is matched by a 33% and 25% increase in the number of such
genes when comparing GM12878 technical to biological replicates.
3.2.2.4 Discussion
The preceding simulations suggest that the negative binomial variant of the IsoDeconv model
is questionable for cell type deconvolution in the RNA-seq data setting. It has been demonstrated
that introducing biological variability between the mixture and reference datasets results in poor
estimation quality and a reduction in the number of minimally overdispersed genes. Rather than
expanding the estimation set to consider more genes with sufficiently low overdispersion, the
decision was made to address the extra biological variability observed by restructuring the cell
type abundance model. In particular, an alternative variant of the IsoDeconv model would need to
explicitly account for the biological variation in expression through a probabilistic mechanism for
sample-specific gene and isoform expression parameters to improve estimation. Ultimately, this
necessitated a switch to a multinomial structure for the distribution of read counts within genes
with Dirichlet distributions over gene and isoform expression parameters. It also requires multiple
purified RNA-seq reference experiments for each cell type k to capture both the mean and variance
of these parameters across independent experiments. We detail this model in the following sections.
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3.2.3 IsoDeconv - Multinomial Model with Dirichlet Penalty (IsoDeconvMM)
Pure Sample Expressions
Value Dim. Description
Ykj(E) 1× 1 Total read count outside gene of interest in pure sample j of cell type k.
YkjA 1× 1 Read count at exon set A in pure sample j of cell type k.
Ykj E × 1 Collection of read counts across all exon sets in the given gene for pure sample j
of cell type k.
γkj I × 1 Isoform expression parameters unique to pure sample j of cell type k.
τkj 1× 1 Probability that a randomly selected read maps to the gene of interest in pure
sample j of cell type k.
tkj 1× 1 The total read count in pure sample j of cell type k.
Mixture Sample Expressions
Value Dim. Description
ZA 1× 1 Read count at exon set A in the mixture cell type sample.
Z E × 1 Collection of ZA in a single vector.







ZkA∗ 1× 1 Read count at exon set A in the mixture cell type sample attributable to cells of
type k.
γ∗k I × 1 Isoform expression parameters unique to cells of type k found within the mixture
cell type sample.
τ∗k 1× 1 The probability that a randomly selected read from cells of type k in the mixture
sample maps to the gene of interest which is unique to the cells in the mixture
sample.
Cell-Type Specific and Cluster Level Parameters
Value Dim. Description
X E × I Matrix of effective lengths for each exon set within each of the isoforms.
Xij 1× 1 Effective length of gene i in isoform j.







pk 1× 1 Proportion of cell type k present in the mixture tissue.
p K × 1 Collection of abundances for each of the K cell types which compose the mixture.
αk I × 1 Hyperparameters governing average isoform expression levels and variances within
cells of type k.
βk 2× 1 Hyperparameters governing gene expression levels within cells of type k.
Value Dim. Description
◦ NA This operator indicates element-wise multiplication of two vectors.
Table 3.4: Notation for defining the IsoDeconv Model.
In order to specify the multinomial variant of the IsoDeconv model (IsoDeconvMM), revised
definitions of several parameters must be specified and additional model parameters governing gene
and isoform expression must be introduced. As before, the model specification will pertain to a
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single gene only. Each gene will be modeled independently and the per-gene cell type abundance
estimates will be aggregated afterwards.
All parameters for IsoDeconvMM have been described in Table (3.4). Several notes are
necessary to clarify the new meanings of these parameters. Firstly, the γkj values represent the
isoform expression quantities for a single sample. These expressions are interpreted as per-unit-of-
effective-length conditional probabilities that a read maps to isoform i given that it maps to the gene
which utilizes isoform i. Secondly, the gene expression parameters τ are not normalized in a manner
that allows for comparison across genes (e.g. FPKM). These parameters are raw probabilities that a
randomly selected read pair, not a randomly selected transcript, maps to the gene of interest. The
addition of the subscripts kj allows us to capture the biological variation across samples.
Using this notation, the cell type abundance model within purified reference samples can be
detailed as follows:
τkj ∼ Beta(βk)
l̃ ◦ γkj ∼ Dirichlet(αk)Ykj(E)
Ykj







where ◦ in l̃ ◦ γkj denotes element-by-element product. In the mixture tissue, then, the cell type
abundance model is given by:
τ ∗k ∼ Beta(βk)
l̃ ◦ γ∗k ∼ Dirichlet(αk)[
Z





Within the IsoDeconvMM model, independence is assumed across samples and across genes
within samples.
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3.2.3.1 Model Fit Algorithm
Within each gene, the model is fit using a staged estimation approach with three stages. In
stage one, the gene and isoform expression parameters are estimated separately for each purified
reference sample by maximum likelihood estimation. The likelihood used for stage 1 involves only
the multinomial component of equation (3.1). Under such a framework, closed form estimates of
τkj are obvious and a logarithmic adaptive barrier algorithm can be used to obtain estimates of the
γkj subject to boundary constraints. Once obtained for each cell type and sample, these estimates
are held fixed for all further stages.
Within stage 2, the estimated values of τkj and γkj are treated as observations from the Dirichlet
component of equation (3.1). Estimates of αk and βk are obtained via maximum likelihood
estimation within separate Dirichlet models. Once obtained, these estimates of αk and βk are fixed
for stage 3.
Finally, in stage three, the αk and βk estimates are used in Dirichlet distributions as penalty
functions in the estimation of the γ∗k , τ
∗





to be like those estimates obtained in the pure cell type samples. Use of an EM algorithm allows
separation of the full likelihood intoK+1 independent components. The firstK components pertain
to the isoform expression parameters from each of the K cell types. Each of these components
is optimized using a Newton-Raphson algorithm on the log (γ∗k) until convergence of isoform
parameters. The last component contains information regarding the pk and log(τ ∗k ) values, which
are optimized using a quasi-Newton’s method optimization procedure (BFGS). Estimation is seeded
at various start points to identify global maxima. The EM algorithm is iterated until convergence in
the proportion estimates. Proportion estimates across multiple genes are then aggregated using the
spatial median to obtain final estimates of cell type proportions.
3.2.3.2 Explaining Modeling Decisions
Several facets of the preceding discussion deserve illumination. First, consider the switch from
the negative binomial model to the Multinomial-Dirichlet model. In order to incorporate the isoform
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expression parameters as conditional probabilities, the model within a gene must condition on the
number of reads mapped to that gene in the purified reference samples. Supposing this conditioning
is performed and that an independent negative binomial distribution is assumed at each exon set,
the likelihood becomes inconsistent. This arises because the independent negative binomials could
theoretically exceed the read count upon which the model is conditioned. The multinomial model
maintains its consistency despite the conditioning argument.
Secondly, the use of the described staged estimation approach became necessary after an
initial version of the model, which attempted to estimate αk and γk values simultaneously, proved
intractable. This approach led to unstable estimates of the γk and αk parameters wherein the αk
parameters became unbounded. This would suggest little to no variability in the isoform expressions,
an impossibility in the simulated data upon which the model was tested.
Finally, the incorporation of the log(τ ∗k ) and log(γ
∗
k) transformations was performed after initial
testing with untransformed parameters proved inaccurate. “Hill-climbing” estimation methods such
as Newton Raphson and BFGS require that the likelihood is sufficiently stable across the parameter
space so that the crest of the “hill” is not continually overstepped. The proposed optimization
approach is more stable with respect to the log parameters since the log scale spreads out the small
parameter values. Under these reparametrizations, model accuracy and the mobility of proportion
estimates improved.
3.2.3.3 Simulation Study
In order to evaluate the fit properties of the IsoDeconvMM model, a simulation study was
conducted for the two cell type case. To ensure that simulated gene- and isoform-construction
models are sufficiently complex, the models estimated from the GM12878 and HMEC data are
utilized as the “true” constructions from which to simulate. These simulations seek to capture the
influence of three factors on model fit: variability in isoform expression across subjects, the number




































































































































3 Pure Samples per CT
Simulation Results






































































































































50 Pure Samples per CT
Simulation Results
(b) 50 replicates per cell type
Figure 3.2: (a) Simulation Results for 3 replicates per cell type (b) Simulation Results for 50
replicates per cell type.
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Simulations are conducted as follows. Suppose that there are 3 purified references per cell
type and that 100 genes will be utilized for estimating cell type proportions. Across these 100
genes, gene expressions will be simulated from a normal distribution with a mean of 130 reads
and a standard deviation of 33. Gene- and isoform expressions will be simulated as described in
the supplementary materials. Of note, the variabilities in isoform expression are set to ensure that
90% of observations fall within X% of the cell-type average where X is allowed to vary from 55 to
100%. To simulate cell-type differences in average isoform expression profiles, average isoform
expression levels are permuted to ensure that there is no overlap in the top 2 or 3 isoforms used by
each cell type.
The results of these simulations are displayed in Figure (3.2). Here we see that IsoDeconvMM
provides strong results across the range of parameters tested. In addition, the results appear
consistent with expectations regarding the effects of larger gene set size and increased isoform
expression variability. As one incorporates more genes into the estimation set, the accuracy and
stability of the estimator improves. As one increases the variability in isoform expression, the
accuracy and stability of the estimates decrease.
We do note that there is decrease in the accuracy of the model when one moves from 3
references per cell type to 50. This counterintuitive result is likely due to the following. Consider
the 3 reference sample case. When one draws these 3 samples very little of the support of the
underlying reference distribution is interrogated. Thus, while drawing three subjects may increase
the variability across repeated sampling, the probability of drawing three highly similar subjects
is greater than the probability of drawing 50 highly similar subjects. In this way, the model’s
perception of variance may decrease for genes in the 3 reference sample setting causing stronger
penalties than those in the 50 reference sample case.
3.2.3.4 Discussion
We have presented two formulations for the IsoDeconv model for cell-type abundance es-
timation utilizing isoform expression information from RNA-seq data. IsoDeconvNB, the first
37
variant, was a direct extension of the IsoDot framework proposed by Sun et al [17]. Extensive study
of simulated mixtures generated from genuine RNA-seq read experiments found that estimation
was sound only in the limited variability setting, as was the case when references and mixtures
were generated from non-overlapping samples from a single read experiment. The introduction
of additional variability due to the use of biological replicates saw diminished performance and
an increased perception of variability in exon-set level counts. Due to the limited availability of
RNA-seq experiments performed on purified samples of various tissues, it was decided to extend
the IsoDeconv model to explicitly incorporate biological variation.
The second variant of the IsoDeconv model, IsoDeconvMM, involved a major restructuring
to allow for subject-specific gene and isoform expressions. This restructuring necessitated a shift
to a multinomial framework to maintain coherence in the proposed likelihood. The behavior of
IsoDeconvMM was explored via simulation study. IsoDeconvMM was found to provide quality
estimates of cell type proportions via simulation across a range of simulated parameters. The
impact of increased isoform expression variability and diminished gene set size were consistent
with expectations. Increasing the number of purified reference samples resulted in a counterintuitive
result wherein increasing sample size saw decreasing stability in the proportion estimates.
Future research regarding IsoDeconvNB and IsoDeconvMM should focus on two primary
avenues: decreasing the computational complexity and refining their application to real data.
Both IsoDeconvNB and IsoDeconvMM are computationally complex algorithms. In the case of
IsoDeconvNB, the convolution of negative binomial models with differing means and variances is a
particular challenge. In this setting, we utilized numerical approximations techniques proposed by
[58]. Such a technique introduces approximation error as well as high computational cost due to the
need to compute large sums for K different cell types with each update. The multistage modeling
approach used by IsoDeconvMM and the need for multiple estimation start points creates a slow
down in model optimization. Future study will need to address these complexities to improve the
behavior and time to solution for the model in each gene.
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In addition, both IsoDeconvNB and IsoDeconvMM have shown limited utility in the real data
setting. IsoDeconvNB’s behavior has been thoroughly catalogued in the simulated mixture profiles
developed from real data. IsoDeconvMM was also applied to such a dataset composed of CD8+
T-cell and CD4+ T-cell mixtures from real data with 3 pure sample references per cell type[60].
Results were highly unstable with the majority of genes optimizing at proportions of 0% CD8+
T-cells or 100%. Exploration to uncover the cause of this behavior is needed. It is suspected that this
behavior could result from the limitations of the current pipeline to identify genes with differential
expression of isoforms in the low replicate setting when two highly similar cell types (e.g. CD4+
and CD8+ cells) are considered. Without reliable information regarding which genes experience
differential isoform expression, the model cannot be expected to perform well.
Finally, future research should examine simplifying the IsoDeconv framework to account for
highly similar isoforms. Consider the design matrix X for any gene. Isoforms which differ by
the removal of a single exon are likely to induce high correlation in X . This instability in the X
matrix can cause unreliable isoform expression estimation which may influence model estimates. To
this end, a consideration of the IsoDeconv framework which could model groups of highly similar
isoforms or even utilize some form of dimension reduction (e.g. PCA) could improve model fit and
time to solution.
Please see Appendix 1 for the mathematical supplement for this chapter. This supplementary
material contains additional information regarding model optimization, the mathematical founda-
tions behind IsoDeconvNB and IsoDeconvMM, and additional information regarding the simulation
structure for IsoDeconvMM.
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CHAPTER 4: ICED-T PROVIDES ACCURATE ESTIMATES OF IMMUNE CELL
ABUNDANCE IN TUMOR SAMPLES BY ALLOWING FOR ABERRANT
GENE EXPRESSION PATTERNS
4.1 Introduction
The evolving relationship between a cancer and its host’s immune system is well summarized
by a hypothesis known as immunoediting. Immunoediting stresses that the immune system not only
suppresses tumor cells, but also shapes tumor immunogenicity in ways that may promote tumor
growth [32, 61]. For example, consider the relationship between tumors and tumor-infiltrating T
cells. Infiltrating T cells can be cytotoxic, contributing to death of cancer cell populations. However,
these T cells express immune checkpoints which inhibit their function; such checkpoints prevent the
immune system from indiscriminately attacking healthy host cells. Under selective pressure from
the immune system, cancers can evolve defense mechanisms which activate immune checkpoints
and thereby limit the anti-tumor activity of the infiltrating T cells.
Early strategies in immunotherapy were developed based on the insights of immunoediting [35].
Among the best known immunotherapy strategies, immune checkpoint inhibitors block immune
inhibition pathways that restrict effective anti-tumor T cell responses [62]. Checkpoint inhibitors
have achieved phenomenal successes in a fraction of cancer patients, exhibiting response rates
around 40% and 20% for melanoma and lung cancer, respectively [63]. It is of great clinical
interest to identify the subset of cancer patients who may respond to checkpoint inhibitors. Use of
tumor-infiltrating immune cells to predict clinical response to therapy has shown promising results.
Previous studies have shown that the patients with CD8+ T cells around tumor cells have higher
response rate to checkpoint inhibitors [64]. In addition to benefiting development of precision
immunotherapies, immune cell composition estimates of tumor samples have also demonstrated
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prognostic value [38, 39]. Therefore, studying immune cell composition in tumor samples is timely
and potentially has high impact on cancer research.
Several groups have studied immune cell composition using gene expression data from bulk
tumor samples [40, 41, 65, 25, 43, 44]. These pioneering works have demonstrated promising
results, but also bear some limitations. For example, a subset of these works estimate immune
cell presence using the expression of few genes [40, 41], or calculate average expression of the
genes with cell type-specific expression[42] instead of estimating immune cell composition. As
an alternative, several methods have been proposed to estimate immune cell composition using a
regression-based approach, with gene expression from bulk tumor samples as the response variable
and reference gene expression from purified cell types as covariates. CIBERSORT [25] employs
support-vector regression. TIMER [43] uses a linear regression and removes the genes with very
high expression due to their strong influence on model fitting. EPIC [44] is the most recent work. It
uses weighted linear regression to give the genes with lower expression variation higher weights.
These regression-based methods, when applied to tumor expression data, explicitly or implicitly
assume that they start with a set of genes that have negligible expression in tumor cells, and that the
expression of immune cells are conserved between purified reference samples and tumor samples.
These assumptions are questionable as many environmental factors that affect gene expression may
differ between tumor and reference samples.
In this paper, we propose a new statistical method for cell type deconvolution entitled ICeD-T,
which stands for Immune Cell Deconvolution in Tumor tissues. ICeD-T is an extension of existing
regression based methods [25, 43, 44] with two major novel features designed to overcome the
limitations of these methods.
First, ICeD-T employs a likelihood based framework, which assumes that gene expression fol-
lows a log-normal distribution. Previous work has shown that deconvolution should be performed on
linear-scale instead of log-scale of gene expression data since linear-scale mixing of gene expression
better captures the biological realities of cell mixing in a bulk tissue sample [66]. However, since
gene expression variation increases with expression level, genes with higher expression may become
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outliers with great influence on linear scale deconvolution models. Therefore one may need to
remove genes with high expression for robust deconvolution analysis [43]. The log transformation,
often used in expression studies, enjoys variance-stabilizing and skew-mitigation properties which
counteract this relationship in expression data [67, 68]. ICeD-T is able to perform gene expression
deconvolution on the linear-scale while simultaneously incorporating the beneficial properties of
the log-transformation through our method design and the use of log-normal distribution.
Second, ICeD-T automatically identifies the genes whose expressions in tumor samples are
inconsistent with reference profiles due to altered immune cell behavior in the mixture or unexpected
tumor cell expression. Within its estimation algorithm, ICeD-T down-weights the contribution of
such genes in cell type abundance estimation using a mixture model that separates all the genes into
two groups: an “aberrant” group and a “consistent” group.
4.2 Statistical Methods
4.2.1 The Input Data
While ICeD-T can be applied on microarray data, we focus mainly on RNA-seq data as it is
more popular now and in the foreseeable future. We assume that RNA-seq data from bulk tumor
samples are available for n independent subjects. Gene expression from purified samples may be
pre-computed or processed from raw RNA-seq data of multiple replicates for each cell type. Across
reference expression profiles and bulk samples, the RNA-seq measurements of gene expression
are appropriately normalized in a consistent manner using FPKM, FPKM-UQ, or TPM. More
specifically, to calculate FPKM, we divide gene expression (# of RNA-seq fragments) by total
number of mapped fragments (in millions) and the gene length (in kilo bases). FPKM-UQ is a
variant of FPKM where sample-specific read-depth is measured by 75 percentile of gene level
fragment counts across all genes, instead of the total number of mapped fragments. TPM reverses
the order of the two normalization steps. It first divides the gene-level fragment counts by gene
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length, and then divides it by the summation of gene-length corrected fragment counts across all
genes.
Additional information utilized by ICeD-T’s deconvolution model includes a pre-selected gene
set (ideally, genes with immune-specific expression) and tumor purity, if available. Several such
gene sets have been prepared by previous work, such as the gene sets used by CIBERSORT of EPIC
[25, 44]. Provision of tumor purity is optional, and it can be computed, for example, using somatic
copy number aberration data [69].
4.2.2 Statistical Model
Specification of the ICeD-T model begins with a consideration of expression behavior in
purified references samples of constituent cell types. Denote by Zjkh the expression of gene j in the
h-th purified sample of cell type k. ICeD-T assumes that the Zjkh follows independent log-normal
distributions, given by:
log(Zjkh) ∼ N (µjk, σ2jk), (4.1)
where
E[Zjkh] = γjk = exp(µjk + σ
2







Therefore, the distribution parameters for each cell type’s gene expression (e.g., µjk and σ2jk) may
be estimated by the mean and variance of the log-transformed Zjkh values. Once estimated, these
parameters represent expression profiles for each cell type in our deconvolution model. Optionally,
ICeD-T accepts previously computed profiles which would replace the γjk above.
Shift focus to the n bulk tumor samples. Assuming that each sample is composed of K immune
cell types and other extraneous cell types, the expression of gene j in bulk tumor sample i - denoted
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where Xijk represents the expression of gene j for cells of type k in the i-th sample, and ρik is
the proportion of expression attributable to cell type k. The residual error εij represents signals
from other cell types (e.g., tumor cells) or random noise. If tumor purity information is provided,∑K
k=1 ρik = 1− ρiT , where ρiT is tumor purity. If tumor purity is not provided,
∑K
k=1 ρik ≤ 1.
One potential question for the above deconvolution model is: if we only consider genes
expressed in various immune cells, and assume these genes are not expressed in other cell types
(e.g., tumor cells), shouldn’t
∑K
k=1 ρik = 1? This is not true because gene expressions were
normalized by FPKM or TPM using genome-wide gene expression data. Therefore, the expression
of a immune-specific gene is affected by the expression of other genes. For example, if tumor purity
is high, then the expression of some other genes that are expressed in tumor are high, and thus after
FPKM or TPM normalization, the expression of those immune genes are relatively lower, which
will lead to smaller values of ρik estimates, hence reflecting the fact of higher tumor purity.
We begin to develop the probabilistic framework utilized by ICeD-T to model the relationship
posited above by first assuming that there are no aberrant genes (i.e. gene expression of each
cell type in reference samples is consistent with gene expression in tumor microenvironment).
Under such an assumption, Xijk has the same distribution as the Zjkh for any i, h, and j (i.e.
Xijk ∼ Zjkh). The summation of independent log-normal random variables does not have a closed















and ∆j is the weight for the j-th gene.
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The approximation used above is based upon the Fenton-Wilkinson approach which states that
the summation of log-normals can be approximated by another log-normal whose parameters are
obtained via moment-matching [70]. Under a strict Fenton-Wilkinson approach, the distribution of
Yij would be given by:





















We replace the variance structure posited by Fenton-Wilkinson with the weighted variance model of
equation (4.3) as the weighted model demonstrated improved fit and stability in simulated data.
Regarding the variance weights used by ICeD-T, we implement two different options. One
assumes a homogeneous weight for all genes, i.e., ∆j = 1 for all j. Later we refer to this option as
“No Weights”. The second option for the weight of each gene is termed maximal variance weights
or “Max Var Weights”. To define maximal variance weights, let σ∗2j be the maximum expression















Thus, a gene’s weight compares its maximal expression variance to the median of all such maxima
across genes. Under this construction, genes with larger variances will have larger variance weights.
Larger variance weights ensure that residuals from such genes will have smaller impact on estimation
of cell type composition.
The ∆j specified above require slight modification to improve stability of the model fit. Unad-
justed, this procedure can provide some genes with excessively small variance weights and some
genes with excessively high variance weights. To control this extreme behavior, the bottom 15% of
variance weights are replaced with the 15th percentile variance weight across all genes. Similarly,
the top 15% of all variance weights are replaced by the 85th percentile variance weight. In this way,
no genes are allowed to become too minimally or maximally important to model fit.
Return to the specification of Yij in equation (4.3). Now assume that some genes in the dataset
are aberrant. For aberrant genes, ICeD-T borrows the expression structure proposed for consistent















−∆jσ2iA and σ2iA > σ2iC .
By allowing aberrant genes to have larger variance, the ICeD-T model flattens the likelihood for
such genes, and thus down-weights their contributions to cell type proportion estimates.
Direct use of the likelihoods provided by equations (4.3) and (4.4) within bulk data is impossible
since it is unknown whether a gene is consistent or aberrant a priori. Thus, ICeD-T must model
expression at any gene as a mixture of the log-normal distributions pertaining to consistent and















where LN denotes the density function of a log-normal distribution, and pi and 1− pi denotes the
proportion of genes being consistent and inconsistent, respectively. This likelihood function can be
maximized using an EM algorithm. Missing data necessary for the EM algorithm is introduced in
the form of class membership indicators Hij , where Hij = 0 or 1 denotes an aberrant or consistent



























where nG is the number of genes used in our model.
Within each EM step, maximization of Q function with respect to (ρi1, ..., ρiK , σ2iC , σ
2
iA) and
pi are separable. Given the other parameters, the estimate of pi has a closed form. Given pi, the
remaining parameters are grouped into two blocks: the mixture proportions ρik’s (block 1) and the
two variance parameters (σ2iC , σ
2
iA) (block 2), and the parameters of two blocks are iteratively up-
dated. Given the estimates of (σ2iC , σ
2
iA) , the mixture proportions ρik are estimated using numerical
optimization (the BFGS algorithm) while the constraints are incorporated using the Augmented
Lagrangian method (R function auglag). Given the estimates of the mixture proportions ρik, the
two variance terms (σ2iC , σ
2
iA) are involved in separate pieces of the complete data log-likelihood,
and thus can be estimated separately. Given variance weights, each of σ2iC and σ
2
iA is estimated by
numerical optimization (R function optimize). Without variance weights, they can be estimated
by closed form. See Appendix B Section 1.5.2 for details of the parameter estimation steps.
The ρik’s estimated by any regression based deconvolution approach should be interpreted as
the proportion of gene expression contributed by certain cell types. If one seeks to estimate the
proportion of cells, these ρik’s should be adjusted by cell size factors. We borrow the cell size
factors, denoted by sk, from Racle et al. [44] and construct revised relative abundance of immune
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cell types by ρ∗ik = (ρik/sk)/
∑K




We conducted a simulation study to evaluate the performance of ICeD-T, CIBERSORT, and
EPIC. For each method, we seek to assess the estimation accuracy and the robustness of estimation
in the presence of aberrant gene behavior. For ICeD-T only, we also assess its ability to identify
aberrant genes.
We simulated reference expression of 250 genes for 5 cell types: one tumor cell type and four
immune cell types. Our simulations assume that these 250 genes were selected to be expressed
in immune cells but not tumor cells. When there are no aberrant genes, the expression of these
250 genes in a bulk tumor sample was simulated by mixing the 4 immune cell types with known
proportions. For each gene, we assume it is expressed in one of the four immune cell types and has
low/background expression in the other three immune cell types. To better mimic the complexity
of real data, we do not assume one homogeneous background expression. Instead, we assume the
background expression has a three-tiered scale to reflect lowly, moderately or highly expressed
genes (range: 2.0-8.0). Average log-transformed expression for the expressed cell type is simulated
from by an up-shift of background expression level (range: 3.5-9.0). See Supplementary Materials
Section B.1 for more details. Using RNA-seq expression data from immune cells taken from
Linsley et al. [60], a mean-variance relationship was computed from FPKM-UQ normalized data
across immune specific genes. The simulated average expression profiles are then mapped to a
corresponding variance using this relationship with allowance for random error. Fifteen reference
samples were simulated for each cell type from its unique expression profile using a log-normal
distribution.
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To generate the expression of a bulk tumor sample, a tumor purity value was simulated from
a normal distribution (mean=0.60, sd=0.15) and truncated at endpoints of 0.17 and 0.95. The
remaining immune cell proportions were then simulated from a Dirichlet distribution with average
abundances ranging from 15% to 40%. For each gene in the bulk tumor sample, its expression in
each immune cell type was simulated from a log-normal distribution and a weighted summation
of these expression values was computed as the expression in the bulk tumor sample. These gene
expression profiles are then perturbed to account for aberrant behavior. Zero or approximately
twenty percent of genes were randomly selected as aberrant genes. Among them, 25% have down-
regulated expression in the highly expressed cell type, 25% have up-regulated expression of the
highly expressed cell type, and 50% have expression in tumor cells at a background level. See
the Appendix B for further details regarding the construction of these simulations and additional
simulation results.
The expression profile of each cell type was estimated from the 15 simulated samples of that
cell type. This reference is used for deconvolution in each of the following models: ICeD-T without
variance weights, ICeD-T with variance weights, LNORM with variance weights, CIBERSORT
(version Jar 1.06), and EPIC. LNORM is a variant of the ICeD-T model which does not consider
aberrant gene behavior.
When there is no aberrance in gene expression, all methods perform well, while ICeD-T
provides the most accurate estimates of cell type proportions (Figure 4.1). When 20% of the 250
genes are aberrant, the performance of LNorm, EPIC, and CIBERSORT all become worse, while
the performance of ICeD-T method remain similar (Figure 4.2). Both EPIC and LNorm’s cell
type proportion estimates suffer from bias and larger variance in the presence of aberrant genes.
CIBERSORT still performs relatively well, but has an apparent inflation of the estimation variance.
While the weighted variant of ICeD-T provides the best results, both weighted and unweighted
ICeD-T are able to maintain high accuracy with minimal estimation variance (Figure 4.2(a)-(b)).
To identify aberrant genes, ICeD-T computes the posterior probability of a gene being consistent.
Examining the distribution of this quantity across consistent and aberrant genes, we see that both the
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Figure 4.1: Visualized results of model fits on simulated data without aberrance. Figure (f)
summarizes the accuracy across all 135 subjects for each model.
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Figure 4.2: Visualized results of model fits on simulated data when∼ 20% of the genes are abberant.
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Figure 4.3: (a) The posterior probabilities of being consistent for those aberrant genes. (b) The
posterior probabilities of being consistent for those consistent genes. (c) Estimates of the proportion
of consistent genes.
weighted and unweighted versions of ICeD-T separate consistent and aberrant genes reasonably well
(Figure 4.3). The weighted variant of ICeD-T provides more accurate estimate of the proportion
of aberrant genes, and identify consistent genes with higher confidence. For aberrant genes,
the posterior probability of being consistent show a bi-modal distribution, implying that a small
proportion of aberrant genes are missed. This is partly due to our very challenging simulation
setting, with three types of aberrant patterns and three tiers of expression levels for background
genes. Such three tiers of background diminishes the difference between background cell types and
expressed cell types, and further complicates the identification of aberrant genes.
4.3.2 Validation in Microarray Expression of PBMCs
In the CIBERSORT paper, Newman et al. [25] described the collection of peripheral blood
mononuclear cell (PBMC) gene expression data from 20 healthy adults. After extraction of PBMC
samples from each subject, these samples were subjected to microarray expression analysis and
flow cytometric measurement to establish ground-truth cell type proportions. We use this dataset to
evaluate our method and compare its performance with CIBERSORT and EPIC.
To be consistent with the approach used by Newman et al. [25], we use the their LM22
reference of cell type-specific gene expression for all methods. The LM22 reference matrix is
derived from microarray gene expression data, and thus is consistent with the gene expression
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platform of the bulk tissue samples. EPIC had developed its own reference matrices from RNA-seq
data (TRef for bulk tumor samples and BRef for bulk normal samples), but they are inappropriate in
microarray settings. Because EPIC and ICeD-T both require that the gene expression from bulk
samples and reference samples are measured on the same scale, gene expression data from bulk
samples were quantile normalized to a target distribution established by the reference samples used
to derive the LM22 matrix. The results of each method are then restricted to the nine cell-types
examined in Newman et al. [25]: naive B-cells, memory B-cells, CD8+ T-cells, naive/memory
resting/memory activated CD4+ T-cells, γδ T-cells, Natural killer cells, and monocytes. Estimates
for each mixture sample are renormalized so that their summation equals 100 after correction for
cell size of different cell types. The accuracy of each method is assessed by comparing sums of
squared errors and correlations between the expression-based cell type proportion estimates and
flow-cytometry estimates. Correlations are computed by pooling all cell type proportions for all
subjects and all cell types.
Model SSE Cor
ICeD-T (no weight) 13.10 0.53




ICeD-T (no weight) 10.48 0.75
ICeD-T (w/ weight) 9.44 0.78
CIBERSORT 11.02 0.77
EPIC 32.01 0.18
Table 4.1: Validation of immune cell proportion estimates by flow cytometry for 9 cell types [left]
and 6 cell types after grouping naive B-cells and memory B-cells as B cells, and naive/memory
resting/memory activated CD4+ T-cells as CD4+ T cells [right].
Examining the results of the 9 original cell types, ICeD-T provides the most accurate estimates
of cell type proportions in terms of sum of squared errors. CIBERSORT, on the other hand, provides
the most accurate estimates with respect to the correlations (Table 4.1, Figure 4.4). However, the
superior correlation of CIBERSORT is due in part to several cell subsets with positive correlations
but severe bias (e.g. memory activated CD4 T-cells, memory resting CD4 T-cells) (Supplementary
Materials Section C.4). After grouping a few highly similar cell types (e.g., grouping naive B-cells
and memory B-cells as B cells, and naive/memory resting/memory activated CD4+ T-cells as CD4+
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(b) ICeD-T (with weight)
Figure 4.4: Comparison of cell type proportion estimates by CIBERSORT and ICeD-T versus the
cell type proportions measured by flow cytometry. Red lines indicate the least squares model fit to
the estimated immune proportions.
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proportion estimates and flow-cytometry estimates while maintaining the smallest sum of squared
errors (Table 4.1, Figure 4.4). In this dataset, EPIC has very poor performance, which may be due
to the fact that it is designed for RNA-seq data.
4.3.3 Flow Cytometry Validation in Melanomas
In the EPIC paper, Racle et al. [44] obtained metastatic melanoma samples from the lymph
nodes of four patients with stage III melanomas. A portion of each of these samples was used for a
flow cytometric analysis while the remaining portion was used for bulk RNA-sequencing. Results
from flow cytometry were used to establish a ground-truth cell type composition. TPM-normalized
RNA-seq expressions and flow cytometry measured compositions were extracted directly from the
EPIC R package.
We used EPIC’s TRef matrix as reference gene expression for both EPIC and ICeD-T. ICeD-
T was run in four different modes, with or without variance weights (denoted by wY and wN,
respectively) and with or without sample purity as part of the inputs (denoted by pY and pN,
respectively). For this analysis, purity is defined as the proportion of non-immune content plus the
proportions of cells not assessed via flow cytometry (e.g. Macrophages, CAFs, and Endothelials,
and others). CIBERSORT was fit using both the LM22 and TRef matrices directly to the TPM data.
All cell type proportion estimates were corrected by cell size factors reported by Racle et al. [44].
To allow comparison of ICeD-T and EPIC with CIBERSORT that only computes relative immune
cell abundance estimates, we obtain relative proportions for all methods by normalizing cell type
proportions so that they add up to 1.
Overall EPIC provides more accurate estimates of the total proportion of all immune cells,
while ICeD-T provides more accurate estimation of the relative proportions of immune cells among
the modeled immune cell types (Table 4.2, Figure 4.5). Comparing non-relativized proportions of
the remaining immune cells, ICeD-T (pY, wY) improves upon EPIC’s fit in terms of the overall


































































Figure 4.5: Plots of EPIC and ICeD-T model estimates against flow cytometry estimates. ICeD-T is
fit using variance weights and sample purity.
Model LAU125 LAU1255 LAU1314 LAU335
CIBERSORT (LM22) 0.12 0.16 0.003 0.010
CIBERSORT (TRef) 0.32 0.10 0.021 0.095
EPIC 0.86 0.15 0.066 0.013
ICeD-T (pN, wN) 1.03 0.10 0.042 0.003
ICeD-T (pN, wY) 1.07 0.14 0.005 0.004
ICeD-T (pY, wN) 0.85 0.08 0.039 0.008
ICeD-T (pY, wY) 0.85 0.14 0.020 0.002
Table 4.2: Sum of Squared Errors for relative immune proportions among all immune cell types.
ICeD-T fits are labeled with (pX, wX) to indicate use of purity (pY=Yes and pN=No) and weight
(wY=Yes and wN=No).
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We also evaluated the performance of CIBERSORT versus the flow cytometry estimates.
Compared with other methods, CIBERSORT has comparable or less accurate estimates of cell
type proportions in three subjects, but much better performance than the other methods in subject
LAU125 (Table 4.2). Based on flow cytometry estimates, this subject has somewhat unexpected
immune cell proportion: almost entirely B-cells. All methods perform much worse in this subject
than other subjects, with larger sum squared errors. CIBERSORT has relatively better performance
for this challenging subject could be due to a combination of its objective function and use of LM22
reference matrix. CIBERSORT’s performance becomes worse when using LM22 instead of TRef
as reference matrix, though it still has much smaller sum squared error than EPIC and ICeD-T.
In addition, we also compare the cell type proportion estimate of one cell type across subjects.
This is arguably more interesting when we want to use immune cell composition as predictor or
treatment response. The limited sample size of this dataset does limit our ability to make comparison,
though we do note that ICeD-T provides the best fit for the CD8+ T-cell subset across subjects
(Supplementary Materials, Section D.3). CIBERSORT and EPIC particularly struggle to capture
the CD8+ T cell proportion for subject LAU1255.
4.3.4 Application to anti-PD-1 Immunotherapy Data
Finally, we use ICeD-T, CIBERSORT, and EPIC to analyze an RNA-seq dataset from bulk
tumor samples of melanoma patients [71]. The RNA-seq data are available in 28 patients before
treatment with pembrolizumab. We seek to predict treatment response (Complete Response, Partial
Response, or Non-response) using CD8+ cell type composition estimated by each of the three
methods.
Fastq files of RNA-seq data were downloaded from NCBI Sequence Read Archive, mapped
to human genome (hg38) and the number of RNA-seq fragment per gene were counted. Then
such counts were normalized by TPM. We ran EPIC and ICeD-T using the TRef reference gene
expression data. ICeD-T was fit without using tumor purity as this information was not available.
CIBERSORT was fit using LM22 reference matrix. Abundance estimates across each method are
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corrected using EPIC’s cell type size factors. In addition, to ensure comparability across all methods,
immune cell proportions are renormalized so that their summation equals to 1.
Differences in relative CD8+ T-cell abundance across response categories was assessed using a
Jonckheere-Terpstra test for trended differences. The Jonckheere-Terpstra test can be considered
as an extension of non-parametric ANOVA tests (e.g. Kruskal-Wallis) to allow greater power to
detect ordered population differences [72]. Previous studies have shown that those cancer patients
with more CD8+ T cells within tumor microenviroment are more likely to respond to anti-PD-1
treatment [73]. Thus, as one moves across response categories from most to least responsive to





































































































































































































































































(c) ICeD-T (No Weight) (d) ICeD-T (Max Var Weight)
Figure 4.6: Comparison of model fits to PD-1 Immunotherapy Data
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CIBERSORT and EPIC capture the expected relationship between CD8+ T cell proportion and
immunotherapy response to some extent, but have trouble in separating the members of at least
two groups. For CIBERSORT, individuals in the partial response group behave similarly to those
in the progressive disease group. For EPIC, individuals in the complete response group behave
similarly to those who exhibited partial response. The Jonckheere-Terpstra tests provide numerical
confirmation of these difficulties as the tests are not significant, with p-values for CIBERSORT and
EPIC being 0.30 and 0.14, respectively.
ICeD-T, on the other hand, provides clear visual distinction between these three groups show
less CD8+ T cells for those who do not response to anti-PD-1 treatment. This relationship is
reinforced through consideration of the significant Jonckheere-Terpstra test (p=0.038). Introduction
of variance weights further separates these categories (p=0.017), but does so at the expense of inflated
contributions of CD8+ T-cells to the immune response in the TME. Cell type proportions estimates
by either versions of ICeD-T have higher within group similarities than either CIBERSORT or
EPIC.
4.4 Discussion
In this paper, we have outlined a novel statistical method for immune cell expression decon-
volution within tumor tissues, ICeD-T. ICeD-T utilizes the variance stabilizing properties of the
log-transformation while simultaneously controlling for aberrant gene behavior within the tumor
tissue. In addition, ICeD-T incorporates a variance weighting structure which diminishes the
impact of highly variable genes on abundance estimation. Optionally, ICeD-T can refine cell type
abundance estimation through use of tumor purity information, if available.
We have demonstrated that ICeD-T is an accurate model in both simulated and real datasets. The
robustness of ICeD-T to misbehaved genes and its ability to identify these genes was demonstrated
in simulated data. ICeD-T’s accuracy was reinforced in real datasets using both microarray and
RNA-seq expression where it was consistently a top performer compared with other methods.
In particular, it was noted that ICeD-T can provide more accurate estimates of the CD8+ T-cell
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proportions than other methods. We applied ICeD-T to study the relation between CD8+ T cell
proportion and response to anti-PD-1 immunotherapy and found significant associations between
CD8+ T cell proportions and patients’ response to immunotherapy.
There is room to further improve the performance of ICeD-T. One direction is to refine the
reference matrix of cell type-specific gene expression. In this paper, we have adopted the reference
gene expression matrix (TRef) used by EPIC’s. TRef was constructed using single cell RNA-seq
(scRNA-seq) data from melanoma cancer samples. Cell type-specific expression was estimated
by pooling cells of the same cell types, identified by clustering method. However, some technical
limitations of scRNA-seq, such as dropout (expression of many genes were measured at 0 while
they may be lowly expressed) [74]. Careful examination of such effects may improve the reference
matrix of cell type-specific gene expression. On the other hand, techniques for scRNA-seq are a
very active research area. New techniques and new data (e.g. Human Cell Atlas [75]) may help
generate higher quality data for such a reference matrix.
Another future direction to improve ICeD-T is to refine the the variance weights. We have
implemented the variance weight for each gene based on the maximum of cell type-specific
variances. Other options that use the variances across all cell types may be more desirable. As is,
some minimally variable genes may be overweighted since the maximal variance was utilized for
weights. By refining the weighting structure, the perception of gene-expression variance in the
mixture could improve and allow for genes to contribute to cell type composition estimation in a
way which more closely mirrors their true behavior. However, with limited cell type-specific gene
expression data, we have not yet identified a clear choice.
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CHAPTER 5: MAPPING TUMOR-SPECIFIC EXPRESSION QTLS IN IMPURE
TUMOR SAMPLES
5.1 Introduction
Genetic variants (e.g. Single Nucleotide Polymorphisms (SNPs)) that are associated with the
expression of one or more genes are referred to as gene expression quantitative trait loci (eQTLs).
Genome-wide eQTL study is a powerful tool for understanding the functional roles of genetic
variants. For example, eQTL analyses can help interpret the results of genome-wide association
studies (GWASs) [46].
There are two types of eQTL, cis-eQTL and trans-eQTL [47, 48], which are distinguished
by the pattern of expression change they induce. To precisely define these eQTL types, we first
define the term “allele”. Consider a diploid genome, which has two homologous copies of each
chromosome: a maternal copy and a paternal copy. As such, each genetic locus (e.g., a SNP or
a gene) has two copies within a cell, which are referred to as the two alleles of this locus. For a
gene affected by a cis-eQTL, the expression of each allele is moderated by the genetic content of
the corresponding homologous chromosome, which leads to allelic imbalance of gene expression.
In contrast, for a gene affected by a trans-eQTL, the expression of both alleles are modified to the
same extent.
The concepts of cis- and trans-eQTLs are crucial to our method development, and thus we
further illustrate them by two examples. Consider a cis-eQTL, which is a SNP with A and T alleles.
The A allele inhibits the binding of a transcription factor, which up-regulates the expression of a
nearby gene. In contrast, the T allele does not affect transcription factor binding. If we refer to the
two alleles of this gene by A or T allele (based on known phase between this cis-eQTL and and the
nearby gene of interest), this cis-eQTL leads to lower expression in the A allele than the T allele.
An example of a trans-eQTL could be a SNP that affects the activity of a transcription factor, which
61
in turn regulates the expression of a gene and it has the same influence on the gene expression from
both alleles.
Cis-eQTLs are often falsely conflated with local eQTLs since cis-eQTLs are often located
nearby the genes they affect. Trans-eQTLs, on the other hand, can be located anywhere in the
genome in relation to the genes which they regulate [47]. It is important to reinforce that the defining
characteristics of cis-eQTLand trans-eQTLare not based on their proximity to their target genes, as
local eQTLs can induce cis- or trans- patterns of expression change.
Traditional eQTL mapping methods implicitly assume an eQTL has the same effect on all cells
within a sample. This is a reasonable assumption for samples with a relatively homogeneous cell
population. However, tumor samples invariably contain both tumor cells and infiltrating normal
cells (e.g., immune cells) and eQTL effects could differ between these two types of cells. To
quantitatively capture this concept of inhomogeneity within a tumor cell population, we consider
its tumor purity, defined as the proportion of tumor cells within the tumor sample. Previous eQTL
studies in tumor samples often ignore tumor purity information and directly apply eQTL mapping
methods that assume the tumor samples are composed of homogenous cells [49, 50, 51, 53, 76].
When tumor and normal eQTL are discordant, our results show that ignoring tumor purity may lead
to severely inflated type I error in the identification of tumor-specific eQTL.
In this paper, we focus on eQTL mapping using germline genetic variants. The proposed
methods may be extended to study eQTL mapping using somatic variants, but such extensions must
address the challenge of intra-tumor heterogeneity with respect to somatic mutations. To the best
of our knowledge, only one previous work has considered a similar problem of cell-type-specific
eQTL mapping given cell type proportion estimates [54]. Specifically, Westra et al [54] identify
neutrophil-specific eQTLs using a linear model: y = β0 + β1G + β2P + β3GP where y is gene
expression, G is genotype, and P is an estimate or proxy of neutrophil proportion. Loci where
eQTL effects are different between neutrophil and other cell types were identified by testing the
hypothesis β3 = 0. This approach does not directly estimate or assess cell-type-specific eQTL
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effects. We show in our analysis that a variant of this method that explicitly models a tumor-specific
eQTL effect has lower power than our proposed method.
The proposed methods are applied to the genetic expression data of 547 women with breast
cancer provided by The Cancer Genome Atlas. We examine the agreement and disagreement
between each posited model with respect to eQTL identification as well as a discussion of some
interesting eQTL identified by our method.
5.2 Model
Our model is an extension of the TReCASE method, which performs eQTL mapping using
RNA-seq data [55]. The TReCASE method models RNA-seq data along two dimensions, Total
Read Count (TReC) and Allele-Specific Expression (ASE), and simultaneously uses these two types
of data for eQTL mapping [48, 55]. The TReC for a gene of interest is the total number of RNA-seq
reads mapped to this gene. Under the TReCASE framework, TReCs across samples are modeled by
a negative binomial distribution. The ASE of a gene is quantified by the number of allele-specific
reads that match the genotype of one haplotype, but not the other haplotype of this gene. Thus,
an RNA-seq read is allele-specific if it overlaps with at least one SNP that is heterozygous across
the two haplotypes. The number of allele-specific reads from one allele given the total number of
allele-specific reads follows a beta-binomial distribution in the TReCASE framework.
The TReCASE method jointly analyzes the TReC and ASE data for cis-eQTLs as these two
types of data provide consistent information regarding the effect sizes of cis-eQTLs. In contrast, for
a trans-eQTLthe eQTL effect is non-zero for TReC but zero for ASE, and thus only TReC data
are used for mapping trans-eQTLs. The TReCASE model implicitly assumes eQTL effects are the
same across all the cells within a sample, which may not be correct for tumor samples. In this paper,
we extend the TReCASE model for tumor eQTL studies through the incorporation of tumor purity
and separate tumor- and normal-specific eQTL effects into our likelihood model. We refer to this
new model as pTReCASE.
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5.2.1 The Data
We assume that phased germline genotype data and RNA-seq data from tumor samples are
available for n independent subjects. Since germline genotype data have been phased, we have
genotypes for each of a subjects’ two haplotypes. We also assume that an estimate of tumor purity
is available for each tumor sample. For example, one could estimate tumor purity using somatic
copy number aberration data [69].
While pTReCASE is designed to be applied across multiple gene-snp pairs, in the following
discussion, we consider the model for a specific gene of interest and a single potential eQTL of this
gene. For clarity and simplicity in the following notation, we suppress subscripts related to gene
and eQTL and note that the given structure applies across any Gene-SNP pairing. Let G(i) be the
genotype of subject i at the potential eQTL. G(i) can take values in {AA,AB,BB} where A and
B denote two alleles of the potential eQTL. Let ρi, di, and xi = (xi1, ..., xip)T be the tumor purity
estimate, read depth measurement, and a vector of p covariates for the i-th sample respectively.
We set di as the 75-th percentile of the TReCs across all genes in the i-th sample, which is a more
robust way to measure read-depth than the summation of the TReCs across all genes.
5.2.2 Purity Corrected Total Read Count (pTReC) Model
The total read count Yi is defined as the number of RNA-seq reads that are mapped to a
given gene. We assume that Yi follows a negative binomial distribution with over-dispersion φ and












with E(Yi) = µi and V ar(Yi) = µi + φµ2i . Summarizing across all n subjects, the log-likelihood




log [f(Yi;µi, φ)] . (5.1)
.
In impure tumor samples, pTReC captures the genetic effects of a potential eQTL on Yi through
its specification of µi (equation 5.3). In order to illuminate the structure of µi , we must first
quantitatively define these genetic effects for both tumor and normal cells. Let µiA and µiB be the
mean expression of alleles A and B for the i-th subject, and use superscripts (T ) and (N) to denote
measurements from tumor and normal cells, respectively. Values of µiA and µiB are allowed to
vary across subjects, but we assume that the ratios of these quantities are fixed across subjects.
Symbolically:
For all i, µ(N)iB /µ
(N)









Thus, γ represents an eQTL effect within tumor tissues that is common to all subjects and η is its
counterpart for tumor tissues. The remaining parameter, κ, is a nuisance parameter that models the
baseline gene expression difference between tumor and normal tissues.
To further elucidate these eQTL effects, focus on γ. When γ = 1, no eQTL effect exists
within the tumor as the mean expression of alleles A and B are identical within a subject
(
for
all i, µiA = µiB
)
. Suppose now that γ < 1; this implies that the B allele is under-expressed
relative to A by a multiplicative factor of γ (e.g. µiB = γµiA). On the other hand, γ > 1 implies
over-expression of the B-allele relative to A. Identical rules govern the interpretation of η for normal
tissues. Note that by specifying common values of η and γ across subjects, we imply that the ratio
of over/under-expression of the B allele relative to A is consistent across subjects while allowing
each subject a unique mean-expression level of alleles A and B.
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Now let ξi = µiB/µiA. Assuming that the mean expression of an allele is the weighted





(1− ρi)µ(N)iB + ρiµ
(T )
iB




(1− ρi)η + ρiκγ
(1− ρi) + ρiκ
= (1− ci)η + ciγ, (5.2)
where ci = (ρiκ)/(1− ρi + ρiκ). The third equality is obtained by dividing both the numerator and
denominator by µ(N)iA . Therefore, the overall genetic effect in a tumor sample is a mixture of the
genetic effects within tumor cells and normal cells.
Next we consider modeling the µi across different genotypes. First, if the i-th subject has
genotype AA at the candidate eQTL,
µi = µiA + µiA = 2µ
(N)







using a linear function of log read-depth and p covariates: β0 + βdlog(di) +∑p
j=1 βjxij . Applying similar derivations for the subjects with genotypes AB and BB, we have:
log(µi) =

β0 + βdlog(di) +
∑p
j=1 βjxij + log(1− ρi + ρiκ), if G(i) = AA
β0 + βdlog(di) +
∑p





, if G(i) = AB
β0 + βdlog(di) +
∑p
j=1 βjxij + log(1− ρi + ρiκ) + log(ξi), if G(i) = BB
(5.3)
In the pTReC model, estimates of β, κ, η, γ, and φ are obtained by maximizing equation 5.1
with respect to these parameters. We maximize this likelihood using a block coordinate ascent
algorithm. Within block coordinate ascent, optimization proceeds by maximizing the likelihood
with respect to a single set of parameters – called a block – at a time while holding all other blocks
of parameters fixed. Each block of parameters is then optimized iteratively until covergence of
parameter estimates. For pTReC, block 1 consists of parameters κ, η, and γ; block 2 consists
of parameters φ, βd, βj for j = 0, 1, ..., p. Thus, holding the values of all parameters in block
2 constant, a single update of block 1 is accomplished via a quasi-Newton method (LBFGS).
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Then, holding the parameters of block 1 fixed, the parameters in block 2 are updated via negative
binomial regression. As described, we then iteratively update the parameters in blocks 1 and 2 until
convergence.
5.2.3 Purity Corrected Allele Specific Expression (pASE) Model
We refer the reader to Sun and Hu [48] for details on how allele specific reads are counted
in RNA-Seq data. In the following, we briefly describe this process for a single candidate eQTL.
For each subject, we have genotypes available for arbitrarily labeled haplotypes, haplotype 1 and
haplotype 2. We extract all RNA-seq reads that overlap with at least one heterozygous SNP within
the body of the gene and assign each of these reads to the haplotype that matches its nucleotide
sequence. As haplotypes 1 and 2 are arbitrarily labeled for each subject, we ensure comparability
across subjects by relabeling these haplotypes with respect to the genotype of the candidate eQTL.
For subjects who are heterozygous at the candidate eQTL, haplotype A contains the A allele of the
candidate eQTL and haplotype B contains the B allele. For subjects who are homozygous at the
candidate eQTL, haplotypes A and B may be defined arbitrarily without affecting the likelihood
function or statistical inference.
Let RiA and RiB be the number of allele specific RNA-seq reads assigned to haplotypes A
and B, respectively. Let Ri = RiA + RiB be the total number of allele-specific RNA-seq reads.
We model RiB given Ri using a beta-binomial distribution with probability of success πi and
over-dispersion ψ, the likelihood of which is given by:
g(RiB;Ri, πi, ψ) =
Ri!
RiA!RiB!
Γ (ψ−1) Γ (ψ−1πi +RiB) Γ (ψ
−1(1− πi) +RiA)
Γ (ψ−1πi) Γ (ψ−1(1− πi)) Γ (ψ−1 +Ri)
.




log [g (RiB;Ri, πi, ψ)] ,
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where ξi,ASE = µiB/µiA and
πi =

µiB/(µiA + µiB) = ξi,ASE/(ξi,ASE + 1), if G(i) = AB
0.5, otherwise.
Recall that we had defined ξi similarly in equation (5.2). We introduce the slight change in
notation for the pASE model in order to distinguish cis-acting and trans-acting eQTL. For cis-eQTL,
ξi,ASE = ξi as defined in equation (5.2). For trans-eQTL, however, ξi,ASE = 0.5 since expression of
the A and B alleles are impacted to the same extent. A consequence of the above modeling strategy
is that ASE is uninformative regarding κ, η, or γ when an eQTL is trans-acting. In addition, for cis-
eQTL, subjects who are homozygous at the potential eQTL do not contribute to the estimation of the
eQTL parameters κ, η, or γ. However, such subjects are informative regarding the over-dispersion
parameter ψ.
As for pTReC, model fitting in pASE is also achieved via block coordinate ascent using two
blocks of parameters: block 1 consists of parameters κ, η and γ; block 2 consists of the lone
parameter ψ. We employ the cyclical algorithm described in the previous section to iteratively
update the parameters of blocks 1 and 2 until convergence. Updates for each block are accomplished
via LBFGS.
5.2.4 pTReCASE: Unifying pTReC and pASE Models
Restricting to cis-eQTLs, the pTReC and pASE models share the κ, η, and γ parameters allowing
for unification into a single likelihood model:
P (Yi, Ri, RiB|Θ) = P (Yi|Θ)P (Ri|Yi,Θ)P (RiB|Yi, Ri,Θ)
= f (Yi|Θ)P (Ri|Yi) g (RiB|Ri,Θ) ,
where Θ = (κ; η; γ; βj for j = 0, 1, ..p;φ; ηASE; γASE;ψ), the set of all parameters found in the
pTReC and pASE models.
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Note that the likelihood above explicitly relates Yi and Ri. Since the set of allele-specific reads
(Ri) is a subset of all reads mapping to the i-th gene (Yi), it is clear that Ri ≤ Yi. Despite this
relationship between these two variables, it is reasonable to assume that given Yi, the distribution of
Ri does not depend on our covariate or eQTL effects. Given the total read count at the i-th gene, the
number of reads overlapping at least one heterozygous SNP in gene i is a function of the number
of such SNPs present within the gene-body; thus, this value is not likely to be related to eQTL
effects. Therefore, we may remove P (Ri|Yi) from the likelihood function. The log-likelihood of all




log [f (Yi|Θ)] + log [g (RiB|Ri,Θ)] = `TReC + `ASE.
Model fitting is achieved via block coordinate ascent using three blocks: block 1 consists of
κ, η and γ; block 2 consists of φ, βd and βj for j = 0, 1, ..., p; and block 3 consists of ψ alone. A
single update is defined by the following steps. First, given the parameters of blocks 2 and 3, the
parameters of block 1 are updated using LBFGS. Then, given the parameters of blocks 1 and 3, the
parameters of block 2 are updated via negative binomial regression. And finally, given the other
parameters, the parameter of block 3 is updated using LBFGS. These cyclical updates are repeated
until convergence.
5.2.5 Hypothesis Testing
Under the proposed models of sections 2.2 through 2.4, there are three critical questions of interest.
Should we use the pTReC or pTReCASE model to assess an eQTL? Does an eQTL exist within
normal tissue? Does an eQTL exist within tumor tissue?
Addressing the first question requires consideration of the biological mechanisms driving cis-
and trans-eQTLs. For a cis-eQTL, the TReC and ASE components share the same parameters for
eQTL effect sizes, and thus jointly modeling TReC and ASE (i.e., TReCASE) increases power. For
a trans-eQTL, expression of both alleles of the affected gene are altered to the same extent, and
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thus ASE is not informative in the detection of eQTL or estimating eQTL effect size. Therefore,
only TReC data should be used for eQTL mapping of trans-eQTL. We develop a “Cis-Trans” score
test to aid in model selection by addressing a null hypothesis of consistent eQTL effects across the
TReC and ASE components of the model.
To structure this test, let ηASE and γASE be the eQTL effects for a gene and a candidate eQTL
within the ASE component of the model. We still use η and γ to model eQTL effects in TReC
data. Define ηASE = η + αη and γASE = γ + αγ where αη and αγ reflect the discrepancy between
ASE and TReC eQTL effects for normal and tumor tissues, respectively. The null hypothesis of
equivalent eQTL effects in TReC and ASE components of the model is defined using the notation
above by αη = αγ = 0. See the supplementary information for a detailed description and derivation










where Θ̂ are the MLEs of our parameters under the null hypothesis; ˙̀ is the gradient of the TReCASE
likelihood with respect to the parameters; and I(Θ̂) is the Fisher’s Information Matrix.
The presence of eQTL in normal tissue (i.e., η 6= 1) or tumor tissues (i.e., γ 6= 1) can be













where Θ̂0 represents parameter estimates under the null and Θ̂ represents estimates under the
alternative. To test for the presence of an eQTL in normal or tumor tissue, Θ̂0 is obtained by fitting
the model under a null hypothesis of η = 1 or γ = 1, respectively.
To identify eQTL within a single gene-snp pair, we propose the following procedure.
(1) Conduct the “Cis-Trans” score test to determine use of pTReC or pTReCASE model.
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(2) Under the prescription of the “Cis-Trans” test, conduct independent LRT of γ = 1 and η = 1
to determine the presence of eQTL effects.
The above algorithm is designed to ensure that inconsistent effects in the pTReC and pASE models
do not limit the power to detect trans-eQTL. For trans-eQTL, the eQTL effect modeled by pASE
should be 1 whereas that modeled by pTReC should be non-unity (6= 1). Thus, joint estimation
using pTReCASE will dilute effect strength resulting in a loss of power. Since the goal of the
“Cis-Trans” score test is to determine whether the eQTL effects modeled by pTReC and pASE are
consistent and not to assess the presence of an eQTL effect, the sampling properties of the eQTL
effect tests should remain unaffected.
5.3 Results
5.3.1 Simulation Study
We conducted a simulation study to compare the statistical power and type I error rate of
pTReCASE and several other methods. Simulations were conducted across a range of eQTL effect
sizes in normal and tumor cells. To assess Type I error, we set γ at 1 and allowed η to vary. To
assess power to detect tumor-specific eQTL, we set η at 1 and allowed γ to vary. For each pair
of η and γ, we simulated 400 replicates of gene expression and genotype data for 500 subjects.
Genotypes were simulated assuming a minor allele frequency of 0.2. Read counts were simulated
according to the pTReCASE model using the following algorithm:
(1) Randomly generate tumor purities from a uniform distribution on (0.5,1) for each of the 500
subjects.
(2) Simulate TReC via a negative binomial model with:
(A) Mean of 100 reads for subjects with genotype AA and tumor purity of 0%.
(B) κ = 1.5 and φ = 0.2.
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(3) Assume that 5% of the simulated TReC reads are allele specific reads, rounded to the nearest
integer. Partition allele specific reads to haplotypes according to the established beta-binomial
model using an overdispersion of ψ = 0.2.
Each considered eQTL model is then fit to the simulated data. For any given modeling procedure,
the type I error is estimated by the proportion of simulations which incorrectly identify a tumor
eQTL when none is present. Power is estimated by the proportion of simulations which correctly
identify a tumor eQTL when one is present.
The competing eQTL models that we considered include the TReC/TReCASE model without
correction for tumor purity, and the TReC model with tumor purity (pTReC). In addition, we
also considered a naı̈ve approach of linear regression ignoring tumor purity, labeled LR, and a
modification of the approach adopted by Westra et al [54] denoted by pLR. To fit a linear model,
we first applied a normal quantile transformation to (read-depth corrected) TReC values of each
gene across n samples, and then used the transformed TReC as a response variable for linear
regression. Specifically, we first replaced TReC values by their ranks across n samples, and then
replaced the ranks by their corresponding normal quantiles. For example, rank r was replaced by





= β0 + β1G, where G is the genotype of the candidate eQTL.





β0 + β1G + β2ρ + β3Gρ where ρ is an estimate of tumor purity. The interaction test employed
by Westra et al [54] (i.e. β3 = 0) does not assess the strength of a tumor eQTL. Rather, it tests
whether eQTL effects differ between tumor and normal tissues. Under pLR, we assessed tumor
eQTL effects by testing β1 + β3 = 0 since β1 + β3 is the genetic effect of the candidate eQTL when
tumor purity is 1.
All three methods that control for tumor purity (pTReCASE, pTReC, pLR) control Type I
error at the desired level. As eQTL strength in the normal tissue increases, the methods that do not
account for tumor purity see a rapid increase in Type I error (Figure 1A). In terms of power (Figure


































Figure 5.1: Examining Type I error [A] and Power [B] from simulation studies.
their anti-conservative control of Type I error. Among those methods that control Type I error (i.e.
pLR, pTReC, pTReCASE), pTReCASE has the highest power. This is a result of its joint analysis
of TReC and ASE.
5.3.2 The Cancer Genome Atlas (TCGA) Data
5.3.2.1 Data and Model Fitting
We applied the pTReCASE model to analyze gene expression and germline SNP geno-
type data from 550 breast cancer patients of The Cancer Genome Atlas (TCGA) project. All
the data were downloaded from TCGA data portal (https://tcga-data.nci.nih.gov/
docs/publications/tcga/), which has now been replaced by NCI Genomic Data Com-
mons (https://portal.gdc.cancer.gov/). We started with 728 patients with RNA-seq
data from tumor samples. In order to assess allele-specific gene expression, we downloaded raw
RNA-seq data in bam file format. For genotype data, we downloaded the Affymetrix CEL files. We
restricted our analysis 550 of 728 patients who had available genotype data, passed quality controls
for both genotype and RNA-seq data, and were Caucasian females (See Supplementary Materials
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Section B for details). Males were excluded as breast cancer in men is rare and may have a different
disease etiology. The restriction to Caucasian samples is not necessary, but it helps to eliminate
possible confounders [77].
For the remaining 550 patients, genotype imputation and haplotype phasing was performed by
MACH [78] using reference haplotypes from the 1000 Genomes Project. Starting with ∼800,000
SNPs genotyped by Affymetrix 6.0 array, we imputed the gneotypes for∼36 million SNPs. For each
sample, we used all the SNPs with heterozygous genotypes to estimate allele-specific expression
(See Supplementary Materials Section B for details). For the purposes of eQTL mapping, we
restricted our analysis to those SNPs with MAF ≥ 0.02 (6,825,065 SNPs after imputation) because
there is limited power to detect eQTL at lower values of MAF. Tumor purities were estimated
using ABSOLUTE [69], which led to the exclusion of three additional subjects lacking valid
purity estimates. Estimated haplotypes and tumor purities were treated as truth in the subsequent
pTReCASE and linear regression models.
Linear models for eQTL analysis and the revised Westra approach (i.e. pLR) were fit using
matrixEQTL [79] and customized R code on normal quantile transformed RNA-Seq count data,
respectively. TReC, TReCASE, pTReC and pTReCASE models were fit using our own package.
The median analysis time for a single gene-SNP pair using pTReCASE was 2.71 seconds (IQR =
2.93 seconds). The covariates used for eQTL mapping include read-depth of RNA-seq experiments
(Supplementary Figure 7), RNA sample plates, age, and the top two principal components derived
from the genotype data of the 550 Caucasian samples. Since our method is designed to identify
cis-eQTLs and most cis-eQTLs are local to the genes which they affect, we restricted our analysis
to SNPs located within 100Kb of the gene of interest.
5.3.2.2 eQTL Identification
Figures 5.2A-B illustrate a tumor-specific eQTL identified by the pTReCASE model. The
estimates of effect sizes (ratio of gene expression of the B allele versus the A allele) for normal and
tumor-specific eQTLs are 0.96 (η) and 3.51 (γ), respectively. The fold change of gene expression
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in tumor versus normal cells (for genotype AA) is 0.19 (κ) (Figure 5.2D). In other words, gene
Figure 5.2: (A) Covariate-corrected total expression estimated via pTReCASE plotted against genotype and
tumor purity. Outliers were suppressed for clarity. Dot plot instead of boxplot was used when sample size
of a category is too small. (B) Examination of the allele specific expression corresponding to case shown
(A). (C) Covariate-corrected total expression estimated via pTReC plotted against genotype and tumor purity.
(D) Table providing Gene, SNP, and estimated parameters for the displayed assessments. pCT references the
value of the Cis-Trans score test.
expression in tumor cells is lower than that in normal cells, but the eQTL effect is only present
in tumor cells. These numerical estimates were well demonstrated by Figures 5.2A-B. As tumor
purity increases, gene expression measured by TReC decreases (Figure 5.2A), and the strength
of the eQTL increases. Both TReC and ASE show consistent signals that the B allele has higher
expression, with a “Cis-Trans” test p-value of 0.95.
75
To highlight the functioning of the pTReC model, another example of tumor-specific eQTL was
identified and shown in Figure 5.2C. In this example, gene expression from the ASE model was not
used for eQTL mapping due to a significant “Cis-Trans” test using the full model. In this example,
gene expression is higher in tumor compared to normal cells and the B allele has lower expression
than the A allele in tumor cells, but not in normal cells. Note that we can still see some signals of an
eQTL in the category with the lowest tumor purity. This results from TCGA samples being selected
to have relatively higher tumor purity, thereby creating a categorization schema wherein even the
lowest tumor purity category has a non-negligible amount of tumor cells.
We use another example to demonstrate the utility of the Cis-Trans score test (Figure 5.3).
Considering only the TReC data, the B allele has slightly higher expression than the A allele when
tumor purity is high (Figure 5.3A). In contrast, considering only the ASE data, the B allele has
much lower expression than A across all tumor purity levels. This inconsistency between TReC
and ASE data led to a highly significant Cis-Trans p-value (Figure 5.3C). In such cases, only the
TReC data is trusted and used to estimate eQTL effects. ASE tends to be noisier in real data as
mapping biases, incorrect genotype data, and/or other biological and technical factors can lead to
the observed ASE imbalance as opposed to eQTL effects. Failure to consider the Cis-Trans test
could lead to the acceptance of spurious eQTL results.
Next, we systematically compare the results for all eQTLs using the pTReCASE, TReCASE,
and pLR approaches at various p-value cutoffs. One way to compare the results is to check the
overlap of each significant eQTL association, i.e., each gene-SNP pair (Supplementary Table 2).
However, due to LD, the expression of one gene may be associated with multiple SNPs that are in
close proximity to one another and often represent redundant eQTL signals. Therefore, we focus on
the eQTL results summarized at the gene level. In other words, for a given p-value cutoff, we count
the number of genes with at least one eQTL with a p-value falling below the cutoff (Table 1).
Compared to pTReCASE, the TReCASE model identifies eQTLs in a larger number of genes.
For those genes where TReCASE identifies a significant eQTL and pTReCASE does not, the
significant findings of the TReCASE model are most likely driven by an eQTL in normal tissue.
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Figure 5.3: Demonstrating the utility of the Cis-Trans score test. (A) Covariate-corrected total
expression plotted as a function of genotype and tumor purity. (B) Allele Specific Expression with
respect to genotype and tumor purity. (C) Table containing relevant modeling information for A and










pLRTotal Genes = 18,134









pLRTotal Genes = 18,134
(B) P < 5× 10−8
Figure 5.4: Visual summary of the number of genes with at least significant eQTL at the prescribed
p-value cutoff for each model fit and their overlaps.
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Genes
P-value Cutoff Category pTReC(ASE) TReC(ASE) pLR
# of Genes 1245 2982 268
5× 10−6 overlap/alternative – 27.0 85.4
overlap/pTReC(ASE) – 64.7 18.4
# of Genes 496 1612 110
5× 10−8 overlap/alternative – 21.4 93.6
overlap/pTReC(ASE) – 69.6 20.8
Table 5.1: Summarizing the results of pTReC(ASE), TReC(ASE), the Westra-inspired models for
TCGA data. Here the notation pTReC(ASE) indicates that we used the pTReCASE or pTReC model
depending on the results of the Cis-Trans test. “Overlap” represents the genes with at least one
significant eQTL identified by both pTReC(ASE) and an alternative method. “Overlap/alternative”
is the number of overlaps divided by the number of findings using the alternative method. “Over-
lap/pTReC(ASE)” is the number of overlaps divided by the number of findings using pTReC(ASE).
If we consider the results of pTReC(ASE) as true findings, then “overlap/alternative” is the true
discovery rate and “overlap/pTReC(ASE)” is the sensitivity
TReCASE recaptures around two-thirds of eQTL findings identified by pTReCASE. The one-third
missed by TReCASE are more likely to have weaker effect size and/or are only present in tumor
cells.
Across p-value thresholds, the pLR model identifies relatively fewer significant gene-SNP
pair relationships. Of those relationships identified by the pLR model, 85- to 93- percent are also
identified by pTReCASE. The pLR model also misses at least 73% of significant results identified
by pTReCASE. Possible reasons for the poor performance of the pLR model could arise from the
fact that ASE is not incorporated and/or the relationship between transformed gene expression and
tumor purity is not examined on the linear scale.
At the time of this writing, these authors were unable to find many studies seeking to identify
eQTL in breast cancer tissues. Of those available, none utilized information regarding tumor purity
when constructing analysis models which may limit the comparability of results. However, we
identified one such study of breast cancer eQTL which controls for both somatic copy number
and methylation [53]. We compare the results of pTReCASE against those in Li to determine
the extent of overlap in their eQTL calls [53]. At the 5e-6 significance level, Li identifies 165
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genes in common with pTReCASE whereas 91 genes would be expected by chance. In fact, the
hypergeometric probability of observing 165 or more genes in common is 1.6.e-14. At the 5e-8
level, Li identifies 86 genes in common with pTReCASE whereas 37 genes would be expected by
chance (hypergeometric p = 3.5e− 14). Note, Li et al examine eQTL using a reduced set of SNPs,
a reduced sample size, and expression data derived from microarrays and not RNA-seq. The lack of
stronger overlap between Li et al and pTReCASE could be due to Li’s use of microarray expression
instead of RNA-seq, smaller set of considered SNPs, and smaller sample size of breast cancers.
5.3.2.3 Assessing Copy Number Effects
Within tumor samples, copy number aberrations (CNA) are pervasive. Involving the addition
or deletion of copies of genomic loci (e.g. SNPs or genes), CNA can increase or decrease the
expression of various genes by virtue of adding or deleting copies of this gene. At present, the
pTReC and pTReCASE methods do not assess the impact of copy number aberration on gene
expression. Future extension of these models is needed to account for such impacts. However, we
contend that CNA are unlikely to result in false positive results for pTReC and pTReCASE, instead
resulting in a likely loss of power.
To examine the extent of copy number aberration within the TCGA dataset examined above,
we define the following terms. Cij is the total copy number of gene i in sample j. Ni is the ploidy
of subject i. To determine the impact of CNA on a subject’s gene expression, consider the metric
Dij where:
Dij = Cij −Ni.
Thus, Dij represents the difference between a gene’s copy number and the average copy number
across all loci within the subject. For a single subject and gene, we define a copy number event to
occur whenever |Dij| > 0.5.
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To motivate the use of Dij to define copy number events, compare a sample a with no CNA
across the entire genome to a sample b with CNA such that, on average, any gene is expected to have
one additional copy (e.g. Ni = 3). Assuming identical expressions of each copy of a gene in the
two samples and equivalent sampling depth during measurement, sample b would experience gene
expressions 1.5 times larger than those in sample a. However, if one were to relativize expression
within these samples (i.e. using FPKM, FPKM-UQ), the CNA across all genes within sample
b would be eliminated. This is a direct result of the fact that the measure of read-depth would
incorporate a consistent increase in expression due to the CNA seen in b. Thus, CNA should only
impact relative gene expression when a gene’s copy number is different from the average such copy
number across the genome. Since pTReC and pTReCASE incorporate measures of read-depth




































Figure 5.5: Evaluating the extent of copy number aberration within the TCGA dataset. [A]
Distribution of the correlations between Dij and Cij for subjects where |Dij| ≤ 0.5 summarized
across all 18,134 genes. Red line indicates density of N(0,1/
√
296). [B] Distribution of the
correlations between Dij and relative gene expression summarized across all 18,134 genes [C] The
distribution of the number of subjects with |Dij| > 0.5 across all 18,134 genes.
To justify use of |Dij| > 0.5 to define copy number events, consider figure (5.5). Focusing on
subjects such that |Dij| ≤ 0.5, or the group of subjects assumed not to have experienced a copy
number event, we would expect to see no relationship between relative gene expression (Yij/di)
and Cij . Thus, assuming relative expression can help mitigate the effects of CNA, the distribution
of the correlation between Cij and (Yij/di) should be approximately 0. Indeed, panel (A) suggests
this to be a reasonable assumption. While there is a slight positive skew, the correlation strengths
remain low and are reasonably consistent with their expected distribution assuming the true mean
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is 0. As an additional note, the expected distribution is computed assuming that all correlations
are computed with the same group size. However, the number of subjects not experiencing a CNA
varies across gene and thus is not meant to provide an exact alignment.
Further, consider the relationship between a variable
Gij =

0 if Dij < −0.5,
1 if |Dij| ≤ 0.5
2 if Dij > 0.5
and relativized expression (Yij/di). Under the argument posited above, one would expect to see a
positive correlation between these two variables. This would indicate that as one increases the CN
of a gene relative to the ploidy of the individual, the relative expression should also increase. Panel
(B) provides support for this assertion, demonstrating positive correlations the bulk of which fall
between 0.0 and 0.6.
Thus, considering the support displayed above, panel (C) suggests that approximately 75% of
genes have 50% or fewer subjects impacted by copy number events. Indeed, copy number aberration
is pervasive within the TCGA dataset.
However, the presence of copy number aberrations is unlikely to indicate the presence of false
positive calls from pTReC and pTReCASE. If the correlation between copy number and eQTL
genotype is weak or non-existent, CNA would add noise to the statistical models but would not
induce false signal. To substantiate this claim within the TCGA dataset, we examine the correlation
between Dij and eQTL genotype. For each gene with at least one significant eQTL at the 5× 10−6
level, we select its most significant SNP and compute the correlation between Dij and the genotype
of this SNP. Figure (5.6) plots the distribution of these correlations across the 1,271 significant
genes with the red-line indicating the expected distribution assuming that these correlations have
mean 0. Figure (5.6) demonstrates that these correlations are often weak, and thus pTReC and












Figure 5.6: Computes the correlation between the eQTL genotype of a gene’s most significant SNP
and the gene’s copy number difference Dij
5.4 Discussion
Due to contamination of tumor samples with infiltrating normal cells, the identification of
eQTL within tumor tissues poses several challenges. First and foremost, one needs to separately
estimate the eQTL signals in tumor and normal cells. Second, while total gene expression has
been widely used for transcriptome studies, it is important to leverage the additional information
provided by allele-specific expression which can be effectively derived using RNA-seq data. We
have developed a statistical model and software package, pTReCASE, to address these issues. The
desirable performance of pTReCASE has been validated using simulations and real data analysis.
In constrast, a naı̈ve approach for eQTL mapping that ignores tumor purity may lead to a large
fraction of false positives.
Readers may note that the mean structure utilized by pTReCASE involves two critical assump-
tions: (1) Expression in the tumor is composed of two cell groups, tumor and normal; and (2) the
mean structure precludes the modeling of dominant and recessive eQTL effects. As mentioned
in the introduction, intra-tumor heterogeneity is an ongoing challenge in the analysis of cancer
expression data that provides a natural challenge to the assumption in (1). However, assumption
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(1) allows pTReCASE to identify eQTL effects that are common to the majority of tumor cells
across samples. Further refinement of eQTL effects into effects arising within different subclones is
likely not possible due to the high degree of difference between subclones across cancers. Thus,
assumption (1) does not seek to imply that it is impossible for certain subclones to experience
different eQTL regulation. Instead it restricts the ability of pTReCASE to identify eQTL that are
present in poorly represented subclones.
With regard to assumption (2), the additive structure used by pTReCASE is a natural conse-
quence of cis-acting regulation. Should dominance and recessive relationships exist, it is unlikely to
result from cis-acting regulation and thus one should not incorporate ASE information in the model.
The pTReC model could be modified to capture dominance and recessive relationships in future
studies.
In addition, the effects of γ and η on mean expression through formulas involving ξi rather than
introducing a genotype covariate directly into the regression equation. The relationship between
genotype and genetic expression is assumed to occur on the linear scale. The relationship between
genetic expression and covariates is assumed to occur on the log-scale. Thus, replacing η and γ
with extra elements in the covariate vector β is impossible due to the different scales.
Within the current established framework for pTReC(ASE), there are three additional avenues
for further development and research. The first is to improve the computational efficiency of our
software package. Using the current implementation, it takes about thousands of CPU hours for
genome-wide local eQTL mapping. This can be easily done using a moderately sized computing
cluster, but is not computationally feasible for a single computer. High computational costs also
prevent us from using permutations to assess the significance of eQTL results. Thus, we recommend
use of Bonferroni correction, Benjamini-Hochberg FDR control [80], or calculation of the number
of independent tests by examining the correlation structure of the genotype data [81].
We have assumed that the haplotypes connecting candidate eQTLs and the SNPs within the
gene body are known. In practice, such haplotypes are imputed/phased using statistical methods.
Phasing is usually accurate within short genetic distances around the gene of interest. However, if
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we would like to consider potential eQTLs further from the gene, there is a possibility of phasing
error. The second avenue for improving the posited model is to allow for uncertainty in the haplotype
phasing by following the approach of Hu et al [56].
Lastly, both the TReC and ASE components of the pTReCASE model have assumed no copy
number change across subjects. Suppose that an eQTL for a given gene modifies expression through
copy number changes. More specifically, suppose the B allele at the candidate eQTL is associated
with a larger copy number in tumor tissues. This would lead to increased expression from the B
allele and would be interpreted by the pTReCASE model as higher expression of B allele. In such a
scenario, the pTReCASE model is applicable without modification. However, if both eQTL and
copy number affect gene expression independently, the pTReCASE model should be adjusted for
copy number differences. We have demonstrated in section 3.2.3 that, despite not controlling for
pervasive CNA in its analysis, pTReC(ASE) is unlikely to have experienced false positive calls as
the correlation between SNP genotype and gene copy number are often weak.
Given estimates of allele-specific copy number, our model can be modified to address copy
number variation across subjects. Estimation of allele-specific copy number in tumor samples is a
very challenging task due to the confounding effects of tumor purity, ploidy, and the possibility of
subclonal copy number changes [82, 83]. It is desirable to systematically study the effects of both
germline SNPs, somatic copy number changes, and even somatic point mutations (single nucleotide
variants or indels) while also accounting for intra-tumor heterogeneity, but such explorations are
beyond the scope of this paper and warrant a series of future studies.
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CHAPTER 6: CONCLUSIONS AND FUTURE WORK
Within this dissertation, we have explored the analysis of bulk expression experiments from
heterogeneous cell type samples. Two main problems from such data have been examined: esti-
mating the cell type abundance profile from which the mixture expressions were generated and
conducting cell-type specific differential expression analyses controlling for cell type abundance.
While the abundance estimation and differential expression analyses are of interest in general cell
type samples, we focused the majority of our model development and application on tumor tissue,
namely estimating immune cell abundance within tumor samples and identifying tumor-specific
eQTL.
Within chapter 3, we posited an RNA-seq framework (IsoDeconv) for cell type abundance
estimation using isoform expression information. The presented work displays the promise of
isoform expression for use within the cell type deconvolution setting, but challenges remain. As
noted in chapter 3, future work on the IsoDeconv model should focus on reducing its computational
complexity and refining its application to real data settings. In particular, excessive variation has
been shown to hamper the estimation process. Strategies for mitigating the impact of this variation
have been proposed but require further development. Improving IsoDeconvs ability to handle higher
levels of expression variance is critical for its use in capturing the additional information regarding
cell type identity provided by isoform expression.
Chapter 4 provided an alternative cell type abundance estimation framework for use within
tumor tissues. The presented model, ICeD-T, was found to be both accurate and robust to aberrant
gene behavior within mixture expression experiments. Future work on the ICeD-T model should
focus on the development of superior reference matrices for immune cell deconvolution and a refined
set of variance weights for use in the estimation process. By refining the reference matrices and
variance weights, the accuracy of ICeD-Ts estimates and its ability to detect aberrant gene behavior
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is likely to improve. Single cell RNA-seq is a promising technology for the development of superior
reference matrices and variance weights. scRNA-seq experiments represent an opportunity to
capture reference immune cell expressions within the tumor context. As the variability and accuracy
of scRNA-seq improves, so too will our ability to accurately capture immune cell expression within
references.
Finally, the problem of cell-type specific eQTL was addressed within chapter 5. Our model,
pTReCASE, was demonstrated to properly control Type I error and provide superior power in the
analysis of tumor-specific eQTL when compared to alternative modeling strategies. One avenue
for future improvement of the pTReCASE model includes the incorporation of copy number
aberration data. While it was found that copy number aberration data was unlikely to introduce false
positives to the pTReCASE model, incorporating CNA data could improve its power in tumors types
with high levels of CNA. In addition, extension of pTReCASE to the study of somatic mutations
could reveal the biological processes behind the behavior of tumor subclones. While the study of
somatic mutations is promising, such work must overcome the challenge of estimating intra-tumor
heterogeneity, an ongoing topic of research.
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APPENDIX A: SUPPLEMENT FOR CHAPTER 3




Ykje 1× 1 Total read count at exon set e in pure sample j of cell type k.
tkj 1× 1 Measure of read-depth (e.g. total read count) in pure sample j of cell type
k.
γk I × 1 A vector of Isoform expression levels unique to cells of type k.
νk 1× 1 An overdispersion parameter governing read count variance at exon sets for
expression in cells of type k.
nk 1× 1 Number of pure samples of cells of type k.
Mixture Sample Expressions
Value Dim. Description
Ze 1× 1 Read count at exon set e in the mixture cell type sample.
Y ∗ke 1× 1 Unobserved read count attributable to cells of type k at exon set e in the
mixture.
tm 1× 1 Measure of read-depth (e.g. total read count) in the mixture sample.
pk 1× 1 Abundance of cell type k in the mixture sample.
p K × 1 Vector of cell type abundances in the mixture across all K cell types.
Cluster Level Parameters
Value Dim. Description
X E × I Matrix of effective lengths for each exon set within each of the isoforms.
Xij 1× 1 Effective length of gene i in isoform j.
Xe I × 1 e-th row of effective length matrix X .
Gamma-Poisson Mixture Parameters
Value Dim. Description
λkje 1× 1 Unobserved, gamma-distributed, Poisson-mean read count at exon set e for
pure sample j of cell type k.
λ∗ke 1× 1 Unobserved, gamma-distributed, Poisson-mean read count at exon set e for
cells of type k in the mixture.









Ψ0() NA The digamma function, defined as the first derivative of the lnΓ () function.
Table A.1: Notation for defining the IsoDeconv Model.
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A.1.2 Optimization Algorithm
PROCESS PURE / MIXTURE DATA 
Gene + Isoform Models: 
• Construct read length distn.
• Construct non-overlapping
exons and exon sets
• Compute effective lengths
for each exon-set-isoform pair
UPDATE 𝜸𝜸𝒌𝒌 and 𝝂𝝂𝒌𝒌 
EM Algorithm: 
Gamma-Poisson Missingness separates cell types 
UPDATE p 
constrOptim:  
Gradient-free, constrained optimization 
COMPILE PER-GENE ESTIMATES 
Mixture + Pure Samples: 
• Summarize reads by exon set
• Group into R List object
Figure A.1: Visual representation of the IsoDeconv Negative Binomial algorithm from early stage
data processing to iterative update algorithm.
Model parameters in the IsoDeconv model are estimated through a maximum-likelihood
framework on a gene-by-gene basis. An estimate of pk is obtained for each gene and then aggregated
across genes to provide a final abundance estimate. Within each gene, optimization proceeds via
block coordinate descent. The steps are as follows:
(1) Assume the pk are fixed, update γk and νk.
(2) Assume the γk and νk are fixed, update the pk.
Steps (1) and (2) are cycled until convergence of the cell type proportions, pk. Within step (2),
optimization of the pk terms proceeds using a gradient-free, numerical optimization routine, R’s
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constrOptim. Use of the gradient free approach is incorporated to avoid the intractability of a
gradient function in the convolution of negative binomials model. Within step (1), optimization
proceeds under an EM algorithm, described in section 4 of Appendix 1. We derive some useful
results first.
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A.1.3 Derivations involving Gamma-Poisson Random Variables
The optimization procedure utilized by IsoDeconv relies upon the categorization of a nega-
tive binomial random variable as a gamma-poisson mixture. To see this, consider the following
hierarchical framework for two random variables Y and λ:
Y
∣∣λ ∼ Poisson (λ) and λ ∼ Γ (µ, ν)














































We recognize this as the density function of a negative binomially distributed random variable, as
desired. It is clear from the properties of gamma random variables, poisson random variables, and
conditional expectations that:
E[Y ] = E {E[Y |λ]}
= E [λ]
= µ
V [Y ] = E {V [Y |λ]}+ V {E[Y |λ]}
= E[λ] + V [λ]
= µ+ (1/ν)µ2
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where ν can be characterized as our overdispersion parameter for the negative binomial distribution.
The optimization algorithm that follows relies upon certain conditional expectations developed
under this framework. Thus, we specify the following additional necessities constructed from
Gamma-Poisson mixtures.
(1) Conditional Distribution of λ|Y
(2) Conditional Expectation of λ|Y
(3) Conditional Expectation of log(λ)|Y
(4) Sums of Gamma-Poisson Mixtures
Each of these necessities are developed below.
D.1 - Conditional Distribution of λ|Y :
By properties of conditional distributions, we know that














, ν ′ = Y + ν
)
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D.2 - Conditional Expectation of λ|Y :
By properties, of the gamma distribution we know that
E[λ|Y ] = µ′ = Y + ν
ν/µ+ 1
D.3 - Conditional Expectation of log(λ)|Y :
Consider the moment generating function (MGF) of the random variable R = log(λ) given Y.
MR|Y (t) = E
[
etR
































Γ(ν ′ + t)(µ′/ν ′)t
Γ(ν ′)
]
The existence of this MGF implies the existence of the moments of R. We compute the first such







Γ̇(ν ′ + t)
Γ(ν ′)
(µ′/ν ′)t +
Γ(ν ′ + t)
Γ(ν ′)




′) + log(µ′/ν ′)
= Ψ0(ν + Y )− log (ν/µ+ 1)
D.4 - Sums of Gamma-Poisson Mixtures:
Consider a framework wherein we haveK independent Gamma-Poisson mixtures and are examining
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λk ∼ Gamma(µk, νk)
and
(Yj, λj) ⊥ (Yk, λk) ∀j 6= k
Now, we’ll consider variations of D.2 and D.3 defining instead the following conditional frameworks:
(D.3.1) Conditional Expectation of λk|Z
(D.3.2) Conditional Expectation of log (λk) |Z





























∣∣Z] = E {E[log(λk)|Y1, ..., YK , Z]∣∣∣Z}
= E
{










We note that the remaining expectations are now finite sums over the support of Yk from 0 to Z.




Using an approximation to the distribution of a convolution of negative binomial pieces utilized
by Efron, we can approximate the densities fZ−Yk() and fZ(). Thus, we render this expectation
computable. If K = 2, no approximation is necessary as fZ(), fY1 , and fZ−Y1() = fY2 are easily
computed.
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A.1.4 EM Algorithm: Update γk and νk
Recall the likelihood framework established within the text of “IsoDeconv: Cell Type Abun-
dance Estimation using RNA Isoform Expression”. We restate it briefly here for completeness
utilizing the notation specified in the table in section A.1. For purified samples of cells of type k,
we have:




e γk, φ = 1/νk
)
Within the mixture tissue, reads attributable to cells of type k are assumed to arise from the following
model:
Y ∗ke





In order to construct an EM algorithm, we need to represent the given stochastic system using
missing values. The missing values in this setting become evident when we re-characterize the
negative binomials as Gamma-Poisson mixtures. Within these mixtures, the poisson mean for each
cell type’s read count is unknown–specified by λkje for pure samples and λ∗ke in the mixture. Thus,
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−λkje + Ykje log(λkje)− log(Ykje) + (νk − 1) log(λkje)+
νk [log(νk)− log(µkje)]− (νk/µkje)λkje − lnΓ (νk)
)
+































































This regrouping makes it explicitly clear that we can perform optimization separately within each
cell type.
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Optimization in k-th Cell Type: Isoform Gradient
To assist in the numerical optimization routines used within the R software, we compute the gradient
of the likelihood with respect to the isoform parameters. To this end, we specify the restricted




























































Optimization in K-th Cell Type: Overdispersion Gradient
To assist in the numerical optimization routine used with the R software, we compute the gradient of
the likelihood with respect to the overdisperion parameter νk. To this end, we specify the restricted





























− (nk + 1)lnΓ (νk)]


















+ (nk + 1)−









− (nk + 1)Ψ0(νk)
]
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A.1.5 Choosing Aggregation Technique
Simulations similar to those in section 2.2.2.3 are performed to determine the best method
for aggregating per-gene estimates of cell type abundance. To generate a set of simulated mixture
and reference samples, one paired-end RNA-seq experiment each of GM12878 and HMEC were
downloaded from the ENCODE database. Reference samples were generated similarly by again
downsampling the GM12878 and HMEC files to 10 million reads apiece.












Figure A.2: Estimates of the proportion of GM12878 using Median and Mean aggregation of
per-gene estimates.
The mixture sample generation methodology described here was found to be flawed. Oversam-
pling of the GM12878 and HMEC files created references and mixtures which were exceedingly
similar. Thus, the accuracy of the observed results was determined to be a function of this similarity
and not the appropriateness of the IsoDeconvNB model. Despite this fact, these original examina-
tions allowed determination of the most appropriate way to aggregate cell type abundance estimates
across genes. As is seen in figure (A.2), the median per-gene estimate of cell type abundance
provides superior estimation of the overall cell type abundance within the sample. Thus, in the
following results, per-gene estimates of cell type abundance are aggregated using the median.
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Ykj(E) 1× 1 Total read count outside gene of interest in pure sample j of cell type k.
Ykje 1× 1 Read count at exon set e in pure sample j of cell type k.
Ykj E × 1 Collection of read counts across all exon sets in the given gene for pure sample j
of cell type k.
γkj I × 1 Isoform expression parameters unique to pure sample j of cell type k.
τkj 1× 1 Probability that a randomly selected read maps to the gene of interest in pure
sample j of cell type k.
tkj 1× 1 The total read count in pure sample j of cell type k.
Mixture Sample Expressions
Value Dim. Description
Ze 1× 1 Read count at exon set e in the mixture cell type sample.
Z E × 1 Collection of Ze in a single vector.







Zke∗ 1× 1 Read count at exon set e in the mixture cell type sample attributable to cells of type
k.
γ∗k I × 1 Isoform expression parameters unique to cells of type k found within the mixture
cell type sample.
τ∗k 1× 1 The probability that a randomly selected read from cells of type k in the mixture
sample maps to the gene of interest which is unique to the cells in the mixture
sample.
Cell-Type Specific and Cluster Level Parameters
Value Dim. Description
X E × I Matrix of effective lengths for each exon set within each of the isoforms.
Xij 1× 1 Effective length of exon set i in isoform j.






pk 1× 1 Proportion of cell type k present in the mixture tissue.
p K × 1 Collection of abundances for each of the K cell types which compose the mixture.
αk I × 1 Hyperparameters governing average isoform expression levels and variances within
cells of type k.
βk 2× 1 Hyperparameters governing gene expression levels within cells of type k.
Value Dim. Description
◦ NA This operator indicates element-wise multiplication of two vectors.
Table A.2: Notation for defining the IsoDeconv Model.
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A.2.2 Lemmas Involving Multinomial Distribution
PROCESS PURE / MIXTURE DATA 
Gene + Isoform Models: 
• Construct read length distn.
• Construct non-overlapping
exons and exon sets
• Compute effective lengths
for each exon-set-isoform pair
UPDATE 𝜸𝜸∗ 
Section A.5 (M-Step 2): 
Constrained, Numerical Optimization with gradients 
UPDATE EM EXPECTATIONS 
Section A.5 (E-Step): 
Closed-form updates for 𝐸𝐸[𝑍𝑍𝑗𝑗𝑒𝑒∗|𝑍𝑍1, … ,𝑍𝑍𝐸𝐸 , 𝜏𝜏∗,𝛾𝛾∗] 
COMPILE PER-GENE ESTIMATES 
Mixture + Pure Samples: 
• Summarize reads by exon set
• Group into R List object
UPDATE p and 𝝉𝝉 ∗ 
Section A.5 (M-Step 1): 
Constrained, Numerical Optimization with gradients 
STAGE 1: Expression Profiles in Pure Samples 
Estimate Isoform Expression: 
• Numerical Opt. (Section A.3)
• Each subject est. separately
STAGE 2: Construct Mixture Penalties 
Estimate Isoform Penalty: 
• Fix 𝛾𝛾�𝑘𝑘𝑗𝑗  from stage 1
• Dirichelet MLE
• Independent of Gene Penalty
Estimate Gene Penalty: 
• Fix ?̂?𝜏𝑘𝑘𝑗𝑗  from stage 1
• Dirichelet MLE
• Independent of Isoform Penalty
Estimate Gene Expression: 
• Closed-form update (Section A.3)
• Each subject est. separately
STAGE 3: EM Algorithm
Figure A.3: Visual representation of the IsoDeconv Multinomial algorithm from development of
reference matrices to Stage 3 EM Updates.
102
A.2.3 Lemmas Involving Multinomial Distribution
Prior to specification of the IsoDeconv model, we develop a set of lemmas for the multinomial
distribution which will allow easier specification in the following materials. For completeness,
we define a multinomially distributed vector X = (X1, ..., XR) with size n and proportions ρ =










Lemma 1.1: Sum over Groups
W.L.O.G. construct the sum X· = X1 + ... + Xg and consider the grouped multinomial X ′ =
f(X) = (X·, Xg+1, Xg+2, ..., XR). Let S represent the set of vectors X such that X ′ = f(X) = x
where x is an arbitrary (R− g + 1)-dimensional non-negative vector summing to n. The density of
this random variable is given by:
P
{
X ′ = x
































Thus, it is clear that X ′ ∼ Multinomial (n, ρ′) where ρ′ = (ρ1 + ...+ ρg, ρg+1, ..., ρR).
Lemma 1.2: Marginal of a Single Element
We extend (1.1) to the case where X· = X1 + ... + XR−1 and consider the distribution of X ′ =
f(X) = (X·, XR). Using (1.1) it is clear that X ′ ∼ Multinomial (n, (1− ρR, ρR)). Thus, it is
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obvious that:
XR ∼ Bin (n, ρR)
104
Lemma 2.1: Conditional over Multiple Elements
W.L.O.G. consider conditioning on the first g elements. Thus, we seek to specify the conditional
density of X∗ = (Xg+1, ..., XR) given (X1, ..., Xg). By lemma (1.1), we know that:
P {X1, ..., Xg} =
 n





(1− ρ1 − ...− ρg)n−X1−...−Xg










X1, ..., Xg, , n−
∑g
r=1Xr








1− ρ1 − ...− ρg
)Xi]
Thus, it is clear that:
X∗









Lemma 2.2: Conditional of a Single Element
We consider a specific case of lemma (2.1) where X∗ = (X2, · · · , XR). Thus, it is clear that:
X∗
∣∣X1 ∼ Multinomial (n−X1, ρ∗1) where ρ∗1 = ( ρ21− ρ1 , · · · , ρR1− ρ1
)
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Lemma 3: Conditional Over Sums
Under the original framework, consider splitting the R elements of X into K distinct groups.
W.L.O.G. we specify:
Group 1 Group 2 · · · Group K
X1, · · · , Xk1 Xk1+1, · · · , Xk2 · · · XkK−1 , · · · , XR
ρ1, · · · , ρk1 ρk1+1, · · · , ρk2 · · · ρkK−1 , · · · , ρR
For convenience, define Sj =
∑kj
i=kj−1+1




























The second equality holds through repeated application of Lemma 1.1. The final equality demon-
strates that the desired conditional distribution is the product of independent multinomials. Symbol-
ically, we have:
X1, · · · , XR














A.2.4 Stage 1 Estimation: Pure Sample Necessities
For the following, refer to Table A.2 regarding notation. Additionally, note that the following
specification is performed for a single gene only; subscripts related to gene identity are omitted for









Implicit in this construction are restrictions upon the τkj and γkj . As a single probability value, it
must be that 0 ≤ τkj ≤ 1. However, the γkj pose a more complicated set of restrictions. Consider
the following:
1 = (1− τkj) + τkj1TXγkj
= 1TXγkj
It is clear from the above that the Xγkj are conditional probabilities and thus must be non-negative.
To ensure this, we restrict the γkj to be non-negative since the elements of Xkj are non-negative by
definition. Using our summation constraints, we have:




This shows that the l̃iγkji are probabilities that a randomly selected read is attributable to isoform i
for reference j of cell type k. Thus, it is clear that the γkj are collections of per-unit of effective
length conditional probabilities that a read belongs to isoform i given that it maps to the gene of
interest.
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Thus, the likelihood for sample j of cell type k is given by:




















Given the gene and isoform expressions, the reference samples within and across cell types are
independent. Thus, we may estimate the τkj and γkj separately within each sample.
Estimate τkj:





In order to estimate the isoform expressions for a single subject, we make some simplifying
alterations to the effective length matrix X and reparametrize the isoform expression parameters.
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Consider the following, where Xcj refers to the j-th column of X.









































































X∗c1 · · · X∗cI
]
γkji = e
−γrkji for i ∈ {1, 2, ..., I − 1}
γ′kj = (γkj1, ..., γkj,I−1, 1)
We optimize the likelihood with respect to these isoform expression parameters using R’s constrOptim
from the alabama package. To this end, we specify the derivative to improve efficiency of the
routine. This derivative is found on the next page.
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In the following, let X∗e refer to the e-th row of the matrix X
∗ and Xe,(I) be the truncated version of
















A.2.5 Stage 2 Estimation: Defining Penalties
We must now incorporate the estimates from purified reference samples to guide estimation
within the mixture. We choose to accomplish this using a penalty function over the isoform
expression parameters within the mixture. As we have allowed for biological variance in gene and
expression parameters across subjects and because these parameters are probabilities, it is natural to
propose a dirichelet distribution over these parameters.
Normally, by placing a dirichelet distribution over these parameters, one would construct a
likelihood function containing both pieces simultaneously. This likelihood would then be optimized
with respect to all parameters, including hyperparameters, at the same time. However, we found
this approach to be unstable. Thus, we separate the estimation of individual expression parameters
from the hyperparameters to improve results. Fixing the individual gene and isoform expression
parameters, we construct a likelihood optimization using the dirichelet piece. Optimization of this
likelihood proceeds numerically using quasi-Newton methods and non-negativity constraints. The
following derivatives improve accuracy of the estimates obtained from R’s nlminb.
Gene Expression Penalty:




[lnΓ (αk1 + αk2)− lnΓ (αk1)− lnΓ (αk2) + (αk1 − 1) log(τkj) + (αk2 − 1) log(1− τkj)]
The necessary derivatives are provided here. Denote the digamma function by ϕ() and trigamma by
ϕ1() for this derivatives.
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∇`τk = nk
ϕ(αk1 + αk2)− ϕ(αk1)





Hess (`τk) = nk
ϕ1(αk1 + αk2)− ϕ1(αk1) ϕ(αk1 + αk2)
ϕ(αk1 + αk2) ϕ(αk1 + αk2)− ϕ(αk2)

Isoform Expression Penalty:
As for the gene expression penalty, we define the likelihood here. To clarify the following terms,
define βk· =
∑I






































Hess (`γk) = nk
(
11Tϕ1 (βk·)− diagi (ϕ1(βki))
)
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A.2.6 Stage 3 Estimation: Mixture Sample Estimation
To structure the likelihood model within the mixture sample, consider the following underlying
likelihood model. In this model, we assume that the number of reads mapping to each cell type
within each gene and outside of it can be observed and that tm represents the total read count in the
mixture.







∣∣∣∣τ ∗k , γ∗k ∼ Multinomial
tm,





1 · · · pKτKXγ∗k


When allowing IsoDeconv to consider genes mapping outside of the gene of interest, initial
simulations demonstrated that these terms dominated estimation. This occurs since over 99% of all
reads map outside the gene of interest and thus drown out the information within the gene due to
sheer abundance. Restricting to reads within the gene of interest only, estimation behavior was seen
to improve (not shown). Thus, using lemma 1.1 to combine all contributions of cell types outside



















However, due to the properties of bulk expression datasets, we do not observe the number of














The update of such a likelihood is a computationally difficult problem - we have I+2 parameters
being measured for each cell type and all must be optimized simultaneously. To improve the
tractability of such a numerical optimization technique, we utilize the EM algorithm.
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For this problem, the missing data that we will assume is the expression from each individual
cell type. Thus, we revert to the likelihood given above in equation (A.1). The complete data























lnΓ (αk·)− lnΓ (αk1)− lnΓ (αk2) + (αk1 − 1) log(τ ∗k ) + (αk2 − 1) log(1− τ ∗k )
lnΓ (βk·)− lnΓ (βk1)− · · · − lnΓ (βkI) +
I∑
i=1






The EM algorithm utilized to solve this problem is composed of three separate steps.
1 E-Step: Update Posterior Means of Zke∗
2 M-Step (1): Update (p1, ..., pk, τ ∗k )
2 M-Step (2): Update γ∗k
These steps are outlined below.
E-Step: Update Posterior Means of Zke∗:
Recall that the observed expression values, the Ze, represent the sum of all counts from each cell
type. Thus, Ze =
∑K
k=1 Zke∗ . By grouping elements of the multinomial according to exon set, a
simple application of lemma 3 provides:
(Z11∗ , ..., ZK1∗ , ..., Z1E∗ , ...ZKE∗)









































M-Step (1): Update (p1, ..., pK , τ ∗K):
It is clear from the complete data log-likelihood specified above that the cell type proportions
and gene expression parameters must be updated simultaneously. These terms are inextricably
linked within the log function. We do note that this set of parameters is separable from the isoform
parameters as the likelihood can be partitioned into a sum of two independent pieces, one containing
the gene expression parameters and cell type proportions and the other containing the isoform
parameters. Thus, we consider recasting the likelihood to include only the cell type proportions and
gene expression parameters.

















+ (βk1 − 1) log(τ ∗k )+




































Zk·∗ log[pk exp{−τ ′k}] + (βk1 − 1) log(exp{−τ ′k})+







Taking the expectation of this likelihood will result in the use of quantities found in (1) to
replace the Zke∗ pieces. In the following, we leave the the Zk· notation for simplicity of notation,
but please note that these values have been replaced by their expectations.
Taking the derivative of `(p, τ ∗) with respect to the reparametrized τ ∗, we have:
˙̀
τ ′r(p, τ
∗) = −Zr· − (βk1 − 1) +







To consider the derivatives of the proportions, we consider the natural linearity constraints to
rewrite the likelihood as follows and subsequently take the derivative:




































The update of the procedures proceeds using a joint, constrained optimization approach using
R’s constrOptim.
M-Step (2): Update γ∗k:
As noted above, we may update the γ∗k separately from one another and from the proportion and
gene expression parameters. The piece of the likelihood governing the update of isoform expression
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(αkI − 1) log
(
1− l̃1γ∗k1 − · · · − l̃I−1γ∗k,I−1
)
For simplicity of notation in the following, we suppress the notation regarding expectations of
the missing parameters. Note, however, that these values are replaced by their expectations derived
in the E-step.
Recall the special definitions of X∗, X∗e and X
∗
e,(I) from their use in the pure sample expression
materials. In addition, we define reparameterized isoform expression parameters for the mixture
given by γ∗ki = exp {−γ∗rki } to simplify constraints. Finally, we define l̃(I) as the l̃ vector with the













− (βk − 1)+(
βkI − 1
1− l̃1 exp{−γ∗rk1} − · · · − l̃I−1 exp{−γ∗rk,I−1}
)(
l̃(I) ◦ exp{−γr∗k }
)
Thus, given the restrictions outlined for the pure sample case, we utilize this derivative in R’s
constrOptim to update the isoform expression parameters.
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A.2.7 Simulation Supplement
To construct a single simulated mixture composed of two cell types, we must construct fac-
similes to the following components of real RNA-seq experiments: Gene and Isoform construction
models, Gene expression averages, Isoform expression level averages for an arbitrary cell type 1,
and isoform expression level averages for an arbitrary cell type 2.
Gene and Isoform Construction Models:
Approximately 400 genes and corresponding gene/isoform construction models were extracted
from the IsoDeconvNB in silico mixtures using GM12878 and HMEC cell lines. Therefore, these
construction models contain genuine gene and isoform constructions as well as realistic distributions
of RNA fragment lengths for construction of an effective length matrix.
Gene Expression Level:
To simulate expression at a single gene, the average read count for cell type 1, r1, is randomly
drawn from a normal random variable with mean 130 and standard deviation 33. From this, we







where v is a Chebyshev derived variance inflation factor. This
provides a mean expression level for an arbitrary cell type 1. For 25% of simulated genes, the
average expression of the gene in cell type 1 is upregulated by 20% for cell type 2. An additional
25% of genes see downregulated expression by 20% for cell type 2. The remaining genes exhibit no
gene-level expression differences across cell types.
Isoform Expression Level (Cell Type 1):
In order to construct an isoform expression profile, simulation methods were developed according




(A) Simulate isoform probability averages from a Dirichlet(7.5,2.5) distribution.
(B) Randomly permute these averages across isoform identities to obtain α∗k.
(C) Utilize a Chebyshev Derived Variance Factor (v) to multiply isoform averages in order to
control variance in simulated isoform expressions. Thus, α1 = vα∗1.
(D) Simulate 3 or 50 purified reference sample isoform expressions utilizing a Dirichlet(α1)
Three Isoforms:
(A) Simulate isoform probability averages from a Dirichlet(6.0,3.0,1.0) distribution.
(B) Randomly permute these averages across isoform identities to obtain α∗k.
(C) Utilize a Chebyshev Derived Variance Factor (v) to multiply isoform averages in order to
control variance in simulated isoform expressions. Thus, α1 = vα∗1.
(D) Simulate 3 or 50 purified reference sample isoform expressions utilizing a Dirichlet(α1)
Four + Isoforms:
(A) Simulate isoform probability averages from a Dirichlet(4.5,2.5,1.5,J) where J is a vector of
length I − 3 with values 1.5/(I − 3) for each entry.
(B) Randomly permute these averages across isoform identities to obtain α∗k.
(C) Utilize a Chebyshev Derived Variance Factor (v) to multiply isoform averages in order to
control variance in simulated isoform expressions. Thus, α1 = vα∗1.
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(D) Simulate 3 or 50 purified reference sample isoform expressions utilizing a Dirichlet(α1)
Isoform Expression Level (Cell Type 2):
To simulate isoform expression level averages in cell type 2, the averages of cell type 1 are permuted
in such a way that none of the top 2-3 isoforms of cell type 1 are the major isoforms of cell type 2.
For genes with 2 or 3 isoforms, this is accomplished by permuting the largest element of α1 to a
new location in α2 and randomly ordering the remainder. For genes with four of five isoforms, the
top two largest elements of α1 are permuted to new locations in α2 and the remainder are randomly
ordered. For genes with 6+ isoforms, the top 3 elements of α1 are permuted to new locations in α2
and the rest are randomly ordered.
Chebyshev Derived Variance Factor:
Chebyshev’s rule states that 90% of observations fall with 3 standard deviations of the mean.
To derive the variance control factor based on Chebyshev’s rule and a desire to have 90% of
observations fall within Z*100% of the truth, we have:
3
√







For isoform expressions, variance is largest when p = 0.5. Thus, to specify the value v for isoforms,
we utilize an assumption of p = 0.5 to control the variance in the worst-case setting.
Simulate Mixture Expression:
After the preceding steps have been accomplished, the Dirichlet structure specified in the paper is
fully specified. Thus, we plug these simulated parameters into the multinomial structure to simulate
a single mixture experiment.
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APPENDIX B: SUPPLEMENT FOR CHAPTER 4
B.1 Supplementary Methods
B.1.1 Notations and overview
B.1.1.1 Notation Table
The following table contains the notation used to develop and mathematically interrogate the
ICeD-T model and its variants. Subscripts for aberrant genes, denoted by (·) in the following table,
may take values (A) or (C); (A) indexes quantities pertaining to aberrant genes and (C) indexes
those in consistent genes.
Model Design Quantities
Value Dimension Description
n 1× 1 The number of mixed cell type samples for deconvolution.
nk 1× 1 The number of purified samples of cell type k.
K 1× 1 The number of constituent cell types, excluding the tumor.
nG 1× 1 The number of signature genes used in cell type modeling.
Pure Sample Quantities
Value Dimension Description
µjk 1× 1 Mean log-transformed expression of gene j in cell type k.
σ2jk 1× 1 The variance of log-transformed expression of gene j in cell type k.
γjk 1× 1 The mean expression of gene j in cell type k on the untransformed scale.
γ nG ×K Matrix of mean expression across all genes and cell types.
γj K × 1 Vector of mean expressions of gene j across the K cell types (j-th row of γ).
Zjkh 1× 1 Normalized expression of gene j in purified sample h of cell type k.
Zk nG × nq Collection of Zjkh across all genes and purified samples.
Mixture Sample Quantities
Value Dimension Description
µ̃ij(·) 1× 1 Mean expression of gene j in mixture sample i
ρik 1× 1 Proportion of RNA expression attributable to cells of type k in mixture i.
ρi K × 1 Collection of ρik across cell types for subject i only.
σ2ij(·) 1× 1 Variance of expression for gene j in mixture sample i.
σ2i(·) 1× 1 Unweighted variance parameter governing expression in mixture sample i.
∆j 1× 1 Optional variance weight for gene j.
Yij 1× 1 Normalized expression of gene j in mixture sample i.
Yi nG × 1 Collection of Yij across genes for subject i only.
Table B.1: Notation for defining the ICeD-T model.
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B.1.1.2 Overview of Optimization Algorithm
 
REFERENCE MATRIX  
Reference Cell Types: 
• 𝜇𝜇𝑗𝑗𝑗𝑗 ,𝜎𝜎𝑗𝑗𝑗𝑗2  
• Use all samples 
• Fixed after est. 
INITIALIZE PARAMETERS 
Weights �𝚫𝚫𝒋𝒋�: 
• Estimate once 
• Not Updated 
 
Proportions (𝝆𝝆𝒊𝒊): 
• Linear model per subject 
• 𝐸𝐸�𝑌𝑌𝑖𝑖𝑗𝑗� =  ∑ 𝜌𝜌𝑖𝑖𝑗𝑗𝛾𝛾𝑗𝑗𝑗𝑗𝐾𝐾𝑗𝑗=1  
UPDATE 𝒑𝒑𝒊𝒊 
Section A.5.2 –  
• Closed form update  
Prior Constructed Reference 
• LM22 (CIBERSORT) 
• TRef (EPIC) 
• BRef (EPIC) 
Consistent / Aberrant Variance: 
• See (A.5.1) 
• Genes w/ residuals in 






Section A.5.2 –  
• (Un)weighted GLM 
• Constrained Numerical Opt. 
 
UPDATE 𝝈𝝈𝒊𝒊(∙)𝟐𝟐  
 Section A.5.2 –  
• Constrained Numerical Opt 
 
UPDATE 𝒘𝒘𝒊𝒊𝒋𝒋 
Section A.5.1 –  
• Closed form update 
FURTHER ANALYSES 
EM ALGORITHM 
- OR -  
Figure B.1: Visual representation of the ICeD-T algorithm from development of reference matrices
to EM algorithm.
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B.1.2 Pure Sample Optimization
We focus first on estimation using purified reference samples. Recall that for reference sample









The first and second central moments of which are given by:


















Assuming independence of expression across genes within a sample and across samples, the



















In the low sample size setting, we may borrow information across cell types for estimating the






















B.1.3 Variance Weight Selection
The ICeD-T model allows for the provision of variance weights to be used in optimization of
the log-normal model. In essence, variance weights increase or diminish the importance of residuals
across various genes. The larger the weight, the more a residual at the given gene is discounted.
We suggest the following weight schema be used in the ICeD-T model. In order to compute these
weights, the user must provide the variance of the log-expression for each cell type and each gene.
Option 1: Homoscedastic Weights
“Homoscedastic Weights” is a misnomer as this corresponds to setting ∆j = 1 for all j. No dis-
counting is performed as each gene is assumed to have the same variance.
Option 2: Maximal Variance Weights
The second option utilized by ICeD-T is termed “Maximal Variance Weights”. For this weight
















To ensure that the variance weights do not make some genes too over- or under-influential, we let the
top 15% of weights take 85th-percentile value and the bottom 15% take the 15th-percentile value.




To simplify the maximum likelihood optimization used by the ICeD-T algorithm, we seek a
closed-form approximation to the distribution of a sum of independent log-normals. The Fenton-
Wilkinson approximation to the distribution of a sum of log-normals provides such an approach.
Consider a simplified framework of random variables Yj for j = 1, ..., K where Yj ∼ LN (µk, σ2k)
and the variable of interest Y =
∑K
k=1 Yk. Fenton-Wilkinson approximates the distribution Y by






































































B.1.5 Mixture Sample Optimization
The ICeD-T model assumes that distribution of expression at a single gene in tumor sample i
is a mixture over two log-normals, one component assuming the gene is a consistent gene and the

























ICeD-T can be run using two options. Option (1) represents a homoscedasticity assumption and as-
sumes ∆j = 1 for all j. Option (2) allows for these variance weights to differ and must be specified
before optimization. Utilizing these assumptions for variance provide superior performance in the
estimation of cell type proportions compared to a direct application of Fenton-Wilkinson.
We also note that the separating feature between consistent and aberrant genes is the assumed
variance. In particular, aberrant genes are assumed to have a larger variance. In essence, a larger
variance for aberrant genes ”flattens” the observed likelihood, allowing for values inconsistent with
the model proportions to become more likely.
In order to optimize this mixture distribution, we utilize an EM algorithm. We introduce missing
data in the form of indicators of class membership, Hij . When Hij is 1, the gene is assumed




























The EM algorithm will replace Hij with their posterior expectations wij = E
[
Hij
∣∣Yij, φ] prior to
optimization at each iteration where φ is a collection of current estimates of abundances, individual
variances, and aberrance proportions.
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B.1.5.1 Update Posterior Means




















































B.1.5.2 Update pi, σ̃
2,((·))
i , and ρi









we may estimate these parameters separately.
Update pi:















The cell type proportions and variance parameters are not separable within the likelihood and must
be updated simultaneously. We opt for a block coordinate ascent algorithm consisting of two blocks;
cell type proportions compose block 1 and variance terms compose block 2. Block 1 is updated
while block 2 is held fixed, then block 2 is updated while block 1 is fixed. This process is repeated
until convergence.
Consider first the variance terms without variance weights. Holding the cell type proportions
fixed, the terms pertaining to aberrant and consistent genes are separable. We focus on the portion
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Under option (2), we did not find a closed form update for these variance terms opting to use
numerical optimization. Under option (1), we can further reduce this equation by plugging in









































































We now turn to the cell type proportions piece, assuming the variance terms are held fixed. The


























Before constructing the derivative of this likelihood with respect to our cell type proportions, we
examine derivatives an interior of the likelihood to improve clarity of the full derivation. In the

























































































To ensure proper constraints during fit, numerical optimization routines from R’s constrOptim
function in the alabama package are used to optimize the log-likelihood with respect to ρi.
When no information is assumed for the proportion of a (K + 1)-st cell type (e.g. a tumor cell
type), these proportions are non-negative and allowed to sum to a value less than 1. If the proportion
of a (K + 1)-st cell type is assumed (e.g. tumor purity), the proportions are constrained to sum
to 1− ρK+1. As noted in the main paper, the (K + 1)-st cell type is assumed not to express or to
express at a minimal level across the nG genes used for optimization.
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B.2 Simulations Supplement
The first assessment of the estimation properties of the ICeD-T model was performed on
in silico simulated datasets. For each simulation, we constructed two sets of expression pseudo-
experiments: reference expression datasets from 5 simulated reference cell types and reference
expression datasets from 135 mixture datasets composed of expression from 4 of these 5 cell types.
Each expression experiment consists of expression values across 250 common loci. Within the
mixtures, one cell type represents a ”missing” cell type for each sample; this cell type is known to
be present in the mixture but it does not express at the 250 modeled loci.
These simulations were built in three main steps: Step (1) generates purified reference sample
expressions and variance measures; Step (2) generates mixture expression files for deconvolution;
and step (3) edits the output expressions from step 2 to allow for aberrant gene behavior.
B.2.1 Step 1 - Generating Pure Sample Expressions
The first element in generating pure sample expressions is to define profiles from which each
”purified reference” sample is simulated. For each locus separately, it is randomly determined
whether the locus is lowly, moderately, or highly expressed. In addition, one of the four expressed
cell types is labeled the indicated cell type for this locus while the remaining cell types are considered
background. We then simulate a mean log-expression for each gene and cell type according to the
following table:
Level Pct. Loci Background Indicated
Low 33% Uniform(2.0, 4.0) Uniform(3.5, 5)
Moderate 33% Uniform(4.0, 6.0) Uniform(5.5, 7)
High 33% Uniform(6.0, 8.0) Uniform(7.5, 9)
Once the mean log-expressions are simulated, we must construct a reasonable variance schema
for these average log-expression profiles. We construct a mean-variance relationship in the log-
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expression setting by mirroring an example found in FPKM-normalized RNA-seq data.
Read counts from purified samples of B-cells (20), CD4 T-cells (20), CD8 T-cells (20), Monocytes
(20), Neutrophils (20) and Natural Killers (14) were downloaded from the Array Express website
from the Linsley et al study [60]. The read counts for each sample are FPKM normalized, utilizing
the (75th-percentile read count/1000) instead of total read depth for each subject. The mean-variance
relationship is modeled across 441 immune-related genes for each of these six cell types using a
Loess curve, similar to the procedure utilized by VOOM [67]. This Loess curve was used to map the
simulated log-expression means for each gene and cell type to a data-supported variance measure.
Random error was also introduced.
Following the generation of the mean and variance profiles, the 5 or 15 purified, reference-sample
pseudo-experiments are generated for each cell type from its profile via a log-normal distribution.
B.2.2 Step 2 - Generating Mixture Expressions
We must now generate the mixture expression pseudo-experiments. We first generate the
proportion of the missing cell type from a standard normal distribution with mean 0.60 and standard
deviation 0.15. In addition, any of these proportions falling below 17% or above 95% are set at 17%
and 95% respectively. The remaining proportions are simulated from a Dirichlet distribution with
average abundances ranging from 15% to 40%.
With the proportions generated for each of the 5 cell types and each subject, we turn to simu-
lating the expression experiments. For each subject individually, we construct mixture experiments
according to the following algorithm.
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Thus, these mixture expression experiments are simulated as true convolutions of independent
log-normals. In this way, we can examine the adequacy of our approximated distribution.
B.2.3 Step 3 - Edit Mixtures to Create Aberrance
The final step in the mixture experiments is to allow loci to misbehave. We allow 3 mechanisms
for misbehavior. Mechanism 1 takes the expression of the indicated cell type and downregulates
it to 25% - 75% of its true level; mechanism 2 takes the expression of the indicated cell type and
upregulates it to 133% - 400% of its true level; and mechanism 3 allows the missing cell type to
express at the background levels established above. The table below summarizes these mechanisms.
Mechanism Pct. Ab. Loci Indicated CT Effect Missing CT Exp.
1 - Downregulate 25% Uniform(25%, 75%) 0
2 - Upregulate 25% Uniform(133%, 400%) 0
3 - Missing Exp. 50% 0 Uniform(., .)
Table B.2: Pct Ab. Loci = Percentage of Aberrant Loci Effected, Indicated CT Effect = Effect on
the expression of Indicated Cell Type, Missing CT Exp = Expression Level of Missing Cell Type
For impacted loci, expression is resimulated as in B.2 with the revised expression profiles. The




Pct Ab. = 0%, No. Rep. = 5
Figure B.2: Visualizing simulation results with 5 reference samples per cell type and no aberrance.
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Pct Ab. = 0%, No. Rep. = 15
Figure B.3: Visualizing simulation results with 15 reference samples per cell type and no aberrance.
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Pct Ab. = 15%, No. Rep. = 5
Figure B.4: Visualizing simulation results with 5 reference samples per cell type and 15% of genes
behaving aberrantly.
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Model Aberrant 1Q Med 3Q
ICeD-T (No Weight) Yes 0.000 0.114 0.607
No 0.625 0.748 0.824
pi 0.572 0.612 0.655
ICeD-T (Weights) Yes 0.004 0.468 0.823
No 0.804 0.884 0.931
pi 0.718 0.768 0.803
Table B.3: Summarizing ICeD-T’s ability to detect aberrant gene behavior (Pct. Ab. = 15%, No.
Rep. = 5).
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Pct Ab. = 18%, No. Rep. = 15
Figure B.5: Visualizing simulation results with 15 reference samples per cell type and 18% of genes
behaving aberrantly.
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Model Aberrant 1Q Med 3Q
ICeD-T (No Weight) Yes 0.000 0.043 0.538
No 0.647 0.769 0.838
pi 0.579 0.613 0.657
ICeD-T (Weights) Yes 0.000 0.114 0.744
No 0.797 0.872 0.920
pi 0.697 0.738 0.772
Table B.4: Summarizing ICeD-T’s ability to detect aberrant gene behavior (Pct. Ab. = 18%, No.
Rep. = 15).
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Pct Ab. = 30%, No. Rep. = 5
Figure B.6: Visualizing simulation results with 5 reference samples per cell type and 30% of genes
behaving aberrantly.
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Model Aberrant 1Q Med 3Q
ICeD-T (No Weight) Yes 0.001 0.194 0.645
No 0.618 0.659 0.791
pi 0.530 0.555 0.587
ICeD-T (Weights) Yes 0.011 0.552 0.824
No 0.780 0.862 0.897
pi 0.673 0.707 0.725
Table B.5: Summarizing ICeD-T’s ability to detect aberrant gene behavior (Pct. Ab. = 30%, No.
Rep. = 5).
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Pct Ab. = 35%, No. Rep. = 15
Figure B.7: Visualizing simulation results with 15 reference samples per cell type and 35% of genes
behaving aberrantly.
Model Aberrant 1Q Med 3Q
ICeD-T (No Weight) Yes 0.002 0.202 0.582
No 0.574 0.678 0.734
pi 0.480 0.503 0.529
ICeD-T (Weights) Yes 0.013 0.406 0.730
No 0.714 0.790 0.837
pi 0.597 0.621 0.643
Table B.6: Summarizing ICeD-T’s ability to detect aberrant gene behavior (Pct. Ab. = 30%, No.
Rep. = 15).
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We see from the above that the ICeD-T model with and without weights provides the best fit
for these simulated data in terms of both sum of squared error and correlation. The aberrance model
adequately handles the misbehavior across loci even up to 30% aberrance, with the weighted model
providing the strongest estimation. It most closely estimates the proportion of aberrant genes and
provides stronger distinctions in the probabilities of aberrance given the data.
As we reach 30% aberrance, we do note a slight bias in ICeD-T’s results beginning to become
evident near the tails. However, even when compared against CIBERSORT–a method which
provides a very strong runner-up in these simulated data– we see that ICeD-T is superior. This is a
classic case of the bias-variance trade-off. ICeD-T allows some bias to impact results as aberrance
increases, but maintains a strong linear relationship. CIBERSORT, on the other hand, experiences in-
creasing variability and a slightly diminshed linear relationship as the amount of aberrance increases.
We also fit the ICeD-T model without using estimates of tumor purity (data not shown). The
model performs well up to 30% aberrance, however, at around 30% aberrance it begins to struggle
to capture aberrant genes appropriately. Regardless of this fact, the ICeD-T model with weights
continues to be one of the strongest performers even up to 30% aberrance.
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B.3 CIBERSORT Flow Cytometry Validation
The second assessment of the performance properties of the ICeD-T model is performed in
real data. In their paper ”Robust Enumeration of Cell Subsets from Tissue Expression Profiles,” the
creators of CIBERSORT validate their modeling procedure on peripheral blood mononuclear cells
(PBMCs) extracted from 20 adult subjects. We reanalyze this dataset using CIBERSORT’s web
application, the ICeD-T model, and EPIC.
B.3.1 Data
PBMCs were extracted from each of 20 adult subjects. For each sample, expression profiles
were created using microarray expression analysis. Additionally, each sample was examined using
flow cytometry to measure the ground-truth abundance of each of the immune cell types composing
the PBMCs. The resulting datasets were provided to us directly by Newman et al. In addition, the
microarray expression data from purified samples of 22 immune cell types used to construct LM22
were also provided.
B.3.2 Cell Type Size Correction
The authors of EPIC advocate the use of cell size factors to correct regression results for
differences in the productivity of various cell types composing mixture experiments. In their work,
“Simultaneous Enumeration Of Cancer And Immune Cell Types From Bulk Tumor Gene Expression
Data,” they note that cells of various types produce differing levels of mRNA. We borrow these cell
size factors here and use them to correct the results of CIBERSORT and ICeD-T as was performed
below. The cell size factors utilized here are provided below. Cell size factors are incorporated into
model estimates after running the ICeD-T or CIBERSORT models as was done in EPIC. Define sk
to be the cell size factor for a cell type k. Then the revised estimate of abundance for cell type k is
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Cell Size Factor Extensions
B-Cells 0.40 Naive and memory B-cells
T-Cells 0.40 Naive, memory-resting and memory-activated CD4 T-cells;
CD8 T-cells; Delta-Gamma T-cells
NK cells 0.42 None
Monocytes 1.40 Macrophages, Dendritic Cells
Neutrophils 0.15 Eosinophils, Mast Cells







B.3.3 Model Fit Description
CIBERSORT:
The CIBERSORT web application (Version: CIBERSORT Jar 1.06) was used to fit these microarray
data. The model was fit using the LM22 signature matrix run with quantile normalization and 500
permutations.
EPIC:
The EPIC library was downloaded from https://github.com/GfellerLab/EPIC in February 2018. The
mixture expression data is quantile normalized and fit to the LM22 reference matrix using EPIC
with default options, except scaleExprs set to FALSE.
ICeD-T:
The ICeD-T model was fit to the LM22 reference without specifying the proportions of extraneous
cell types in the model and no weights, maximal variance weights, and maximal expression variance
weights. Variance weights were computed using the variance of log-transformed expression across
all purified references of a given cell type.
Quantile Normalization:
EPIC and ICeD-T require that the modeled mixture data be measured on the same scale as the
design matrix utilized for modeling. To this end, the purified references used to compose the LM22
matrix are quantile normalized. The mixture data are then quantile normalized to the target distri-
bution specified by the purified references using the preprocessCore library and its functions
normalize.quantiles.determine.target and
normalize.quantiles.use.target. This normalization is performed prior to specifica-
tion of gene and cell type variance measures.
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Result Renormalization:
Results are handled in the manner suggested by Newman et al in personal correspondence as was
performed for their manuscript. All estimated cell type proportions are restricted to the ten examined
cell types: B-cells naive, B-cells memory, CD8+ T-cells, naive CD4+ T-cells, resting memory CD4+
T-cells, activated memory CD4+ T-cells, Delta-gamma T-cells, Activated and resting natural killer
cells, and Monocytes (including the modeled macrophage populations). These proportions are then
renormalized to sum to 100.
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B.3.4 Fit Comparison
The following table details the correlations and sum of squared errors for each of the fit models.
As noted above, each of these measures use cell size corrected proportions for examination.
Model SSE Cor
ICeD-T (No Wgt) 13099.93 0.53
ICeD-T (Max Var Wgt) 12050.67 0.59
CIBERSORT 14146.59 0.65
EPIC 29427.74 0.31
Table B.8: Fit summary statistics for each model compared against flow cytometry measured
ground-truth.
We note from the above that the CIBERSORT model provides the best results in terms of correla-
tions. However, each of the fit ICeD-T models provide superior fit in terms of sums of squared errors.
When using variance weights, the correlations between ICeD-T estimates and CIBERSORT become
comparable as well (∼0.60 vs. 0.65). Thus, it appears that the ICeD-T method is comparable to
CIBERSORT in terms of correlation and provides superior results in terms of error.
In the following considerations, we will focus on the ICeD-T model with maximal variance
weights. Despite the fact that the maximal expression weights produced the best fit for both overall
correlation and sum of squared errors, it has notably weaker fit for many important cell types
(e.g. CD4, CD8). Compared to CIBERSORT, in addition to having lower overall error, ICeD-T
appears to provide superior performance for memory B-cells, naive CD4 T-cells, and gamma-delta
T-cells. Both CIBERSORT and ICeD-T provide comparable performance with respect to monocyte
expression. Both models struggle with CD8 T expression despite being well correlated for this cell
type as CIBERSORT tends to overestimate expression by in the upper tail where ICeD-T seems to
underestimate.
The results provided by the EPIC model are very poor for this dataset. However, this is not a
condemnation of EPIC’s use in real data. EPIC was designed for RNA-seq data, not for microarrays.
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Figure B.8: Plotting true, relative abundances of 9 immune cell subpopulations against ICeD-T (no
weights) estimates.
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Figure B.10: Plotting true, relative abundances of 9 immune cell subpopulations against CIBER-
SORT estimates.
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B.4 EPIC Melanoma Data Validation
The third examination of the estimation properties of ICeD-T is performed on validation data
provided by Racle et al. It offers an opportunity to evaluate the performance of ICeD-T on RNA-seq
experiments from tumor samples.
B.4.1 Data
For more information regarding this dataset, see ’Simultaneous Enumeration of Cancer and
Immune Cell Types from Bulk Tumor Gene Expression Data’ from Racle et al. In brief, cells were
extracted from the lymph nodes of four patients with stage III melanomas. A portion of each of the
single cell suspensions obtained from these subjects was used for a flow cytometric analysis while
the remaining portion was used for bulk RNA-sequencing.
The data was extracted directly from the EPIC library, file accession pathway given here:
EPIC-master/data/melanoma data.rda. This RData files contains a single list object
melanoma data, which houses fields containing the TPM-normalized RNA-seq expression for
each subject, the flow-cytometry measured cell type proportions, and the predicted EPIC cell type
proportions obtained using the TRef reference matrix.
B.4.2 Model Fit Description
CIBERSORT:
The CIBERSORT web application (Version: CIBERSORT Jar 1.06) was used to fit these TPM




The EPIC model was fit to these TPM normalized RNA-seq data using its TRef reference matrix
and all default options.
ICeD-T:
The ICeD-T model is fit using all 4 combinations of the following options: (1) Use Tumor Purity:
Yes or no? (2) Use maximal variance weights: Yes or No?. For the purposes of this analysis, tumor




For the results shown below, all immune content is corrected for cell type size and renormalized
so that proportions are computed with respect to the immune cells in the mixture (B-cells, CD4+
T-cells, CD8+ T-cells, and Natural Killers).
Table B.9: Melanoma Data - True relative proportions of Immune cells
Table B.10: Melanoma Data - True relative proportions of Immune cells
It is clear from the above that CIBERSORT would produce the minimum sum of squared error
among all model fits due in chief to the manner in which it handles subject LAU125. ICeD-T with
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use of Tumor information (both with weights and maximal variance weights), produced the second
best fit by sum of squared error. EPIC would produce the third best fit by sum of squares. Finally,
ICeD-T without tumor purity would produce the worst results.
Examining subject LAU125, this subject is highly anomalous. This subjects immune response in
this sample is composed almost entirely of B-cells. Both EPIC and ICeD-T struggle to estimate the
B-cell proportions for this subject - a likely consequence of their use of the same reference matrix.
CIBERSORT does not struggle as greatly with this single subject and thus experiences smaller sums
of squared error.
Across the remaining individuals, ICeD-T using any option produces the best results for LAU1255
and LAU335. ICeD-T without tumor purity and using maximal variance weights produces the
best results for LAU1255, LAU1314 and LAU 335. Thus, outside of the strange subject LAU125,
ICeD-T is able to provide the most competitive results across remaining subjects.
Focus now on the estimation of CD8 T-cell abundance across all methods. The use of ICeD-
T without Tumor purity provides the best fit across the singular cell type among all individuals.
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B.5 PD-1 Checkpoint Therapy Use in Melanomas
The final validation datasets for the ICeD-T method examine its application to a set of RNA-seq
experiments derived from patients on PD-1 Checkpoint inhibitor therapies [71].
B.5.1 Data
The raw fastq files of RNA-seq data were downloaded from Sequence Read Archive (https:
//www.ncbi.nlm.nih.gov/sra), under the accession numbers SRP067938 and SRP090294.
We mapped the RNA-seq reads to hg38 reference genome using STAR with gene annotation from




The CIBERSORT web application (Version: CIBERSORT Jar 1.06) was used to fit these TPM
normalized RNA-seq data. The model was fit using the LM22 signature matrix and run with quantile
normalization disabled.
EPIC:
The EPIC model is fit to the TRef reference matrix using TPM-normalized RNA-seq data.
ICeD-T:
The ICeD-T model is fit to the TRef reference matrix using TPM-normalized RNA-seq data. It
is fit both without weights and with maximal variance weights derived from the TRef reference
data. This is made possible through a function, EPIC.Extract, which extracts the fitted data and
reference matrix from the EPIC library’s function and outputs them in a form usable by ICeD-T.
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TPM-normalization:
As noted above, data were provided in gene count form. As such, computation of TPM values using










APPENDIX C: SUPPLEMENT FOR CHAPTER 5
C.1 Supplementary Methods
C.1.1 Notation Table
The following table contains the notation used to develop the TReC and TReCASE models
for an arbitrary gene a candidate eQTL of this gene. Subscripts specifying the gene and eQTL are
suppressed. The A allele and B allele are defined based on the genotype of the candidate eQTL.
TReC + ASE Quantities
Value Dimension Description
G(i) NA The genotype of subject i at the specified eQTL. Can take values:
AA – homozygous for A allele
AB – heterozygous
BB – homozygous for B allele
ρi 1× 1 Estimate of the tumor purity for the tumor sample of subject i, defined as
the proportion of cells that are tumor cells.
TReC Only Quantities
Value Dimension Description
Yi 1× 1 Total read count at the given gene in the tumor sample of subject i.
µiA 1× 1 The mean TReC for subject i at A allele.
µiB 1× 1 The mean TReC for subject i at B allele.
µi 1× 1 The mean TReC for subject i.
φ 1× 1 The overdispersion parameter for the distribution of TReC.
xi P × 1 Vector of covariate values for subject i
β P × 1 Vector of covariate impacts on log total read count.
di 1× 1 Read depth of RNA-Seq experiment for subject i.
ASE Only Quantities
Value Dimension Description
Ri 1× 1 The total number of allele specific reads for subject i.
RiB 1× 1 The number of allele specific reads mapped to the B allele for subject i.
ψ 1× 1 The overdispersion parameter for the distribution of the ASE.
eQTL Parameters
Value Dimension Description
η 1× 1 The eQTL effect in normal tissue: µ(N)iB /µ
(N)
iA .
γ 1× 1 The eQTL effect in tumor tissue: µ(T )iB /µ
(T )
iA .
κ 1× 1 An over-expression effect in the tumor for A allele: µ(T )iA /µ
(N)
iA .
ξi 1× 1 The ratio of gene expression of B allele versus A allele for subject i,
defined as µiB/µiA.
Table C.1: Notation for defining the TReC and TReCASE models.
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C.1.2 Optimization Algorithm
As mentioned in main text, the optimization routine for solving the TReC and TReCASE
models uses a coordinate block ascent routine with the following steps.
(0) Select initial estimates for κ, η, and γ.
(1) Holding κ, η, γ, and ψ constant, use negative binomial regression to update β and φ.
(2) Holding β, φ and ψ constant, use a Quasi-Newton method (LBFGS) to update κ, η, and γ.
(3) Holding β, φ, κ, η, and γ constant, update ψ using a Quasi-Newton method (LBFGS).
(4) Iterate steps (1)-(3) until convergence
The algorithm above is specified for the TReCASE model. A similar algorithm is used for
TReC model except that we need to remove step (3) and iterate steps (1) and (2) repeatedly (while
removing ψ from estimation procedures) until convergence.
To fully define the algorithm above, a discussion of Step (0) is warranted. Under the null
hypothesis η = 1, model fit proceeds following the above algorithm starting at position κ = 1 and
γ = 1 and holding η fixed at 1. Under the null hypothesis γ = 1, model fit proceeds as above,
starting at position κ = 1 and η = 1 and holding γ at 1 throughout. To fit the full model, we choose
initial values for κ, η, and γ in accordance with the fit of the null hypothesis, either η = 1 or γ = 1,
which gives larger likelihood value at its MLE. This initialization method ensures that the suggested
likelihood ratio tests are well-defined by avoiding situations where the likelihood of full model is
less than the likelihood of a restricted model.
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C.1.3 Mathematical Details for Optimization
Mathematical details for section (A.2) are presented in the following. Note that, as defined,
κ, η and γ are strictly positive parameters. Thus, we estimate log(η), log(γ), and log(κ) in the
optimization process to guarantee that κ, η and γ are all positive, and avoid constrained optimization
when working directly with κ, η and γ.
C.1.3.1 Total Read Count (TReC) Model Component
To motivate the structure of the TReC model, consider the ratio of the mean expressions for
alleles B versus allele A for subject i. Assume that the expression of each allele is a weighted sum
of its expression in normal and tumor tissues, weighted by the proportional composition of the





(1− ρi)µ(N)iB + ρiµ
(T )
iB



































(1− ρi)η + ρiκγ
1− ρi + ρiκ
= (1− ci)η + ciγ,
where ci = (ρiκ)/(1− ρi + ρiκ). Assuming now that the total expression for subject i is the sum of
the expressions from each constituent allele and modelling µ(N)i,AA = exp(x
T
i β), the above implies





i β(1− ρi + ρiκ), if G(i) = AA
ex
T
i β(1− ρi + ρiκ)(1 + ξi)/2, if G(i) = AB
ex
T
i β(1− ρi + ρiκ)ξi, if G(i) = BB
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Under a negative binomial distribution, the likelihood component for the TReC model for a single




























− (1/φ+ yi) log(1 + φµi) + yi log(φ) + yi log(µi)
]
.



























− 1 + φyi
1 + φµi
.






















Next, consider ∂µi/∂λ. It is easiest to consider this component separately for each genotype. For
































































































While not used for the C++ implementation of the model, the R-version uses the Hessian matrix
with respect to the κ, η, and γ variables. We derive it here for completeness. Let ˙̀TReC = ∂`TReC∂log(λ)
































































































The last equality holds since ∂
2µi
∂κ2














Similar results hold for η and γ and are given below:
∂2`TReC
∂ log(η)2











































































































0, if G(i) = AA
(1/2)ex
T
i βρi, if G(i) = AB
ex
T
i βρi, if G(i) = BB
C.1.3.2 Allele Specific Expression (ASE) Model Component
In the following, let µi1 represent the number of reads that are expressed by allele 1 on average
for subject i and µi2 be its counterpoint for allele 2. Within a sample prepped for RNA-seq, the pool
of reads for the given gene contains µi1 + µi2 reads. The proportion of reads belonging to allele 1








Thus, viewing the RNA-Seq sampling procedure as drawing a group of reads at random and allowing
for extra-binomial variation, we can model the data-generation mechanism via a beta-binomial dis-
tribution. Extra-binomial variation is often observed in genetic studies and in the case of ASE reads
can in part be attributed to incorrectly genotyped alleles resulting from genotyping or imputation
error.
In order to model a consistent eQTL effect within the TReC and ASE components of the model,
define allele 1 as that containing the minor allele B for heterozygous subjects. In homozygous
subjects, an arbitrary allele is selected as the expression between the two alleles is assumed to be
equal on average. Thus, by the statement above and previous definitions, we may model the average
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reads for allele 1 as:
πi =

ξi/(1 + ξi), if G(i) = BB
(1/2), otherwise
Thus, the likelihood for the ASE component of the model is given by:








Γ (ψ−1πi + riB) Γ (ψ
−1(1− πi) + ri − riB)
Γ (ψ−1 + ri)
]
.









log [f(riB; ri, πi, ψ)] .



































































Before deriving the remaining components necessary for the gradient, we note that only individuals
of heterozygous genotype contribute to the gradient of κ, η and γ, whereas all individuals contributed
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To calculate the above quantity, we need:
∂πi
∂ξi










= (γ − η)ci(1− ci)κ−1.
As noted in the previous section, the C++ fit routine does not utilize the Hessian but we provide its
derivation here for completeness. We will make repeated use of the following terms, so they are


























= −2(1 + ξi)−3
∂2ξi
∂κ2













































































Similarly for η and γ, we have:
∂2`ASE
∂ log(η)2































































































































































C.1.4 Cis-Trans Score Test
Recall that eQTL come in two varieties: cis- and trans-eQTL. cis-eQTLs induce allelic im-
balance of gene expression whereas trans-eQTLs affect the expression of two alleles to the same
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degree. [55] and [56] have developed and refined a “Cis-Trans test” to identify whether eQTL act in
a cis- or trans- fashion. Under the null hypothesis (cis-), the eQTL effect sizes are the same between
TReC and ASE models. A small p-value using this test leads to rejection of the null hypothesis,
and thus the conclusion that the given Gene-SNP pair behave in a trans-eQTL manner. In that case,
only the TReC data should be used for eQTL mapping.
To develop this test for eQTL mapping in tumor tissues, we follow [56] by extending the
likelihood framework through the introduction of new parameters which allow eQTL effects to
differ between TReC and ASE components. Specifically, we define:
ηASE = η + αη, and γASE = γ + αγ,
where η and γ are the TReC-specific eQTL effects in normal and tumor tissues, respectively;
ηASE and γASE are the ASE-specific counterparts; αη and αγ are the discrepancies of eQTL ef-
fects between ASE and TReC components of the model in normal and tumor tissues, respectively.
Then to test cis- versus trans-eQTL, we employ a score test for the two-dimensional hypothesis:
αη = αγ = 0.
C.1.4.1 Structure of the Score Test
Define the following groups of parameters: ε = (κ, η, γ)T ; α = (αη, αγ)T ; and Θ =
(βT , εT , αT , φ, ψ). Let ` = `TReC + `ASE be the full data log-likelihood, ˙̀ be the first deriva-
tive of the log-likelihood with respect to the parameters, and I (Θ) be the Fisher’s Information
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Matrix. We may specify the Fisher’s Information Matrix in the following way:
I(Θ) =

Iβ,β Iβ,ε Iβ,φ Iβ,ψ Iβ,α
Iε,β Iε,ε Iε,φ Iε,ψ Iε,α
Iφ,β Iφ,ε Iφ,φ Iφ,ψ Iφ,α
Iψ,β Iψ,ε Iψ,φ Iψ,ψ Iψ,α






where M1 is the upper-left block of the Fisher’s Information matrix through Iψ,ψ and M2 is the
remaining block excluding Iα,α.




























where θ̂ is the estimate of our parameters under the null. SC is asymptotically chi-squared with two
degrees of freedom under the null.
C.1.4.2 TReC Derivatives
Preceding development of the gradients and Hessians of the TReC components in the following
section, it will be helpful to compose a list of definitions and useful derivatives for later use. Recall
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i β [1− ρi + ρiκ] , if G(i) = AA,
ex
T





, if G(i) = AB,
ex
T
i β [1− ρi + ρiκ] ξi, if G(i) = BB,












This allows us to compose the following derivatives for ξi:
∂ξi
∂κ



































































































The Hessian for µi is identically 0 for genotype AA. However, for genotypes AB and BB, we have


































































































































To simplify the notation in our derivation, we define the following n × n diagonal matrices,
∆1 through ∆6. Elements on the diagonal are contained within the diag() notation below and are
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(yi − µi)(1 + 2 ∗ φµi)
V ar[Yi]2
)




lnΓ (yi + 1/φ)− lnΓ (1/φ)− lnΓ (yi + 1)− [1/φ+ yi] ln (1 + φµi) +
yi (ln(φ) + ln(µi))























































































(yi − µi)(1 + 2φµi)








































(µi + φµ2i )
2
= −Dµ(ε)T∆4JN .









−1)−Ψ0(φ−1)− ln(1 + φµi)
]




































Preceding development of the gradients and Hessians of the ASE component in the following
section, it will be helpful to compose a list of definitions and useful derivatives for later use. Recall
the definitions of ξAi and πi:
ξAi = (1− ci)(η + αη) + ci(γ + αγ)
πi =

ξAi /(1 + ξ
A
i ) , if G(i) = AB
0.5 , otherwise
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For genotypes AA and AB, πi is independent of our parameters. Only genotype AB will be



































0 0 0 0
∂ci
∂κ
0 0 0 0
−∂ci
∂κ
0 0 0 0
∂ci
∂κ
0 0 0 0

Then for an arbitrary λ, we have:
∂πi
∂λ


































































































































































ψ−1(1− πi) + ri − riB
)]






















































































C.1.4.4 Fisher’s Information: Observed or Expected
The traditional form of the score test involves use of the expected Fisher’s Information Matrix.
In the case where the expected value of the Fisher’s Information Matrix is difficult to compute,
the observed Fisher’s Information Matrix is often used [85]. In some situations, while use of
the observed Fisher’s Information Matrix still provides a statistically valid test under the null, it
can be unstable and produce inconsistent estimates of the variance matrix for MLEs [85]. In the
likelihood framework proposed by this paper, there is an inherent, stochastic dependence of Ri on
Yi. Namely, the value of Ri depends on the number of heterozygous SNPs present within the gene
body and cannot exceed Yi. This makes computing the expected Fisher’s Information Matrix chal-
lenging as it becomes an infinite sum of finite sums containing the digamma and trigamma functions.
As such, we may compute an approximation to the expected Fisher’s Information Matrix
which assumes that Yi and Ri are stochastically independent or we may use the observed Fisher’s
Information Matrix. The observed Fisher’s Information Matrix can be computed as in the previous
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section using untransformed κ, η, γ, and ψ or the log-transformations of these quantities. The log
transformation variant of the observed score test, termed Observed Score test (log), is slightly more
stable than its untransformed competitor. A comparison of these three methods [observed, observed
(log), expected] on simulated data is provided below. To evaluate Type I error of the Cis-Trans score
test, simulations follow the structure provided for the power simulations in the body of Chapter
5. To evaluate power, ξi,ASE is set to 0.5 for all subjects regardless of eQTL genotype and eQTL
effect strength. This behavior is designed to mimic trans-eQTL behavior. In the case of numerical
instability for the observed information Cis-Trans score tests, the expected information variant is
substituted.
Observed Score Test Observed Score Test (log) Expected Score Test
γ Value Power Type I Error Power Type I Error Power Type I Error
1.0 – 8.4 (7) – 8.9 (4) – 6.6 (5)
1.2 25.8 (6) 8.0 (2) 25.3 (4) 8.0 (4) 15.5 (0) 5.3 (1)
1.4 66.8 (38) 9.5 (10) 63.5 (35) 8.5 (3) 48.8 (0) 3.5 (0)
1.6 89.0 (88) 9.3 (2) 86.3 (66) 8.5 (4) 82.3 (0) 4.3 (0)
1.8 99.0 (185) 8.5 (2) 98.5 (164) 10.3 (3) 97.3 (0) 3.8 (0)
Table C.2: Summarizing the power and Type I error of the derived score tests. Number in parentheses
represents the number of failures due to numerical instability.
As we can see from Supplementary Table C.2, the observed information matrix variants of
the Cis-Trans Score test display superior power to the expected information variant at the cost of
an inflated type I error (∼8%). In addition, we note that the numerical instability of the observed
information variants leads to a high rate of computation failure for the Cis-Trans score test. Due to
its superior stability and Type I error, we opt to use the approximated expected Fisher’s Information
matrix within the real data analysis.
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C.2 Supplementary Results for Real Data Analysis
C.2.1 Sample Size
Among these 728 patients, 178 were excluded from our analysis: 18 did not have genotype data
(Affymetrix 6.0 array) from both tumor and paired normal samples, 35 failed Affymetrix genotype
quality control (QC), 22 were male or of unknown gender, and 112 were non-Caucasian individuals,





with affy 6.0 SNP data for 
tumor and normal tissues
685 samples

















Figure C.1: Sample size after each step of filtering.
C.2.2 Genotype Data Preparation
C.2.2.1 Genotype calling and quality control (QC)
We started our genotype data analysis with raw data in CEL files. After downloading all
the CEL files of Affymetrix 6.0 arrays, we saved the file locations of these CEL files into file









Low quality samples were determined via low contrast QC (contrast.qc ≤ 0.4) or low QC call rate
(qc.call.rate.all ≤ 0.8) (Supplementary Figure C.2).
Figure C.2: Results of genotype QC by APT. Each sample is labelled by the plate it belongs to. The
cutoff we use to select samples are QC call rate > 0.8 and contrast QC > 0.4.
After removing low quality samples, the new list of 685 remaining CEL files were recorded
in file cel_files_normal_after_qc.txt. We called genotypes and genders for these 685












To determine sample ethnicity, we performed PCA using genotype from TCGA samples together
with genotypes from HAPMAP CEU (Caucasian), YRI (African), and CHB (Asian) samples. The
PC1 versus PC2 plot clearly separated CEU, YRI, and CHB samples, and the TCGA samples that


























































Figure C.3: The left panel shows eigen-values of the PCA, and the right panel shows PC1 versus
PC2 plot. Based on this plot, we choose the Caucasian samples as those with PC1 < 0 and PC2 < 0.
C.2.2.2 Genotype Imputation
We imputed genotype data for the 551 samples that passed all the genotype-related filters. The
output of birdseed includes genotype calls for 909,622 SNPs. We removed those SNPs without
chromosome location information or with more than 5% of missing values leaving 832,334 SNPs
which passed these filters. We used MACH [78] (mach.1.0.18.Linux) to phase and impute the




C.2.3 RNA-seq Data Preparation
We downloaded RNA-seq bam files from the TCGA data portal. First, we pre-processed
these bam files using the R function prepareBAM of R package asSeq (http://research.
fhcrc.org/sun/en/software/asSeq.html), to remove duplicated reads, or reads with
average sequencing quality or mapping quality lower than 10. Next the expression of each gene
in a sample is calculated as the number of RNA-seq reads that overlap with the exonic regions of
this gene, obtained using R function asSeq/countReads. Annotations of exonic regions of
each gene were obtained from Ensembl (version Homo sapiens.GRCh37.66). Based on this version
of gene annotation, we obtained read counts for 53,561 genes. Many of these genes have zero
expression across most of the samples. We selected the 18,827 genes for which the 75 percentile of
gene expression is equal or larger than 20. In other words, we remove those genes whose expression
is less than 20 in more than 75% of samples.
To obtain allele-specific read counts for each sample, we first extracted all the heterozygous
SNPs per sample, and then extracted those RNA-seq reads that overlap with at least one heterozy-
gous SNP by R function asSeq/extractAsReads. Such RNA-seq reads were saved into three
bam files, one for reads that match haplotype 1, one for those that match haplotype 2, and one for
those with conflicts. For example, a conflicting read may overlap with more than one heterozygous
SNPs, and its haplotype assignment is not consistent across these heterozygous SNPs. Usually the
number of reads assigned to the conflict bam file is much smaller than the number of reads assigned
to the two other bam files, otherwise it indicates errors in the data files or the data processing pipeline.
Approximately 3.4% of the RNA-seq reads are classified as allele-specific reads (Supplementary
















































































































































































































































































































































































































































































































































































































y = 0.034 x
Figure C.4: The total number of reads (across all genes) per sample versus the total number of
allele-specific reads per sample. The red point indicates a sample (A15R) that has unexpected low
proportion of allele-specific reads and it is excluded from further analysis.
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as red in Supplementary Figure C.4. We removed this sample in the following analysis.
For any association analysis using TReC per gene, one has to account for read-depth difference
across samples. One way to quantify read-depth of a sample is to simply add up the total number
of reads of this sample. Here we adopted a more robust approach, to quantify read-depth using 75
percentile of TReC across all the genes of a sample. In fact, in this data set, the two measurements



































































































































































































































































































































































































































Figure C.5: The total number of reads (across all genes) per sample versus the 75 percentile of the
TReC of all the genes within a sample.
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C.2.4 eQTL mapping results
We summarize the agreement and disagreement of each tested model in the table below. This
table summarizes the agreement of each model with respect to individual gene-SNP pairs.
Gene-SNP Pairs
P-value Cutoff Category pTReC(ASE) TReC(ASE) pLR
# of gene-SNP pairs 133,599 436,021 48,717
5× 10−4 overlap/alternative – 19.8% 69.4%
overlap/pTReC(ASE) – 64.6% 25.3%
# of gene-SNP pairs 43,605 208,546 14,285
5× 10−6 overlap/alternative – 16.8% 80.5%
overlap/pTReC(ASE) – 80.2% 26.4%
# of gene-SNP pairs 19,867 131,795 6,593
5× 10−8 overlap/alternative – 13.5% 78.5%
overlap/pTReC(ASE) – 89.8% 26.0%
Table C.3: Summarizing the results of pTReC(ASE), TReC(ASE) and Westra models for TCGA
data analysis. Here the notation pTReC(ASE) indicate that we use pTReCASE or pTReC model,
depending on the results of Cis-Trans test. “overlap” represents the gene-SNP pairs identified by both
pTReC(ASE) and an alternative method. “overlap/alternative” is the number of overlaps divided by
the number of findings by the alternative method. “overlap/pTReC(ASE)” is the number of overlaps
divided by the number of findings by pTReC(ASE). If we consider the results of pTReC(ASE)
as true findings, then “overlap/alternative” is true discovery rate and “overlap/pTReC(ASE)” is
sensitivity.
In addition, we perform the same summary with respect gene-level estimates. In this table, we
summarize the number of genes with at least 1 significant eQTL and the prescribed p-value cutoff.
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Genes
P-value Cutoff Category pTReC(ASE) TReC(ASE) pLR
# of Genes 4788 7793 2055
5× 10−4 overlap/alternative – 42.7 70.2
overlap/pTReC(ASE) – 69.5 30.3
# of Genes 1245 2982 268
5× 10−6 overlap/alternative – 27.0 85.4
overlap/pTReC(ASE) – 64.7 18.4
# of Genes 496 1612 110
5× 10−8 overlap/alternative – 21.4 93.6
overlap/pTReC(ASE) – 69.6 20.8
Table C.4: Summarizing the results of pTReC(ASE), TReC(ASE), the Westra models for TCGA
data at gene level. The results are presented in the same format as Table 5.1, though the results are
summarized at gene level instead of the level of SNP-gene pairs.
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C.2.5 Additional results
Using the omic data prepared by [86], we examined the correlation between gene expression
before and after removing copy number effects. Such correlations are very high for most of the














Figure C.6: The distribution of correlations between gene expression before and after removing
copy number effects using a linear regression.
We also checked whether copy number of DNA methylation may confound the eQTLs reported
in Figure 2 of the main paper. The first example is about gene ENSG00000115525 (ST3GAL5). Its
expression is not associated with its copy number (p-value 0.22, R2 = 0.039), but is associated with
the methylation level of two CpG’s: cg10017626 (p-value 6.2e-05, R2 = 0.039) and cg07214715
(p-value 2.8e-05, R2 = 0.043) after correcting for tumor purity and cell type compositions [86].
The second example is about gene ENSG00000142794 (NBPF3). Its expression is not associated
with DNA methylation but is associated with its copy number (p-value 1.3e-07, R2 = 0.067). These
associations are illustrated in Figure C.7.
Next we check whether the associations between eQTL SNP genotype and gene expression are







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure C.7: Scatter plots demonstrate the associations between gene expression and copy number
of two genes ST3GAL5 and NBPF3 (upper panel), and the associations between gene expression of
ST3GAL5 and DNA methylation of two CpG’s.
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analysis in 328 samples (a subset of the 550 samples in main analysis) with all the data needed: SNP
genotype, copy number, gene expression, and DNA methylation. Using a simple linear regression of
gene expression versus SNP genotype (without using allele-specific expression), the eQTL p-value
for ST3GAL5 is 2.3e-4, and after controlling for methylation, the p-values remain similar (1.8e-4
for cg10017626 and 5.4e-4 for cg07214715). The eQTL p-value for NBPF3 is also similar before
and after controlling for copy number (t-statistics being 9.309 and 9.295 before and after controlling





































































































































































































































































































































































































































































































































































































































































































































Figure C.8: Scatter plots demonstrate the associations between eQTL and gene expression before or
after conditioning on two CpG’s for gene ST3GAL5 (upper panel), and associations between eQTL
and gene expression before or after conditioning on copy number alteration for gene NBPF3 (lower
panel).
In the following, we provide visual justification for considering a copy number event as the
difference between a gene’s copy number and a samples ploidy. Each figure utilizes a different
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cutoff for this different in determining a copy number event. These figures also examine the extent


































Figure C.9: Evaluating the extent of copy number aberration within the TCGA dataset. [A]
Distribution of the correlations between Dij and Cij for subjects where |Dij| ≤ 0.25 summarized
across all 18,134 genes. Red line indicates density of N(0,1/
√
232). [B] Distribution of the
correlations between Dij and relative gene expression summarized across all 18,134 genes [C] The




































Figure C.10: Evaluating the extent of copy number aberration within the TCGA dataset. [A]
Distribution of the correlations between Dij and Cij for subjects where |Dij| ≤ 0.40 summarized
across all 18,134 genes. Red line indicates density of N(0,1/
√
296). [B] Distribution of the
correlations between Dij and relative gene expression summarized across all 18,134 genes [C] The




































Figure C.11: Evaluating the extent of copy number aberration within the TCGA dataset. [A]
Distribution of the correlations between Dij and Cij for subjects where |Dij| ≤ 0.5 summarized
across all 18,134 genes. Red line indicates density of N(0,1/
√
296). [B] Distribution of the
correlations between Dij and relative gene expression summarized across all 18,134 genes [C] The
distribution of the number of subjects with |Dij| > 0.5 across all 18,134 genes.
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